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PVN  Paraventricular nucleus 
PYY  Peptide YY 
RANTES Regulated on activation, normal T cell expressed and secreted (aka CCL5) 
RIP  Rat insulin II promoter 
RT  Real-Time 
RNA  Ribonucleic acid 
SCN  Suprachiasmatic nucleus 
SDS  Sodium dodecyl sulphate 
Sec  Second(s) 
SF-1  Steroidogenic factor 1 
SH2  Src homology 2 
SIRT1  Sirtuin 1 
xx 
 
SOCS3 Suppressor of cytokine signalling 3 
ST6Gal-1 TGN-resident β-galactosidase α2,6-sialytransferase 
STAT3 Signal transducer and activator of transcription 3 
TACE  Tumour necrosis factor-α convertase 
TAE  Tris-acetate-EDTA 
TBS  Tris-buffered-saline 
TBST  Tris-buffered-saline-Tween®-20 
TCPTP T cell protein-tyrosine phosphatase 
TEMED Tetramethylenediamine 
Tg  Transgenic 
TGF-β1 Transforming growth factor-β1 
TH  Tyrosine hydroxylase 
TNF  Tumour necrosis factor 
TRH  Thyrotropin-releasing factor  
Tris  Tris(hydroxymethyl)aminomethane 
T2DM  Type 2 diabetes mellitus 
UCP  Uncoupling protein 
VGlut  Vesicular glutamate transporter 
VMH  Ventromedial hypothalamus 
WAT  White adipose tissue 
WT  Wild-type
xxi 
 
Summary 
Obesity is a global problem, with significant rises in obesity levels observed in recent 
years. This is owing to our modern lifestyles, associated with diminished physical activity 
and increased calorific intake. The increase in obesity is closely linked with type 2 
diabetes mellitus (T2DM), leptin and insulin resistance, impaired glucose homeostasis 
and often inflammation and endoplasmic reticulum stress. Worryingly, obesity and 
T2DM are also risk factors for Alzheimer’s disease (AD). 
The β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is critically involved 
in AD development, cleaving the amyloid precursor protein (APP) to generate amyloid-
β (Aβ), which drives progression of the hallmark pathologies of AD. Consequently, 
higher BACE1 levels/activity is considered a primary causative factor for AD. Increased 
BACE1 is driven by chronic stress (e.g. hypoxia, oxidative and metabolic) also associated 
with obesity and T2DM. Thus, impaired glucose homeostasis and insulin resistance is 
common to all three disease states, suggesting that BACE1 and Aβ may contribute to the 
progression of metabolic disease. Consequently, BACE1 knock-out mice have been 
demonstrated to be protected against diet-induced obesity (DIO) and have improved 
insulin and leptin sensitivity. 
Here we show that pharmacological inhibition of BACE1 improves metabolic syndrome 
in mice, and that elevations in BACE1, through altered APP processing, may exacerbate 
obesity and the metabolic syndrome. Furthermore, we show that BACE1 is present in 
hypothalamic nuclei and neuronal populations that control energy balance. Taken 
together, these data suggest BACE1 activity alters energy metabolism through actions on 
the neuronal circuitry regulating energy balance, and chronically raised BACE1 
levels/activity may result in dysregulation of these circuits and consequent metabolic 
disorder. Accordingly, a better understanding of the role of APP processing and BACE1 
activity under physiological and pathophysiological conditions may provide evidence for 
repurposing BACE1 inhibitors, currently in clinical trials for AD, towards treatment of 
obesity and T2DM.
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1.1 Obesity 
Obesity is a metabolic disease defined by an imbalance between energy intake to the body 
and energy expenditure of the body, whereby intake becomes greater than expenditure. 
This results in excessive levels of fat. The standard measure of obesity in the population 
is the body mass index (BMI), which is defined by an individual’s weight in kilograms 
divided by the square of their height in metres (kg/m2). A BMI of 25 or greater classifies 
an individual as overweight and a BMI of 30 or greater is classified as obese. In 2008 it 
was recorded that over 1.4 billion adults worldwide were overweight and over 0.5 billion 
obese, with the incidence having doubled since the 1980’s (www.who.int). This rise in 
obesity is likely attributed to the more ‘modern’ lifestyle many now live, which is one of 
a more sedentary nature involving less physical activity and a higher calorific diet. 
Worryingly obesity carries major health implications, increasing the risk for a number of 
co-morbidities including diabetes, cardiovascular disease and Alzheimer’s disease.  
1.2 The hypothalamus  
The central control centre for whole body energy homeostasis is the hypothalamus, in 
particular the basomedial hypothalamus. The presence of distinct neuronal populations 
within this region, particularly first order neurons in the arcuate nucleus (ARC), form a 
network which control energy regulation via their inputs and connectivity to other higher 
brain regions. The first evidence indicating a key role of the hypothalamus in regulating 
energy homeostasis came from lesion studies in rodents (King 2006). These studies 
crudely demonstrated that damage to the ventromedial hypothalamus (VMH) resulted in 
obesity, whilst lesions to the lateral hypothalamus (LH) resulted in a lean phenotype. This 
led to the ‘dual-centre’ model, which became the accepted model regarding hypothalamic 
control over energy balance (Stellar 1994). This model terms the VMH as a satiety centre, 
where lesions not only cause obesity, as mentioned, but also hyperphagia, and the LH is 
classically referred to as a feeding centre. The ‘dual-centre’ model demonstrated a clear 
role for these hypothalamic regions in the control of body weight and feeding behaviour, 
however subsequent research argued the validity of this model. Studies by Gold and 
colleagues failed to replicate the obese phenotype observed with VMH destruction and 
found only when areas which extended out with the VMH, such as the paraventricular 
nucleus (PVN), were damaged did obesity occur (Gold 1973). Subsequently, many 
groups have since established that VMH damage does result in body weight gain and 
there has been failure to replicate Gold’s work, supporting the original model whereby 
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VMH is crucial for feeding behaviour (King 2006). Nonetheless, as Gold and colleagues 
alluded to other hypothalamic areas may also be important. In keeping with this, studies 
using monosodium glutamate as a toxin found selective destruction of the arcuate nucleus 
(ARC) also evoked an obese phenotype (Olney 1969). Taken together it seems, although 
the VMH and LH are key centres involved in regulating energy homeostasis, that the 
‘dual-centre’ model is rather simplified and the hypothalamic network controlling body 
weight and food intake is extended further than these nuclei. Furthermore, the pathways 
innervating these nuclei may be more important than the specific nuclei themselves in 
regulating these behaviours (King 2006). 
 
 
Figure 1.1 Schematic diagram of the basic anatomy of the hypothalamus. 
The basomedial hypothalamus contains distinct nuclei contributing to the control centre 
for energy homeostasis. ARC, arcuate nucleus. LH, lateral hypothalamus. VMH, 
ventromedial hypothalamus. DMH, dorsomedial hypothalamus. PVN, paraventricular 
nucleus. 
 
The major hypothalamic regions which have subsequently been defined to contribute to 
the control of whole body energy homeostasis along with the VMH and LH, are the ARC, 
dorsomedial hypothalamus (DMH) and PVN (Figure 1.1). These regions contain distinct 
populations of neurons forming the neuronal circuitry which controls energy balance, 
allowing the hypothalamus to act as the central metabolic control centre. The ARC, like 
the LH, is also described as a ‘feeding centre’ (Funahashi et al. 2000). Importantly, the 
positioning of the ARC is key for its role within the hypothalamus, as it is ideally located 
just above the median eminence (ME) which is situated at the base of the hypothalamus. 
The ME allows for the integration of peripheral signals and hormones released from the 
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circulation (Elmquist et al. 1999), therefore the ARC neurons are the first point of contact 
for responding to these signals. Thus, as previously mentioned, the neuronal populations 
within the ARC are defined as ‘first order’ neurons. The first order neurons innervate 
other hypothalamic sites which are populated by second order neurons to relay the 
circulating signals. As briefly mentioned, the VMH is referred to as a ‘satiety’ centre and 
contains a dense population of glucose sensing neurons (Routh 2010), thus plays an 
important role in glucose homeostasis and the response to hypoglycaemia. The LH 
contains second order neurons that receive information from the ARC first order neurons, 
modifies this information, and relays these signals via anabolic pathways to the hindbrain, 
particularly the nucleus tractus solitarius (NTS) (Schwartz et al. 2000). The LH has also 
been described to contain glucose sensing neurons (Arora & Anubhuti 2006) which, along 
with other second order neuronal populations, contribute to its role as a ‘feeding centre’. 
The second order neurons in the LH also project back to the ARC as well as processing 
and receiving information from other hypothalamic nuclei such as the DMH. The DMH 
is situated dorsal to the VMH and plays an important role in regulating feeding and body 
weight, as well as circadian rhythms (Chou et al. 2003). The DMH also connects the other 
hypothalamic nuclei, by receiving information to and from nuclei, particularly the PVN 
(Elmquist et al. 1998). Lastly the PVN, situated in the anterior hypothalamus, is another 
crucial point of connectivity within the hypothalamus receiving heavy input from first 
order ARC neurons. Many pathways both project to and converge here, in particular 
afferents from first order ARC neurons which innervate second order neurons within the 
PVN, as well as neurons from the LH (Arora & Anubhuti 2006). Signals from the thyroid 
and hypo-pituitary axis are also integrated in the PVN (Neary et al. 2004) and neurons, 
from the parvicellular region of this nuclei in particular, innervate the ME as well as 
preganglionic neurons in the medulla and spinal cord, thus playing a role in autonomic 
output (Elmquist et al. 1998; Swanson & Sawchenko 1983). Alike the second order 
neurons in the LH, second order PVN neurons also relay signals back to the ARC as well 
as innervating the NTS via catabolic pathways (Schwartz et al. 2000). The current 
knowledge of these hypothalamic nuclei has demonstrated that the hypothalamus acts as 
an integrative centre vital for controlling energy regulation and metabolic status, via a 
network of neuronal circuitry between these distinct nuclei. More recent research has 
focused on the specific neuronal populations present within these nuclei and the pathways 
they are part of which form this hypothalamic network, in order to respond to endocrine, 
neural and metabolic signals to control energy balance (Spiegelman & Flier 2001). 
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1.3 Arcuate first-order neurons 
1.3.1  Anorexigenic neuropeptides 
1.3.1.1  Pro-opriomelanocortin  
The α-melanocyte stimulating hormone (α-MSH) is a potent anorexigenic neuropeptide 
derived from the pro-opiomelanocortin (POMC) peptide which is part of the central 
melanocortin system regulating energy homeostasis. α-MSH is generated from POMC 
through a series of post-translational modifications by pro-hormone covertases; PC1 and 
PC2 (Nillni 2007), with any abnormalities in their processing resulting in obesity. The 
POMC gene is selectively present in the pituitary, the skin, the immune system and the 
hypothalamus; abundantly expressed in the ARC (Arora & Anubhuti 2006). POMC ARC 
neurons produce and release α-MSH, which acts as an agonist at the melanocortin 
receptors; MC3R and MC4R, to elicit anorexigenic effects (Sohn et al. 2013). POMC 
ARC neurons further project to multiple hypothalamic and extra-hypothalamic sites 
where there are high levels of MC4R neurons, such as the PVN, LH, NTS and the spinal 
cord (Figure 1.2). Noteworthy is that α-MSH is not the only product of POMC. POMC 
processing results in various products via PC1 and PC2 cleavage, including 
adrenocorticotrophin hormone (ACTH), β-endorphin and other intermediate peptides 
(Millington 2007). The POMC products have various roles including involvement in skin 
pigmentation and adrenal steroidogenesis, however other physiological roles particularly 
of the intermediate products are not fully known (Millington 2007; Pritchard et al. 2002). 
Further cleavage of ACTH within the hypothalamus releases α-MSH, and, as referred too, 
this is the predominant POMC product believed to play a functional role in body weight 
and feeding behaviour, via MC3R and MC4R (Pritchard et al. 2002). Thus, MC3R and 
MC4R are vital for allowing the anorexigenic effects of POMC, however three other 
melanocortin receptor subtypes do exist; MC1R, MC2R and MC5R. MC1R and MC5R 
are expressed in low levels centrally, in comparison to MC3R and MC4R, and these 
subtypes along with MC2R are responsible for the skin pigmentation and adrenal 
functions of POMC (Pritchard et al. 2002). MC1R is the predominant receptor for α-MSH 
and responsible for controlling skin colour, and MC2R is the main receptor for ACTH 
and responsible for adrenal functions (Millington 2007). 
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Figure 1.2 Basic schematic diagram of the main neuronal pathways controlling 
energy homeostasis. 
First order neurons (POMC/CART and NPY/AgRP neurons) project to second order 
neurons in the LH and the PVN. MCH and orexin neurons in the LH send orexigenic 
signals to the NTS and cortical regions to control behavioural functions. CRH/TRH 
neurons in the PVN send anorexigenic signals to the pituitary and the NTS. These 
pathways form the main neuronal pathways controlling energy balance. 3V, third 
ventricle.  
Figure adapted from Ashford Lab teaching material.  
 
Central α-MSH acts to reduce food intake (Rossi et al. 1998) and this is reflected by 
mRNA changes in POMC expression during fasted or fed conditions. Following fasting 
in lean mice POMC mRNA expression is markedly reduced, an effect which is 
exacerbated further in genetically obese mice models (Mizuno et al. 1998). However, the 
fasting-induced reduction in POMC expression is restored following a period of re-
feeding in mice (Swart et al. 2002). Furthermore, when there is an absence of POMC 
entirely, for example in POMC-deficient mice, an obese and hyperphagic phenotype is 
observed (Yaswen et al. 1999). Obesity is also observed in humans with a POMC 
deficiency, which also reportedly results in the appearance of red hair, via a lack of 
activity at MC1R, and adrenal insufficiency most likely due to a lack of activity at MC2R 
(Krude et al. 1998). Furthermore, MC3R and MC4R null mice, in particular, show a 
metabolic phenotype, with both mice displaying increased fat mass (Butler et al. 2000; 
Sutton et al. 2006; Huszar et al. 1997). MC4R null mice are also hyperphagic, 
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hyperglycaemic and display hyperinsulinemia (Sutton et al. 2006; Huszar et al. 1997). 
Interestingly, MC4R mutations are found in humans and represent the most common 
cause of monogenic obesity, with homozygote mutations resulting in severe early-onset 
obesity and hyperphagia (Farooqi et al. 2000). This genetic defect clearly demonstrates 
the role of the MC4R in regulating POMC neurons anorexigenic effects, and that this role 
cannot be compensated for by other forms of the receptor. The POMC gene itself is 
predominantly limited to the ARC and the pituitary, with some expression in the NTS and 
retrochiasmatic area, which is situated at the base of the hypothalamus in front of the 
ARC and VMH. However, the ARC neurons project to many other central areas, such as 
the PVN, which send further projections via autonomic pre-ganglionic neurons to the 
medulla and spinal cord (Elmquist et al. 1999). These projections to other central regions 
carry out differential roles in the regulation of energy homeostasis, with the MC4R 
neurons expressed in the PVN acting to reduce food intake and conversely those 
expressed in autonomic pre-ganglionic neurons function to increase energy expenditure 
and control glucose homeostasis (Balthasar et al. 2005; Rossi et al. 2011). POMC neurons 
within the ARC form part of a neural circuitry, in which they receive input from neurons 
containing orexigenic neuropeptides, as well as receiving both inhibitory and excitatory 
inputs. The regulation of this circuitry allows for the control of feeding, energy 
expenditure and glucose homeostasis.  
1.3.1.2  Cocaine and Amphetamine Regulated Transcript 
The cocaine and amphetamine regulated transcript (CART) was identified in rodents 
following treatment with cocaine and amphetamine (Douglass et al. 1995). This led to the 
finding of another anorexigenic neuropeptide. The CART gene is highly conserved in 
both rodents and humans, and, like POMC, is strongly associated with feeding (Elmquist 
et al. 1999; Arora & Anubhuti 2006). CART expression is found throughout the 
hypothalamus, in the PVN, DMH, the perfornica areas of the hypothalamus, the LH and 
the ARC. Studies performed in rats revealed that central injections of CART result in 
reduced food intake, demonstrating its ability to elicit anorexigenic effects (Stanley et al. 
2001). Conversely, in obese rodent models CART transcript expression is reduced, which 
is also observed during periods of fasting, demonstrating a role for CART in regulating 
energy balance. Although CART is expressed throughout hypothalamic sites, within the 
ARC all CART neurons co-express POMC (Elmquist et al. 1999), producing a strong 
anorexigenic neuronal output.  
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1.3.2 Orexigenic neuropeptides 
1.3.2.1  Neuropeptide Y 
Neuropeptide Y (NPY) is a potent orexigenic neuropeptide 36 amino acids in length 
(Williams et al. 2000). NPY is found abundantly in the hypothalamus, particularly within 
first order ARC neurons which project to the DMH, LH and PVN to regulate feeding 
(Figure 1.2) (Sawchenko 1998). Functionally, NPY is known to stimulate feeding and 
acts to restore energy balance when necessary. In a state of starvation expression of NPY 
mRNA is upregulated (Hahn et al. 1998; Swart et al. 2002), and this is partially restored 
during re-feeding in mice (Swart et al. 2002). The strong orexigenic effects of NPY are 
observed following central administration of the neuropeptide in rats which stimulates 
feeding (Billington et al. 1991), and furthermore chronic administration results in obesity. 
Subsequent studies have revealed that injection of NPY directly into the PVN, where the 
most abundant NPY fibres are present, results in increased food intake, fat mass and 
reduced energy expenditure (Billington et al. 1994). These data suggest that the PVN is 
particularly important in the downstream mediation of NPYs effects, not only on feeding 
but also on regulating energy expenditure via brown adipose tissue (BAT) thermogenesis 
(Billington et al. 1994). This proposed role for NPY in regulating thermogenesis is also 
observed when NPY is overexpressed in the ARC and these changes are shown to be 
mediated via sympathetic activity (Shi et al. 2013). Additionally, ARC NPY neurons 
innervating the PVN project to areas of the hindbrain, which control the autonomic 
nervous system, such as the NTS (Figure 1.2) and are involved in controlling sympathetic 
output (Arora & Anubhuti 2006).  
NPY has five G-protein coupled receptors; NPY1-5R, with NPY1R and NPY5R believed 
to mediate NPYs feeding affects (Yulyaningsih et al. 2011; Arora & Anubhuti 2006). 
NPY5R, in particular, is found in abundance in the LH and PVN. Interestingly, deletion 
of NPY in mice does not result in any changes to body weight or feeding phenotypes 
(Erickson et al. 1996). Yet NPY1R and NPY5R deficient animals display increased body 
weight (Kushi et al. 1998; Sohn et al. 2013). Notably, these mouse models display 
different phenotypes in regards to feeding, with NPY1R null mice showing reduced food 
intake whereas NPY5R null mice show increased food intake. In contrast, NPY4R null 
mice show a completely altered phenotype of reduced body weight and fat mass 
(Sainsbury et al. 2002). These studies clearly demonstrate differential roles for the NPY 
receptors and thus their regulation of NPY action may work via different networks, with 
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NPY5R mediating feeding behaviour and NPY1R regulating energy expenditure (Shi et 
al. 2013). Additionally, these studies also suggest that NPY receptors are not solely 
responsible for NPYs orexigenic actions and separate contributors, such as gamma-
aminobutryic acid (GABA), may play a role.  
 
 
Figure 1.3 Schematic diagram of the basic neuronal model of the ARC circuitry 
controlling energy homeostasis. 
Adiposity signals insulin and leptin act on first order ARC neurons to inhibit 
NPY/AgRP neurons and activate POMC neurons. POMC neurons release α-MSH 
which acts on second order neurons and AgRP inhibits this action. GABAergic 
NPY/AgRP neurons can also innervate POMC neurons through synaptic GABA, NPY 
and AgRP release, directly inhibiting POMC neurons. First order ARC neurons project 
to second order neurons to influence food intake and energy expenditure, maintaining 
energy balance. 
Figure adapted from Ashford Lab teaching material.  
 
GABA is the main inhibitory neurotransmitter utilised by the CNS (Delgado 2013) and 
is released by NPY neurons in the ARC which has been shown to mediate, in part, the 
orexigenic actions of NPY (Figure 1.3). In contrast only a proportion of POMC/CART-
expressing neurons release GABA as their main neurotransmitter, with some utilising the 
excitatory neurotransmitter glutamate (Wittmann et al. 2013), supporting the role of 
GABA in mediating orexigenic effects. The contribution of GABA neurotransmission on 
feeding behaviour in regards to NPY-expressing neurons occurs independently of the 
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NPY receptors (Atasoy et al. 2012). NPY therefore acts to stimulate feeding via NPY1R 
and NPY5R in conjunction with other orexigenic mediators such as GABA, whilst 
inhibiting anorexigenic neuropeptides. Both the synthesis and secretion of NPY are 
increased when energy stores are low, suggesting a physiological role for these neurons 
in the regulation of energy homeostasis by restoring energy balance during periods of 
energy deficiency (Arora & Anubhuti 2006).  
1.3.2.2 Agouti-related Peptide 
The identification of another neuropeptide affecting food intake and body weight arose 
from work on the lethal yellow Ay/a mouse. The Ay/a mouse is an obese mouse model, 
which also exhibits a yellow coat colour, increased linear growth, insulin resistance and 
hyperglycaemia (Flier & Maratos-Flier 1998). The phenotype of the Ay/a mouse arises 
due to disruption in the expression of the agouti gene which is normally localised to the 
skin in mice and alters hair pigmentation via α-MSH by acting as antagonist at MC1R. 
The agouti gene is also found in the human genome with high homology to mouse agouti, 
however interestingly in humans it is also expressed in adipose tissue (Kwon et al. 1994). 
In the Ay/a mouse agouti expression is unregulated and expressed throughout the body, 
which led to the finding that in the brain agouti also acts as an antagonist at MC4R (Flier 
& Maratos-Flier 1998). Subsequently, this led to the discovery of an alternative 
neuropeptide responsible for this antagonism at MC4R; the agouti-related peptide 
(AgRP).  
AgRP is a 132 amino acid peptide which has since been shown to mediate strong 
orexigenic actions. As mentioned, AgRP is a potent antagonist of α-MSH via MC4R and 
also MC3R (Lu et al. 1994) and therefore elicits orexigenic effects through inhibition of 
the melanocortin system. AgRP specifically antagonises MC3R and MC4R only, and 
unlike agouti itself, does not inhibit the melanocortin system through MC1R (Flier & 
Maratos-Flier 1998). AgRP acts to stimulate food intake, acting in a similar manner to 
NPY, whereby central administration of AgRP in rats causes increased food intake (Rossi 
et al. 1998) and following prolonged administration in mice a hyperphagic phenotype is 
observed with a concomitant increase in body weight, resulting in obesity (Small et al. 
2001). Interestingly, when AgRP is knocked-out in mice, like NPY, there is no body 
weight or feeding behaviour phenotype (Qian et al. 2002). Furthermore, Qian and 
colleagues demonstrated this was also the case in NPY/AgRP double knock-out mice 
(Qian et al. 2002). This alludes to the potential for different circuits to also be involved 
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in feeding behaviour that could compensate for the normal pathways mediating energy 
balance when necessary for survival.  
Under normal circumstances AgRP acts along with NPY to induce orexigenic effects. 
Within the ARC, AgRP is co-expressed in neurons with NPY (Broberger et al. 1998) and 
these neurons utilise GABA as their main neurotransmitter to elicit inhibitory effects. 
NPY/AgRP ARC neurons respond to both peripheral signals, such as leptin, insulin and 
ghrelin, and central signals, sending this information to other hypothalamic and extra-
hypothalamic centres, including the PVN and hindbrain (Figure 1.2, Figure 1.3).  
1.3.3 Additional first-order arcuate neurons 
As discussed the predominant neuronal populations in the ARC are POMC/CART-
expressing neurons and NPY/AgRP-expressing neurons. However, there are neurons 
within the ARC that are distinct from these neuronal populations, yet owing to their 
location are thought to play a role in the regulation of whole body energy homeostasis. 
One population are RIPCre neurons which are defined by having cre expression driven 
by the rat insulin II promoter. This specific population was discovered when utilising this 
cre expression to study the pancreatic β-cell, where it was noted that there was expression 
present in areas of the brain. Cre expression was found to be largely restricted to the 
hypothalamus, where it is concentrated in the ARC and also the suprachiasmatic nucleus 
(SCN), VMH and DMH, as well as distributed in regions of the cortex and striatum (Song 
et al. 2010). It has subsequently been found that these neurons lie in very close apposition 
to POMC/CART-expressing neurons and NPY/AgRP-expressing neurons in the ARC, 
however are completely distinct (Choudhury et al. 2005). Due to this close proximity it 
is believed that RIPCre neurons may be targets for POMC neurons and communication 
between the two populations may occur. This proposal is supported by the finding that 
RIPCre neurons become depolarised in response to melanotan-II (MTII); an agonist of 
the melanocortin receptor (Choudhury et al. 2005). Furthermore, when the leptin receptor 
is knocked-out of these neurons an obese phenotype similar to that observed in POMC-
leptin receptor deficient mice is observed, accompanied with impaired glucose 
homeostasis (Covey et al. 2006). This is suggestive of a role in glucose homeostasis as 
well as an involvement in the regulation of the body weight actions of leptin. Still, the 
precise function of RIPCre neurons and what they release is unknown, although it is 
believed that they have important functions regarding the regulation of whole body 
energy balance, and further research is required to determine this.  
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Although RIPCre may be key in the regulation of energy balance, along with POMC and 
NPY/AgRP neurons, noteworthy is the presence of additional ARC neuronal populations. 
In brief, other ARC populations exist including neurotensin-releasing neurons and 
galanin-releasing neurons, both of which are implicated in regulating feeding behaviours. 
Neurotensin is produced and released in the ARC, however is also present in the PVN 
and DMH, where it is believed to interact with leptin to stimulate anorectic effects 
(Sobrino Crespo et al. 2014). Galanin is found in the ARC and thought to be involved in 
feeding regulation, however within the hypothalamus it is predominantly found in the 
PVN, as well as existing peripherally in the gut (Sobrino Crespo et al. 2014; Arora & 
Anubhuti 2006). Centrally, galanin is co-expressed with GABA, noradrenaline and 
serotonin (5-HT), and may be involved in many other autonomic functions as the majority 
of galanin terminals are situated in the NTS (Sobrino Crespo et al. 2014). 5-HT is also 
important in the regulation of feeding behaviour in relation to first order ARC neurons 
although it actually originates from the dorsal raphe nucleus in the midbrain (Sobrino 
Crespo et al. 2014). 5-HT neurons project heavily to areas of the hypothalamus, including 
the DMH and VMH, however importantly 5-HT receptors are expressed on POMC and 
NPY/AgRP ARC neurons, thus these first order ARC neurons also sense 5-HT signals 
and regulate responses (Sohn et al. 2013). The outputs of these neurons have many 
functions including sleep, temperature regulation and importantly feeding behaviour 
where 5-HT acts as a satiety signal and reduces food intake as well as regulating glucose 
homeostasis (Sohn et al. 2013). Furthermore, 5-HT along with dopamine present 
themselves as additional neurotransmitters utilised by first order ARC neurons in the 
regulation of energy balance (Flier & Maratos-Flier 1998).  
1.4 Extra-arcuate neurons 
1.4.1  Steroidogenic Factor-1 neurons 
The VMH is a key hypothalamic site involved in regulating body weight and food intake, 
as well as a role in glucose homeostasis. The VMH contains many populations of neurons, 
although steroidogenic factor-1-expressing (SF-1) neurons are considered the most 
abundant. SF-1 is an orphan member of a nuclear hormone family and regulates a number 
of endocrine functions, specifically the hypothalamic-pituitary-gonadal axis and adrenal 
function (Parker & Schimmer 1997). SF-1 neurons are a representative population in the 
VMH, as they are exclusively expressed in this nucleus and although they do not make 
up the entire nucleus they form a dense population within it. SF-1 neurons have been 
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implicated in the control of food intake and whole body energy homeostasis, with SF-1 
deficient mice characterised with hyperphagia and develop obesity in adulthood (Majdic 
et al. 2002). SF-1 deficient mice also display abnormalities of the VMH itself, however 
the ARC and DMH remain intact (Majdic et al. 2002). This phenotype demonstrates the 
importance of SF-1 in the development of the VMH and the regulation of metabolism. 
SF-1 neurons have also been shown to be responsive to leptin, which may mediate its role 
in body weight control. Dhillon and colleagues demonstrated SF-1 neurons depolarised 
following treatment with leptin, a response similar to that observed with POMC neurons 
(Dhillon et al. 2006). Subsequent studies within the same laboratory demonstrated SF-1 
neurons lacking the leptin receptor have increased body weight, particularly adiposity, 
again matching the POMC neuronal response (Dhillon et al. 2006). Additionally, SF-1 
neurons may also mediate a large component of the regulation of glucose homeostasis the 
VMH controls. Tong et al demonstrated that when the vesicular glutamate transporter; 
VGLUT2, is knocked out of SF-1 neurons, not only is body weight increased, 
impairments in glucose homeostasis are observed accompanied with an impaired 
response to hypoglycaemia (Tong et al. 2007). As a result, these studies implicate SF-1 
neurons to play a role, not only in the regulation of body weight and food intake, but also 
presents them as glucose-sensing neurons playing an important role in the response to 
hypoglycaemia.  
1.4.2 Orexin neurons 
Orexin neurons have emerged as a population important in the regulation of energy 
homeostasis. Orexins were first described as hypocretins and have two isoforms; orexin 
A and orexin B, with corresponding receptors OX1R and OX2R (Sakurai et al. 1998). 
Orexins are excitatory neuropeptides found in neurons within the LH. Examination of 
orexin receptor mRNA expression reveal they are distributed throughout the brain, with 
OX1R most abundant in the VMH and OX2R most abundant in the PVN (Trivedi et al. 
1998). However, orexin A and B themselves are not expressed within neurons in these 
areas. Although expression is mainly found in the LH, peripheral mRNA expression is 
observed in the small intestine of rats and orexin neuronal immunoreactivity is observed 
in the gut (Kirchgessner & Liu 1999). Expression of both isoforms of orexin are found to 
be elevated during periods of fasting, furthermore central administration of both isoforms 
results in increased food intake (Sakurai et al. 1998). This mechanism of control over 
food intake may act in part through NPY neurons, as NPY neurons innervating the LH 
(Figure 1.2) have been shown to make close contact with all orexin neurons (Broberger 
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et al. 1998). This proposal has been further supported by central administration of orexin 
A causing an increase in food intake, an effect comparable to those observed with NPY 
treatment (Yamanaka et al. 2000). Additionally, Yamanaka and colleagues found pre-
treatment with an NPY antagonist inhibits the orexin-induced increase in food intake and 
that following treatment with orexin A c-FOS expression in NPY ARC neurons was 
detected, indicating neuronal activation (Yamanaka et al. 2000). These data suggest that 
orexin neurons also innervate ARC NPY neurons, forming another connection between 
the LH and the ARC. Signals from peripheral peptides, such as leptin and ghrelin, are 
also thought to regulate these neurons, with orexin fibres specifically making synaptic 
contact with neurons within the VMH and ARC which express the leptin receptor 
(Funahashi et al. 2000). Outwith their role in energy regulation orexin neurons are also 
thought to carry out many physiological functions, including a role in sleep and 
wakefulness with these neurons heavily projecting to the SCN (Arora & Anubhuti 2006).  
1.4.3 Melanin-Concentrating Hormone neurons 
A separate population of neurons in the LH are those releasing melanin-concentrating 
hormone (MCH), which are distinct from orexin neurons. MCH is a 19 amino acid peptide 
which was first established for its role in the regulation of skin colour, however has since 
been implicated in the regulation of energy homeostasis (Flier & Maratos-Flier 1998). 
Areas of the LH abundant in MCH expression receive input from the ARC, with 
NPY/AgRP and α-MSH projecting to these sites (Figure 1.2) (Elias et al. 1998), however 
MCH has been shown to have opposing actions to α-MSH, with elevated expression 
observed during fasting. MCH has no interaction with the known melanocortin receptors, 
thus its actions are via an unidentified receptor, yet it may still be implicated in body 
weight and food intake control through the melanocortin system, with this pathway 
linking the ARC and the LH to allow regulation of energy balance. (Qu et al. 1996; Flier 
& Maratos-Flier 1998). This was demonstrated in rodent studies by Broberger et al who 
showed that NPY neurons project to the LH and almost all MCH neurons were 
surrounded by and in very close contact to the NPY neurons, suggesting MCH neurons 
are innervated by NPY (Broberger et al. 1998). In an obese state MCH expression is 
elevated, as demonstrated in the genetically obese ob/ob mouse, and central 
administration of this peptide in lean rats causes increased food intake and reduced energy 
expenditure (Qu et al. 1996). Furthermore, MCH deficient mice have reduced body 
weight, food intake and circulating leptin levels (Shimada et al. 1998). The specific 
metabolic role of MCH neurons is yet to be fully elucidated, however it has been 
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implicated in the control of complex behaviours due to these neurons projecting 
throughout the brain, in particular to cortical regions.  
1.4.4  Paraventricular second order neurons 
Second order neurons located in the PVN are also important in regulating anorexigenic 
affects and controlling energy balance. These neurons release corticotropin-releasing 
factor (CRH) and thyrotropin-releasing factor (TRH) which are involved in the release of 
hormones from the pituitary and both act as catabolic mediators (Figure 1.2). Neurons 
releasing these factors have been shown to be involved in regulating food intake and body 
weight (Sobrino Crespo et al. 2014).  
CRH is involved in regulating the hypothalamic-pituitary-adrenal axis. Neurons releasing 
CRH have been shown to have an important role in the control of food intake with 
processes found in the ME, hypothalamus and NTS; areas largely implicated in the 
circuitry controlling food intake. Moreover, central administration of CRH in rats has 
been shown to reduce food intake and body weight (Sobrino Crespo et al. 2014). This 
regulation is possibly mediated via the NPY system and CRH may be a direct target of 
NPY action (Li et al. 2000). Studies by Li and colleagues showed NPY fibres surround 
CRH neurons, providing synaptic input. It can be assumed these NPY projections are 
from the ARC, however as NPY neurons are present elsewhere in the brain contact may 
come from other regions. Additionally, CRH neurons do not express NPY1R receptor (Li 
et al. 2000), suggesting NPY does not directly act upon these neurons, however  NPY 
may mediate the action of CRH neurons through another receptor isoform. NPY may also 
indirectly act upon CRH neurons, as ARC NPY neurons innervate GABA interneurons 
present in the PVN altering GABA release on PVN second order neurons. Thus, NPY 
and GABA may elicit food intake actions in conjunction with and/or by acting upon CRH 
neurons.  
TRH is involved in the regulation of the hypothalamic-pituitary-thyroid axis, releasing 
thyroid-stimulating hormone from the pituitary. TRH is also involved in the control of 
feeding, with treatment in rats causing a reduction in food intake (Choi et al. 2002). This 
action is also thought to occur via NPY pathways as well as the melanocortin system, as 
TRH neurons in the PVN lie in close apposition to α-MSH and NPY/AgRP fibres (Fekete 
et al. 2000). When NPY is administered centrally to rats there is a reduction in pro-TRH 
mRNA staining in the PVN and a reduction in thyroid hormone release corresponding to 
a state of hyperthyroidism (Fekete et al. 2001). The reduction in TRH observed during 
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periods of fasting may be directly due to the increase of NPY in this state. However, the 
fasting-induced reduction in TRH is attenuated following central administration of α-
MSH treatment (Fekete et al. 2000), suggesting TRH neurons may be regulated by α-
MSH neurons.  
1.5 Peripheral peptides regulating energy homeostasis 
1.5.1 Leptin 
Since the discovery of the obese gene (ob) and its product leptin (Zhang et al. 1994), 
leptin has been established in having a key role in regulating whole body energy 
homeostasis. Leptin is secreted from adipocytes and circulating levels are directly 
correlated with the degree of adiposity, whereby increased adipose tissue mass causes 
elevations in leptin levels (Maffei et al. 1995). Leptin therefore reflects the energy status 
of the body and availability of energy stores, predominantly acting to reduce appetite, by 
signalling via central receptors in the hypothalamus and regulating body weight. 
Alternatively, during periods of fasting where energy stores are low, there is a reduction 
in leptin levels (Ahima et al. 1996) which signals to stimulate feeding and reduce energy 
usage, maintaining body weight. A single point mutation in the ob gene, resulting in 
leptin-deficiency, reported in both rodents and humans, results in obesity; observed in the 
ob/ob mouse model (Zhang et al. 1994). The ob/ob mouse does not produce the mature 
form of leptin as a result of the ob mutation and this causes an excessive accumulation of 
fat, hyperphagia, lowered basal metabolic rate and oxygen consumption, and reduced 
energy expenditure and body temperature (Bray & York 1979; Bates & Myers 2003). 
ob/ob mice are also infertile and have reduced linear growth (Bates & Myers 2003). The 
obese phenotype can be completely reversed by recombinant leptin therapy shown, in 
both rodents (Campfield et al. 1995; Halaas et al. 1995) and humans (Farooqi et al. 1999). 
Leptin treatment results in reduced food intake and body weight, particularly a reduction 
in adiposity (Farooqi et al. 1999). This is not only the case in ob/ob mice, but in wild-type 
(WT) lean rodents as shown by induction of chronic hyperleptinemia using recombinant 
adenovirus delivery, which causes reduced food intake and body fat mass in WT rats 
(Chen et al. 1996). In all cases the observed reduction in body weight is primarily due to 
a reduction in adiposity, and arises largely due to the suppression of food intake, although 
leptin also acts to increase energy expenditure. Additionally, the resulting weight loss is 
correlated to the amount of leptin administered, with greater weight loss occurring with 
increasing dosage of leptin (Heymsfield et al. 1999), highlighting leptins weight-reducing 
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effects. Importantly the same results can be observed when leptin is administered 
centrally (Campfield et al. 1995), in which injection of leptin into the lateral ventricle also 
causes a reduction in food intake and body weight. Cumulatively, these studies suggest 
the weight-reducing effects of leptin are through direct action on the CNS. However, work 
in humans produces mixed results with studies demonstrating that recombinant leptin 
treatment in obese individuals who are not leptin deficient does not alter body weight 
(Mittendorfer et al. 2011; Zelissen et al. 2005). The discrepancy between rodent and 
human models in regards to the effectiveness of leptin therapy is unknown, however such 
studies suggest that leptin treatment will not provide a therapeutic intervention for obese 
humans that lack an ob mutation and exhibit high circulating levels of the hormone.  
1.5.1.1 Leptin signalling 
Following the discovery of leptin, the specific receptor was identified by Tartaglia and 
colleagues in 1995 utilising cloning techniques. They were classified as members of the 
interleukin 6 receptor family of class I cytokines with five isoforms existing; ObRa-ObRe 
(Tartaglia et al. 1995). These isoforms can be separated into three distinct categories; the 
secreted form, the short forms and the long form of the receptor (Bates & Myers 2003). 
The secreted form, ObRe, differs to the long and short forms in that it only has 
extracellular domains which bind to leptin, therefore it has been proposed that this form 
may play a role in regulating circulating leptin levels (Li et al. 1998; Bates & Myers 
2003). The function of the short forms; ObRa, ObRc and ObRd, is not well defined. 
However, ObRa is the most highly expressed isoform and is particularly abundant in the 
choroid plexus, suggesting a role in the transportation of leptin across the BBB, from the 
blood to the CSF (Tartaglia 1997).  
1.5.1.1.1 The signalling form of the leptin receptor 
The long form of the receptor (ObRb) is considered the signalling form and is critical for 
leptin body weight actions. This is demonstrated by the genetically obese db/db mouse 
which lack functional leptin receptor signalling. db/db mice have all the leptin receptors, 
however within the region where ObRb and ObRa diverge there is a disruption resulting 
in termination of the intracellular domain of ObRb (Chen et al. 1996). This ultimately 
results in a dysfunctional ObRb which is more like ObRa, and results in a phenotype alike 
the ob/ob mouse; morbidly obese, hyperphagic and with reduced energy expenditure 
(Bray & York 1979; Bates & Myers 2003). 
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ObRb signals via a noncovalently associated family of janus associated kinases (JAK), of 
which four members exist, and ObRb preferentially uses JAK2 (Kloek et al. 2002). When 
leptin binds ObRb there is a conformational change in its structure which allows for 
binding and activation of JAK2, forming an ObRb-JAK2 complex. When JAK2 becomes 
activated this allows for phosphorylation of tyrosine residues present on ObRb and in turn 
activation of downstream signalling events (Kloek et al. 2002; Bates & Myers 2003). 
Three conserved tyrosine residues are present on the intracellular domain of ObRb; 
Tyrosine positions 985, 1138 and 1077 (Tyr985, Tyr1138 and Tyr1077) (A S Banks et al. 
2000; Bates & Myers 2003; Leshan et al. 2006). Tyr985 and Tyr1138 are required for ObRb 
signalling (A S Banks et al. 2000). Tyr1138 is a docking site for a member the signal 
transducer and activator of transcriptions (STAT); STAT3, which is activated as part of 
the main signalling cascade leptin utilises (Münzberg & Myers 2005). Phosphorylation 
of Tyr985 recruits the tyrosine phosphatase SHP-2 which allows for the activation of the 
extracellular signal-related kinases (ERK) and mitogen-activated protein kinases 
(MAPK) signalling pathways, which are also utilised by leptin however are more 
important for growth and differentiation, rather than energy homeostasis (Münzberg & 
Myers 2005). Conversely, the phosphorylation Tyr1077 is not believed to be necessary for 
leptin signalling, although subsequent studies have shown that it may contribute to leptin 
signalling, just less so than Tyr985 and Tyr1138. Patterson et al generated knock-in (KI) 
mice with a mutated form of Tyr1077 present on ObRb and found that these mice display 
moderate obesity and a mild increase in food intake (Patterson et al. 2012), suggesting 
Tyr1077 may play a minor role in the body weight and food intake actions of leptin. JAK2 
can also signal independently without phosphorylation of these tyrosine residues, 
however the sites at which this occurs are yet to be identified and therefore little is known 
about these signals.  
1.5.1.1.2 The JAK-STAT signalling pathway 
As mentioned, the main signalling pathway utilised by leptin is the JAK-STAT pathway, 
which is dependent on phosphorylation at Tyr1138 (Figure 1.4). It is accepted that 
signalling occurs at this site as KI mice which have a mutation at the 1138 position (s/s 
mice) have a similar phenotype to db/db mice (Bates et al. 2003). Interestingly, as 
mentioned, db/db mice are also infertile and have reduced linear growth, however s/s 
mice do not exhibit these traits, with increased hyperphagia and reduced basal metabolic 
rate being the only shared features. When JAK2 phosphorylates Tyr1138 it binds STAT3 
which becomes activated and translocates to the nucleus to initiate gene transcription (A 
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S Banks et al. 2000; Leshan et al. 2006; Bates & Myers 2003) Although ObRa has the 
ability to bind JAKs, unlike ObRb, they cannot activate STAT3, hence ObRb alone 
controls leptin signalling (Sweeney 2002). Upon translocation to the nucleus STAT3 has 
the ability to switch on transcription of certain genes, such as suppressors of cytokine 
signalling (SOCS) which promotes a negative feedback loops, and POMC. 
  
 
 
Figure 1.4 Schematic diagram of the leptin receptor and JAK2/STAT3 signalling. 
Leptin binds the long form of the leptin receptor, ObRb, which activates a Janus 
associated kinase, JAK2. JAK2 allows for phosphorylation of Tyrosine residues, with 
phosphorylation of Y1138 binding the signal transducer and activator of signalling, 
STAT3, to initiate leptin signalling.  
Figure adapted from Ashford Lab teaching material. 
 
ObRb is expressed in many tissues, with highest expression found centrally in the 
hypothalamus, in particular the basomedial hypothalamic areas including the ARC, DMH 
and VMH (Fei et al. 1997; Lee et al. 1996). As mentioned, these are the key sites of leptin 
action, and studies have shown that physically or chemically damaging these nuclei result 
in a phenotype resembling the ob/ob and db/db mice (Bates & Myers 2003). Within these 
areas the highest ObRb expression is present in the ARC, specifically in neurons 
regulating food intake and body weight; POMC-expressing neurons (Cowley et al. 2001) 
and NPY/AgRP-expressing neurons (Hâkansson et al. 1998). The product of the POMC 
gene; α-MSH is implicated in mediating anorectic effects of leptin and conversely AgRP 
is an antagonist of α-MSH, therefore ObRb-STAT3 signalling causes STAT3 activation 
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of POMC, whilst inhibiting NPY and AgRP, in order to suppress appetite (Figure 1.5), 
with the reverse occurring during fasting (Schwartz et al. 2000; Bates & Myers 2003). 
The specific neurons and neuronal circuitry involved in the actions of leptin is not clearly 
defined and ARC leptin signalling needs to be further examined, however leptin action 
on POMC is proposed to be the predominant action. Leptin increases POMC expression 
(Schwartz et al. 1997) and electrophysiology studies demonstrate that application of 
leptin readily depolarises POMC neurons (Choudhury et al. 2005; Cowley et al. 2001), 
accompanied by the speculation that leptin will hyperpolarise NPY/AgRP neurons. The 
obese db/db mice have reduced POMC levels (Balthasar et al. 2004; Mizuno et al. 1998), 
and furthermore daily leptin injections to ob/ob mice result in reduced body weight with 
elevated POMC expression (Schwartz et al. 1997; Mizuno et al. 1998). This shows leptin 
receptor signalling on POMC neurons is necessary for the body weight action of leptin; 
however it is important to highlight that POMC may not be the sole mediator. In addition, 
not all leptin action on POMC neurons is direct, with synaptic innervation directly from 
NPY neurons and GABA-releasing neurons inhibiting POMC neurons (Cowley et al. 
2001). This is accompanied by work suggesting synaptic plasticity in the hypothalamus 
and synaptic alterations on ARC POMC neurons may play a role in regulating body 
weight and food intake (Horvath 2005), independently from leptin action on ObRb-
expressing neurons, further supporting the notion that POMC neurons are not the only 
ARC population implicated in the control of energy balance. Furthermore, Balthasar and 
colleagues found that when ObRb is knocked out of POMC neurons there is only modest 
obesity (Balthasar et al. 2004) and Coppari et al found rescuing ObRb in db/db mice only 
reverses their obese phenotype in part (Coppari et al. 2005). Therefore, other neurons 
must be targets of leptin signalling, and indeed other ObRb-expressing neurons exist in 
the basomedial hypothalamus, particularly the ARC, such as the aforementioned RIPCre 
neurons (Cui et al. 2004) as well as MCH neurons in the LH (Hâkansson et al. 1998), 
however less is known regarding these neurons and their role in energy balance. 
Nonetheless, ObRb-STAT3 signalling is clearly necessary for the hypothalamic anorectic 
effects of leptin, and maintaining overall energy homeostasis. Importantly, the JAK-
STAT signalling pathway is not required for other functions of leptin, including growth 
and reproduction, therefore although this signalling cascade is the principle pathway 
utilised by leptin, it is not the sole signalling pathway mediating its functions. 
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Figure 1.5 Schematic diagram of the first order ARC neuronal model controlling 
energy balance. 
Leptin binds its receptor, ObRb, on first order ARC neurons resulting in 
phosphorylation of STAT3 activating POMC and the release of the POMC product α-
MSH, which acts as an agonist at the melanocortin receptors (MC3R and MC4R), 
whilst AgRP acts as an antagonist at these receptors. In addition, STAT3 inhibits 
NPY/AgRP. Leptin action on these first order ARC neurons causes reduced food intake 
and increased energy expenditure, maintaining energy balance. 
Figure adapted from Ashford Lab teaching material.  
 
1.5.1.1.3 The PI3-kinase signalling pathway  
A separate signalling pathway leptin activates is the phosphatidylinositol 3-kinase (PI3K) 
pathway. PI3Ks are heterodimers which control many functions, including metabolism 
(Donato et al. 2010; Sweeney 2002). The most common form of PI3K includes an 85kDa 
peptide (p85), which forms a regulatory subunit of PI3K, and a 100kDa catalytic subunit 
(p110) (Niswender & Schwartz 2003). This pathway involves insulin receptor substrate 
(IRS) proteins, of which four have been identified (IRS1-4) and are defined as docking 
proteins, which act as intracellular signalling molecules. The docking proteins can be 
phosphorylated by different tyrosine kinases, such as the insulin receptor and other 
cytokine receptors (Bates & Myers 2003), and importantly enable the formation of 
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signalling complexes to form and bring multiple signalling proteins in close proximity 
with each other. IRS2 has been shown to be particularly important in this pathway as 
leptin has the ability to activate PI3K via IRS2 in the hypothalamus, furthermore 
pharmacological inhibition of PI3K results in leptin no longer able to suppress food intake 
(Niswender et al. 2001). The hormone insulin also activates this pathway in the 
hypothalamus, and is in fact required with leptin to induce its anorectic effects 
(Niswender & Schwartz 2003). This STAT3-independent pathway is crucial for the 
majority of insulin action alone, however is also believed to be necessary for regulating 
leptin action on food intake, for example through POMC-expressing neurons. Hill et al 
demonstrated that when PI3K is disrupted in POMC neurons they are no longer activated 
in response to leptin (Hill et al. 2008), thus these neurons require PI3K signalling to 
respond appropriately to leptin. However, in this model mice do not have a body weight 
phenotype, demonstrating that PI3K is clearly involved in mediating leptin actions in part, 
but is not solely responsible for its effects. Conversely, subsequent studies demonstrated 
that mice lacking the β-subunit of p110 (p110β) on POMC neurons show increased fat 
mass and food intake, with reduced leptin sensitivity (Al-Qassab et al. 2009). 
Interestingly, Al-Qassab and colleagues also found a phenotype when p110β was 
removed from AgRP neurons, with AgRP-p110β null mice displaying a lean phenotype, 
hypophagia and resistance to diet-induced obesity (Al-Qassab et al. 2009). Although the 
precise functions of the PI3K signalling cascade in regards to leptin function remain 
unknown, these data indicate it may be important in regulating leptin signalling in POMC 
neurons, as well as AgRP neurons for the control of energy balance. 
1.5.1.1.4 Negative regulators of leptin signalling 
The phosphorylation at Tyr985, following initiation of leptin signalling, is also implicated 
in the negative regulation of leptin signalling as SOCs, in particular SOCS3, binds and is 
activated at Tyr985 inhibiting ObRb-STAT3 signalling (Figure 1.6) (Bjorbak et al. 2000). 
SOCS3 also binds JAK2 directly resulting in further down-regulation of leptin signalling 
(Münzberg & Myers 2005). As SOCS3 binds Tyr985 it has the ability to inhibit both leptin-
stimulated JAK2 phosphorylation and activation of ERK signalling. This was 
demonstrated in studies on obese and lean rats by Wang and colleagues whereby 
overexpression of SOCS3 in islets causes a 75% reduction in the ability of leptin to reduce 
body weight (Wang et al. 2000). It has also been shown that following leptin 
administration in mice SOCS3 mRNA levels rise in areas of the hypothalamus which 
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express ObRb. This results in blockage of leptin signalling (Bjorbaek et al. 1998) and 
thus demonstrates a key role for SOCS3 in the negative regulation of leptin signalling. 
 
 
Figure 1.6 Schematic diagram of the negative regulation of leptin signalling by 
SOCS3. 
The activation and phosphorylation of JAK2 and the tyrosine residue Y985 directly 
binds the suppressor of cytokine signalling SOCS3. This activation of SOCS3 inhibits 
further STAT3 signalling. 
Figure adapted from Ashford Lab teaching material. 
 
The protein-tyrosine phosphatase 1B (PTP1B) is another negative regulator of leptin 
signalling. In vitro studies demonstrate when fibroblast-like cells and human embryonic 
kidney (HEK) 293 cells are transfected with PTP1B a reduction in leptin signalling is 
observed via JAK2/STAT3 blockage (Zabolotny et al. 2002). PTP1B acts directly on 
JAK2, causing dephosphorylation and inhibition (Figure 1.7), demonstrating, like 
SOCS3, that PTP1B negatively regulates leptin signalling. Other protein-tyrosine 
phosphatases also exist and are implicated in the negative regulation of leptin signalling, 
such as T cell protein-tyrosine phosphatase (TCPTP). TCPTP, like PTP1B, also 
dephosphorylates STAT3 inhibiting JAK2/STAT3 signalling (Figure 1.7) and 
furthermore STAT3 phosphorylation is enhanced in brain deficient TCPTP mice (Loh et 
al. 2011). Thus, the presence of additional negative regulators to SOCS3, play an 
important role in the regulation of leptin signalling.  
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Figure 1.7 Schematic diagram of the negative regulation of leptin signalling by 
PTP1B and TCPTP. 
Negative regulation of leptin signalling occurs through directly inhibition of 
JAK2/STAT3 signalling by negative regulators PTP1B and TCPTP. PTP1B 
dephosphorylates JAK2 and TCPTP dephosphorylates STAT3 resulting in blockage of 
JAK2/STAT3 signalling. 
Figure adapted from Ashford Lab teaching material.  
 
1.5.1.2 Leptin resistance 
A problem arises in obesity, where the majority of individuals have high circulating levels 
of leptin, leading to the notion of leptin resistance (Considine et al. 1996). This is 
supported by the diminished response to leptin observed in diet-induced obese (DIO) 
mice compared to genetically obese ob/ob mice (Halaas et al. 1995; Halaas et al. 1997). 
The precise mechanisms underlying the development of leptin resistance are unknown, 
however there are two proposed mechanisms associated with, and likely responsible for, 
leptin resistance; defects in leptin transport across the BBB and/or impaired leptin 
receptor signalling in the hypothalamus.  
A proposed state of peripheral versus central leptin resistance supports the concept that a 
reduction in transport of leptin across the BBB is causative in the development of leptin 
resistance. A longitudinal study examined this and showed that following 8 weeks on a 
high-fat diet (HFD) mice develop leptin resistance and are unresponsive to peripherally 
administered leptin, however at the same time point centrally administered leptin 
stimulated a reduction in food intake (Van Heek et al. 1997). Similarly, El-Haschimi et 
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al demonstrated leptin levels increase in response to HFD and that following 4 weeks on 
a HFD peripheral leptin treatment evokes an increase in STAT3 (El-Haschimi et al. 2000). 
However, at 15 weeks on a HFD this response was diminished unless leptin was 
administered centrally where activation of STAT3 still occurred, which supports the 
notion there is reduced leptin entering the CNS. Furthermore, it has been found that the 
ratio of CSF to leptin levels is reduced in obesity (Banks 2001). 
Although, El-Haschimi and colleagues demonstrated that DIO mice remain sensitive to 
centrally administered leptin, they found this response was still diminished in comparison 
to mice fed a normal chow (NC) diet (El-Haschimi et al. 2000). This supports the idea 
that reduced transport of leptin into the CNS is not solely responsible for the development 
of leptin resistance and is suggestive a second signalling mechanism may be involved. A 
defect in leptin signalling is thought to occur via STAT3, but how this arises is largely 
unknown. One proposed mechanism is through the leptin receptor, as leptin receptor 
mRNA and protein levels are reduced in rodent models of leptin resistance (Martin et al. 
2000) suggesting leptin resistance may be due to downregulation of leptin signalling at 
the receptor level. This proposed mechanism was supported by Wilsey and Scarpace, who 
found DIO rats have reduced leptin receptor expression, as well as elevated basal STAT3 
levels, and central administration of leptin was unable to recover these effects (Wilsey & 
Scarpace 2004). Interestingly, the ARC appears to be the only hypothalamic site to 
become leptin resistant, with a reduced leptin-activated STAT3 response only observed 
in the ARC of mice challenged with a HFD, with expression remaining normal in other 
sites (Münzberg et al. 2004). This is in line with a signalling defect contributing to leptin 
resistance as the ARC is the main site of leptin action and STAT3 activation.  
As mentioned, one of the negative regulators of leptin signalling; SOCS3, inhibits JAK-
STAT3 signalling and in turn blocks the body weight effects of leptin, therefore enhanced 
SOCS-3 expression presents a possible mechanism for leptin reisstance. As leptin levels 
rise, or in a state of leptin resistance, SOCS3 expression is elevated (Bjørbæk et al. 1999) 
and this is observed in genetically obese (Shi et al. 2004) and DIO mice models 
(Münzberg et al. 2004). The elevated SOCS3 expression observed in DIO mice is more 
specifically associated with higher basal mRNA levels in the ARC (Enriori et al. 2007), 
which appears to affect AgRP neurons in the first instance, preceding leptin resistance in 
POMC neurons, which ultimately occurs after chronic high-fat feeding (Olofsson et al. 
2013). Importantly, supporting the association between SOCS3 and leptin resistance, 
Enriori et al show that DIO mice with elevated basal SOCS3 expression do not respond 
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to leptin treatment, whereas SOCS3 mRNA expression is upregulated in the ARC of 
control mice (Enriori et al. 2007). Chronic low-grade inflammation is also associated with 
obesity, resulting in increased levels of pro-inflammatory cytokines. Importantly, 
inflammation also increases SOCS3 expression, which may further exacerbate an 
obese/leptin-resistant state (Zeyda & Stulnig 2009b). In vitro, Chinese hamster ovary 
(CHO) cells exposed to chronic leptin treatment to induce leptin resistance, show elevated 
SOCS3 expression and additionally cells transfected with SOCS3 have a direct blockage 
of leptin signalling via JAK2 (Bjørbæk et al. 1999). Furthermore, mice deficient in 
SOCS3 display increased STAT3 activation in response to leptin with a concomitant 
elevation in POMC expression, resulting in reduced body weight gain when compared to 
WT littermates on a HFD (Mori et al. 2004). Moreover, SOCS3-deficient mice are 
protected against diet-induced obesity and resulting leptin resistance, providing further 
evidence for SOCS3 as a potential contributor of defective leptin signalling.  
PTP1B is also believed to be key in the development of leptin resistance, due to it also 
negatively regulating leptin signalling. Following chronic leptin treatment in rats, or 
models of DIO, PTP1B protein levels become elevated in the hypothalamus, exacerbating 
and contributing to leptin resistance (White et al. 2009). In addition, PTP1B null mice 
have an elevated STAT3 response following leptin and are also resistant to diet-induced 
obesity (Zabolotny et al. 2002). Subsequent studies demonstrated mice with a PTP1B 
deficiency, specifically in the brain, have reduced body weight and adiposity, increased 
leptin sensitivity and energy expenditure, as well as improved glucose homeostasis 
(Bence et al. 2006), which provides further evidence for PTP1B to be implicated in the 
development of central leptin resistance. Interestingly, when PTP1B is deleted solely 
from POMC neurons, the same phenotype is observed; reduced fat mass, increased energy 
expenditure and heightened leptin sensitivity (Banno et al. 2010), suggesting PTP1B may 
specifically alter leptin signalling on the melanocortin system. Furthermore, additional 
negative regulators of leptin signalling may also be implicated in the development of 
leptin resistance, as shown by increased levels of TCPTP in obese mice (Loh et al. 2011). 
Loh and colleagues also demonstrated that both in vitro in CHO cells and in vivo in mice 
that leptin increases TCPTP levels and the observed elevation in TCPTP is associated 
with obesity and is likely driven by hyperleptineamia (Loh et al. 2011). Thus, targeting 
of negative regulators of leptin signalling may provide a therapeutic strategy for the 
reversal of leptin resistance in obesity.  
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1.5.2 Insulin 
The hormone insulin is also key in the regulation of energy homeostasis and was the first 
adiposity signal described (Porte et al. 2002; Niswender & Schwartz 2003) Insulin is a 
small protein produced and secreted from pancreatic β-cells acting predominantly to 
control glucose homeostasis by stimulating glucose uptake into peripheral tissues 
(adipose tissue, liver, skeletal muscle) allowing for glucose to be stored or utilised as a 
fuel when required (Heide et al. 2006). To do this, insulin reduces the breakdown of lipids 
in adipose tissue, particularly white adipose tissue (WAT), blocks gluconeogenesis in the 
liver, and increases glucose uptake in skeletal muscle (Zeyda & Stulnig 2009a). These 
actions occur when insulin binds its receptor and stimulates translocation of the glucose 
transporter, Glut4, from the cytoplasm to the plasma membrane. Although insulin is 
predominantly found in the pancreas, both the protein and its receptor are also found in 
the CNS, thus insulin has the ability to infiltrate the CNS across the BBB (Arora & 
Anubhuti 2006). Although insulin is transported into the CNS there is little evidence of it 
being produced there, and it may act through its receptors in the brain once transported 
across the BBB. Like leptin, within the brain insulin is thought to mediate anorexigenic 
effects. In fact, it is believed that both leptin and insulin are required in conjunction to 
mediate whole body energy homeostasis and that the signals generated by both hormones 
interact and are likely coupled by PI3K. Evidence for this includes investigations in the 
ob/ob mouse, where administration of leptin results in a marked decrease in insulin levels 
and glucose concentrations (Harris et al. 1998). In addition, insulin administration in rats 
causes an increase in STAT3 phosphorylation which mediates the main action of leptin 
(Kim et al. 2000). It has also been demonstrated that leptin can mimic insulin actions in 
vitro, again via the PI3K pathway. Kellerer and colleagues found stimulating C2C12 
muscle myotubes with insulin and leptin both induced PI3K activity (Kellerer et al. 1997), 
thus this may link the insulin and leptin signalling pathways to one another in order to 
control energy homeostasis. 
Insulin, like leptin, is thought to mediate its anorectic effects via the melanocortin system. 
When insulin is administered centrally in fasted mice there is an increase in POMC and 
a concomitant reduction in food intake (Air et al. 2002; Benoit et al. 2002). Work by 
Benoit and colleagues found the majority of POMC neurons within the ARC are co-
localised with a subunit of the insulin receptor, however notably not all neurons 
containing the insulin receptor were POMC neurons (Benoit et al. 2002). Furthermore, 
Air et al found the increased POMC following central insulin treatment also caused 
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reduced body weight gain and adiposity in mice when challenged with a HFD (Air et al. 
2002). When insulin binds its receptor there is recruitment of the IRS proteins, which are 
fundamental for insulin signalling. In particular IRS1 and IRS2 play an important role in 
insulin signalling and are expressed centrally in neurons (Arora & Anubhuti 2006). The 
anorectic effects of insulin may be mediated in particular by IRS2, as Burks et al found 
IRS2 null mice display increased food intake, increased body weight and adiposity, and 
elevated circulating leptin levels (Burks et al. 2000). Due to the effects observed on 
feeding behaviour and insulin action in response to fasting, it is unsurprising that NPY is 
also a target of insulin. When insulin mimetics are administered, following fasting, NPY 
is reduced, attenuating the fasting-induced increase in NPY and AgRP in the 
hypothalamus (Air et al. 2002). Additionally, in diabetic and obese rodent models 
centrally administered insulin improves the phenotype by reducing NPY and AgRP 
expression (Sipols et al. 1995; Dunbar et al. 2005). Therefore, not only is the melanocortin 
system a target of insulin action but it may also mediate NPY/AgRP pathways in the ARC 
to regulate catabolic affects.  
1.5.2.1 Insulin signalling 
Insulin carries out its functions via two signalling cascades; the aforementioned PI3K 
pathway and the MAPK pathway. The MAPK pathway principally regulates cell growth, 
differentiation and cell death mechanisms, whereas the PI3K pathway is the predominant 
pathway regulating glucose uptake affects and, as mentioned in conjunction with leptin, 
mediates food intake. Thus, the PI3K pathway is intricately involved in the regulation of 
energy homeostasis.  
The insulin receptor is a tetramer which consists of two extracellular α-subunits and two 
intracellular β-subunits (Heide et al. 2006). Insulin binds the α-subunits which results in 
phosphorylation of tyrosine residues on the β-subunits, and in turn recruits IRS proteins. 
It is the recruitment of the IRS proteins and their subsequent phosphorylation which 
allows for the binding and activation of PI3K (Figure 1.8). This activation involves the 
most common form of PI3K, including p85 and p110 (Niswender & Schwartz 2003). The 
phosphorylated sites on the IRS proteins bind to a SH2 domain on p85 which allows for 
the activation of p110 and thus PI3K stimulation. When PI3K is activated this causes the 
conversion of phosphatidylinositol (4,5) bisphosphate (PIP2) to phosphatidylinositol 
(3,4,5) triphosphate (PIP3) allowing for the phosphorylation of the main downstream 
target of PI3K signalling; protein kinase B (PKB) (Niswender & Schwartz 2003). PKB 
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allows for insulin induction of glucose transporters and thus increased glucose uptake, 
therefore activation of the IRS-PI3K cascade is crucial for the majority of insulin action. 
However, within the hypothalamus relatively little is known about the specifics of insulin 
signalling. Activation of PKB results in phosphorylation of a member of the forkhead 
transcriptional factor subfamily; forkhead box O1 (FoxO1), which is implicated in the 
regulation of the food intake actions of insulin (Nakae et al. 2008). FoxO1 signalling is 
required for leptin and insulin anorectic actions, as increased expression in the 
hypothalamus inhibits anorexigenic effects by increasing food intake and body weight 
(Kim et al. 2006). Kim et al demonstrated that FoxO1 drives NPY and AgRP expression, 
whilst inhibiting action of POMC neurons by directly anatagonising STAT3 (Figure 1.8) 
(Kim et al. 2006). The precise neurons FoxO1 acts upon is yet to be defined, however the 
melanocortin system may be the predominant target, as FoxO1 ablation in POMC neurons 
only results in reduced food intake and body weight (Plum et al. 2009). This further 
supports that both insulin and leptin are required, likely via P13K-FoxO1 signalling, to 
mediate feeding behaviour.  
Although insulin stimulates PI3K activity via IRS1 and IRS2, leptin only stimulates PI3K 
via IRS2, as well as JAK2 (Kellerer et al. 1997). Therefore, JAK2 and IRS2 may be 
responsible for the coupling of leptin and insulin, and thus the combined effects on 
metabolism. Due to the convergence between insulin and leptin in the hypothalamus the 
development of insulin and leptin resistance may also be coupled by a common 
mechanism, which could be due, in part, to reductions or defects in PI3K signalling 
(Niswender & Schwartz 2003). 
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Figure 1.8 Schematic diagram showing the convergence of insulin and leptin 
signalling controlling neuropeptide expression. 
Leptin and insulin both activate PI3K signalling through activation of IRS1. PI3K 
activates PIP3 and subsequent phosphorylation of PKB, further phosphorylating 
FOXO1. FOXO1 directly inhibits the anorexigenic action of JAK2/STAT3 leptin 
signalling. 
Figure provided from Ashford Lab teaching material. 
 
1.5.2.2 Insulin resistance 
In obesity target tissues become insensitive to the effects of insulin, leading to insulin 
resistance. Obesity is the main risk factor for insulin resistance, as insulin levels correlate 
with body weight and are elevated in an obese state (Bagdade et al. 1967). When there is 
an impairment in insulin sensitivity, causing insulin resistance, free-fatty acids (FFAs) 
increase and glucose uptake is obstructed exacerbating an obese phenotype through 
impaired glucose homeostasis. This phenotype is observed in IRS1 null mice which 
display insulin resistance and are in a state of hyperglycaemia (Araki et al. 1994). 
Additionally, mice lacking IRS2, specifically in neurons, also display impaired glucose 
homeostasis (Choudhury et al. 2005). Furthermore, HFD induces insulin resistance 
(Dresner et al. 1999), which again exacerbates obesity, and is associated with other co-
morbidities such as diabetes. The precise mechanism causing central insulin resistance is 
not fully defined, however like leptin resistance, it is proposed that it develops due to 
reduced transport into the CNS and/or defects in brain, specifically hypothalamic, 
signalling.  
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Little is known regarding insulin transport into the CNS, however as insulin receptors are 
present in the hypothalamus it is likely that a reduction in insulin binding to central 
receptors may account for reduced insulin sensitivity. More is understood regarding 
defects in insulin signalling. Opposed to tyrosine phosphorylation, serine phosphorylation 
of IRS proteins can occur, which leads to blockage of insulin signalling. Such kinases 
that cause this serine phosphorylation are I kappa B kinase-β (IKK-β), C-jun N-terminal 
kinase (JNK1) and MAPK (Zeyda & Stulnig 2009b), which are all activated by insulin. 
This forms a negative feedback loop, whereby increasing levels of insulin occurring in 
obesity may elevate the activity of these kinases and further attenuate insulin signalling. 
Chronic inflammation, associated with obesity, also contributes to insulin resistance as 
pro-inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-
6 (IL-6) can also interfere with insulin signalling. This is supported by the finding that 
TNFα knock-out mice display protection from insulin resistance (Uysal et al. 1997). This 
inflammation particularly affects peripheral tissues; primarily the adipose tissue and liver. 
The adipose tissue produces a large number of pro-inflammatory cytokines and 
chemokines, and in mice it has been shown that body mass correlates with macrophage 
expression, therefore in obesity there is increased adipose tissue derived macrophages 
(ATMs) (Weisberg et al. 2003). This rise in ATMs are potentially crucial in obesity-
induced inflammation and in turn will contribute to insulin resistance. As mentioned, 
inflammatory processing also affects the liver. Hepatic steatosis is another factor 
associated with obesity, and this drives inflammatory processing through nuclear factor-
kappa B (NF-κB) which further exacerbates insulin resistance (Zeyda & Stulnig 2009b). 
In support of this, Wunderlich et al demonstrated that in mice where NF-κB is inactivated 
specifically in the liver there is improved glucose homeostasis and increased insulin 
sensitivity, even when challenged with a HFD (Wunderlich et al. 2008). However, the 
definitive role of liver macrophages in the development of insulin resistant is not fully 
defined yet, although the contribution to obesity-induced inflammation is a major 
contributing factor. The precise cause for this obesity-induced inflammation is unknown, 
although one proposed mechanism is through the development of endoplasmic reticulum 
(ER) stress. Obesity increases ER stress, as shown by an upregulation of ER stress 
markers in the adipose tissue and liversof obese mice (Ozcan et al. 2004). This elevation 
in ER stress markers induces inflammatory signalling via JNK and NF-κB, which inhibits 
insulin signalling through the serine phosphorylation of IRS1. Furthermore, Miller and 
colleagues found that ER stress reduces Glut4 mRNA expression in an adipocyte cell line 
32 
 
 
 
(Miller et al. 2007), thus blocking insulin action. Subsequent studies showed this 
inhibition of insulin signalling could be reversed, as Ozcan et al showed that the 
application of chaperones that reduce ER stress, in obese mice, cause increased insulin 
signalling and sensitivity in the liver and adipose tissue through increased tyrosine 
phosphorylation of IRS1 (Ozcan et al. 2006). In addition, in a separate study Ozcan and 
colleagues inhibited JNK activity in obese mice and found this reversed the ER stress-
induced serine phosphorylation of IRS1 (Ozcan et al. 2004). Therefore, ER stress may be 
causative in obesity-induced inflammation and thus drive the progression of insulin 
resistance.  
Due to the combined actions of leptin and insulin it is likely a mutual mechanism between 
both peptides may exist. This common mechanism potentially involves the negative 
regulators of leptin signalling, SOCS3 and PTP1B. Pro-inflammatory cytokines, as well 
as insulin itself, increase SOCS3 levels (Shi et al. 2004), and this may in turn contribute 
to insulin resistance. Additionally, elevated SOCS3 in response to inflammation leads to 
degradation of IRS proteins (Zeyda & Stulnig 2009b) and furthermore SOCS3-deficient 
adipocytes have increased PI3K activity is observed via inhibition of IRS degradation 
(Shi et al. 2004). PTP1B, on the other hand, is not only a negative regulator of leptin 
signalling but is known to attenuate insulin signalling. PTP1B dephosphorylates IRS 
proteins, in the same way JAK2 is dephosphorylated in leptin signalling, resulting in 
inhibition of insulin signalling (Yip et al. 2010; Chernoff 1999). Furthermore, PTP1B is 
also driven, like SOCS3, by inflammation and, as previously mentioned, is elevated in an 
obese state (White et al. 2009), thus this may contribute to the progression of insulin 
resistance. In addition, PTP1B deficient mice show enhanced phosphorylation of the IRS 
proteins in response to insulin and have heightened sensitivity to insulin, reversing an 
insulin resistant phenotype (Elchebly et al. 1999). These data provide evidence indicating 
that SOCS3 and PTP1B are potential targets for not only leptin resistance, but also insulin 
resistance, with these two outcomes of obesity sharing common mechanisms.  
1.5.3 Additional peripheral peptides 
Although leptin and insulin are key in the regulation of energy homeostasis other 
peripheral peptides exist which also play essential roles. Key examples include the 
orexigenic acting hormone ghrelin and the satiety signal peptide YY (PYY), which are 
both released from the gut (Figure 1.9). PYY belongs to the same family of peptides as 
NPY, acting to control food intake through negative regulation of NPY (Arora & 
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Anubhuti 2006; Sobrino Crespo et al. 2014). Peripheral administration of PYY in both 
mice (Challis et al. 2003) and humans (Batterham et al. 2003) reduces food intake and 
furthermore levels of PYY are low in obese individuals (Batterham et al. 2003). Similarly, 
ghrelin acts to inrease appetite via direct action on NPY and AgRP neurons, antagonising 
the actions of leptin (Arora & Anubhuti 2006). Ghrelin levels fall during feeding and 
elevate during periods of fasting (Ariyasu et al. 2001) and central administration of the 
hormone causes increased food intake and consequently body weight (Tschöp et al. 
2000).  
Other satiety signals exist which signal the feeling of fullness during a meal and marks 
the period of time between meals. Thus, these peptides are involved in short-term 
processes mediating food intake rather than altering adiposity signalling which results in 
obesity. Examples include glucagon-like peptide 1 (GLP-1), oxyntomodulin (OXM) and 
cholecystokinin (CCK) that are found in the gut, and others include amylin from the 
pancreas, and bombesin.  
1.6 Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is a disease characterised by the body’s inability to 
make sufficient amounts of insulin or when insulin that is produced does not function 
normally. This results in a constant state of hyperglycaemia and an inability to handle 
glucose efficiently. T2DM accounts for 85-95% of all diabetes, mostly occurring in 
people over the age of forty; however the number of children diagnosed is rising 
(www.diabetes.org.uk). As mentioned, a principle factor responsible for T2DM is insulin 
resistance, and therefore the increasing prevalence is closely associated with obesity. The 
underlying mechanisms associated with obesity such as chronic low-grade inflammation, 
particularly in adipose tissue and liver, and ER stress thus contribute to the progression 
of insulin resistance and T2DM. In regards to obesity, the rise in T2DM particularly in 
the younger population can likely be attributed to lifestyle factors such as less physical 
activity and consumption of a HFD. Combatting such factors by leading a healthier 
lifestyle can aid prevention of T2DM and obesity or delay the onset of T2DM, however 
often diagnosis is at a later stage when damage has already ensued. Therefore, effective 
treatments of T2DM and contributing metabolic disease are required. 
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Figure 1.9 Schematic diagram of the main pathways between the CNS and the 
periphery. 
First order neurons in the ARC sense signals from peripheral tissues and organs through 
peripheral peptide release. Major signals include adiposity signals leptin and insulin, 
from adipose tissue and the pancreas, and satiety signal peptide YY (PYY) and 
orexigenic signal ghrelin from the stomach. First order ARC neurons receive these 
signals project to second order neurons which form anabolic and catabolic pathways 
projecting to the NTS, in the brainstem. The NTS also receives signals from the vagus 
nerve and the sympathetic nervous system forming part of the circuitry controlling 
energy balance. 
Figure provided from Ashford Lab teaching material. 
 
1.7 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, accounting 
for the majority of dementia cases worldwide. Dementia currently affects 850,000 people 
in the UK, which is expected to rise over 1 million by 2025, and double by 2050. This 
places a huge burden on society as at present, in the UK, it is estimated to cost the 
economy over 24 billion pounds per year (www.alzheimersresearchuk.org). 
AD is characterised by progressive memory loss and cognitive decline, with a number of 
associated pathologies including neuronal dysfunction and death particularly in the 
hippocampus and the cortex. Neuronal loss in these brain regions is thought to occur long 
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before classical symptoms are observed (O’Brien & Wong 2011). Alois Alzheimer noted 
two pathologies post-mortem associated with the disease in 1907; intracellular 
neurofibrillary tangles (NFTs) and neuritic plaques (Alzheimer et al. 1995). 
Consequently, these are recognised as the hallmark pathologies associated with AD, and 
both are required for definitive diagnosis of the disease, however are only achievable 
post-mortem. As a result, a great deal of research has focused on the contribution of these 
pathologies on the progression of AD, and research into methods to detect early diagnosis 
of AD.  
1.7.1 Neurofibrillary tangle pathology 
NFTs are tangles of paired helical filaments (PHFs) and are a pathology found not only 
in AD but many neurodegenerative diseases. In AD, the PHFs collect as bundles of 
tangles and surround the neuritic plaques; the other hallmark pathology of the disease. 
The main component of the PHFs was found to be the microtubule associated protein; tau 
(Grundke-Iqbal et al. 1986). Tau is predominantly localised to neurons and is involved in 
the assembly and stability of the microtubules present in neurons, and does so through 
phosphorylation (Iqbal et al. 2005). The NFTs in AD are due to accumulation of 
hyperphosphorylated tau, and this tau pathology is also observed in other 
neurodegenerative diseases which, in all cases, causes degeneration and dementia 
symptoms. It has also been found that abnormal phosphorylation of tau can occur in the 
cytosol in AD, and thus may occur prior to PHF accumulation and presence in the tangles 
(Kopke et al. 1993).  
1.7.2 Amyloid plaque pathology 
The neuritic plaques observed in AD brains consist of neuronal processes surrounding a 
distinct protein within its core, which was discovered to be amyloid-β (Aβ); a 4.2kDa 
peptide (Glenner & Wong 1984). Glenner and Wong utilised microscopy with congo red 
staining which allowed visualisation of amyloid fibres within these neuritic plaques. The 
Aβ protein was further purified and characterised from the plaques by other groups, and 
found to be approximately 40 amino acids in length and present in AD and Down’s 
syndrome (DS) brains (Masters et al. 1985). According to the ‘Amyloid Cascade 
Hypothesis’ proposed by Hardy and Higgins in 1992, the presence of this Aβ protein is 
the predominant cause for AD pathology and progression (J. Hardy & Higgins 1992). 
This model states that Aβ is toxic and its generation leads to the formation of NFTs and 
subsequent neuronal death. Following its identification as the component of the 
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extracellular plaques Alois Alzheimer described in 1907, Aβ was shown to be the product 
of the amyloid precursor protein (APP) gene which is found on chromosome 21 (Kang et 
al. 1987). 
1.7.3 Amyloid precursor protein 
As mentioned, Aβ is a product of the proteolysis of APP (Kang et al. 1987). APP is a 
transmembrane protein, which is a member of a family of related proteins including APP 
like protein 1 and 2 (APL1 and APL2) (O’Brien & Wong 2011), however only APP itself 
generates the formation of Aβ. Alternative splicing of APP results in eight isoforms of 
the protein, with the three most common being a 695, 751 and a 770 amino acid forms 
(APP695, APP751 and APP770) (O’Brien & Wong 2011). These isoforms are expressed 
throughout many tissues, APP751 and APP770 in particular are ubiquitously expressed 
whereas APP695 is predominantly found within neural tissue in the CNS (Sinha & 
Lieberburg 1999).  
1.7.3.1 APP processing 
Owing to the fact APP generates Aβ, which is considered the causative factor in the 
pathogenesis of AD, the processing of APP has been well studied (Sathya et al. 2012; 
Stockley & O’Neill 2008; Sun et al. 2012; Vassar et al. 2009b). APP can be processed 
down two distinct pathways; the non-amyloidogenic pathway and the amyloidogenic 
pathway, under the control of three protein secretases; α, β and γ (Figure 1.10). The 
preferential pathway, utilised under normal circumstances, is the non-amyloidogenic 
pathway, which is under the control of the α-secretase(s). APP is cleaved by the α-
secretase at amino acid positions 16 and 17 resulting in the production of a secreted APP 
derivative (sAPPα) and a short C-terminal fragment 83 amino acids in length (C83). A 
sequential cleavage then occurs of C83 by a γ-secretase which generates a non-toxic 3kDa 
peptide (p3) and a cytoplasmic APP intracellular domain (AICD). The initial α-secretase 
cleavage of APP occurs within the Aβ domain, thus under normal circumstances this 
precludes Aβ production. 
Through the amyloidogenic pathway APP is first cleaved by the β-secretase at two sites; 
methionine position 671 and aspartic acid position 672. This cleavage generates a secreted 
APP derivative (sAPPβ) and a longer membrane C-terminal fragment; 99 amino acids in 
length (C99). A subsequent cleavage of C99, again via the γ-secretase releases the mature 
form of Aβ predominantly 40 amino acids long (Aβ40), as well generating AICD in the 
cytosol. This final cleavage step by the γ-secretase is heterogeneous and as a result forms 
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Aβ of varying lengths, which in some cases results in a form 42 amino acids in length 
(Aβ42). The production of Aβ42 is considered to be toxic and leads to the pathologies 
associated with AD (J. A. Hardy & Higgins 1992). 
  
 
 
Figure 1.10 Scehmatic diagram showing the non-amyloidogenic and amyloiogenic 
pathways of APP processing. 
Preferentially APP is processed down the non-amyloiodgenic pathway involving α-
secretase cleavage giving rise to soluble APP derivative (sAPPα) and an 83 amino acid 
C-terminal fragment (C83). Subsequent cleavage by γ-secretase produces a non-toxic 
peptide (p3) and a cytoplasmic APP intracellular domain (AICD). Amyloiodgenic 
processing occurs through β-secretase cleavage forming a soluble APPβ derivative 
(sAPPβ) and a 99 amino acid C-terminal fragment (C99) and subsequent γ-secretase 
cleavage forms an AICD as well as the mature form of Aβ. The production of Aβ 
through this pathway is considered the causative factor for the symptoms observed in 
Alzheimer’s disease.  
 
1.7.3.2 Identification of the α–secretase 
The α-secretase is considered a zinc metalloproteinase and its activity has been attributed 
to a group of enzymes forming the a-disintegrin and metalloproteinase (ADAM) family. 
The ADAM family are type 1 integral membrane proteins which have multi-domain 
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structures consisting of a N-terminal signal peptide, a propeptide, a cleavage site, a 
catalytic domain, a cysteine rich domain, a hydrophobic domain and a short cytoplasmic 
domain (Allinson et al. 2003). In particular the activity of three members of the ADAM 
family are considered to mediate α-secretase activity; ADAM17, ADAM9 and ADAM10.  
ADAM17 is also referred to as TACE (tumour necrosis factor-α convertase) which is 
involved in the release of TNFα from TNF (Black et al. 1997). TACE is a glycoprotein 
which is found in areas of the brain affected by AD, expressed in neurons and co-localised 
with Aβ (Skovronsky et al. 2001). TACE inhibitors have been utilised to confirm its role 
as the α-secretase, demonstrating inhibition in primary neuronal cultures reduces α-
secretase activity (Blacker et al. 2002). ADAM9 was first isolated from mouse lung 
cDNA by Weskamp and colleagues (Weskamp et al. 1996) and is also considered to 
contribute to α-secretase activity. ADAM10 was isolated and sequenced by Howard and 
colleagues (Howard et al. 1996) and it has been shown that overexpression of this enzyme 
in HEK 293 cells results in increased α-secretase activity (Lammich et al. 1999). 
Conversely, transfection of a dominant negative form of ADAM10 causes a reduction in 
α-secretase cleavage (Lammich et al. 1999). ADAM10 is also expressed in neurons and 
in situ hybridisation (ISH) studies reveal that within these neurons there is co-expression 
with APP (Marcinkiewicz & Seidah 2000). Furthermore, this enzyme, in particular, is 
found to be reduced, as well as the sAPPα product, in AD platelets and CSF (Colciaghi 
et al. 2002). ADAM10 is considered to be the predominant α-secretase responsible for 
constitutive activity. This was supported by work from Kuhn and colleagues who 
knocked-down ADAM17, 9 and 10 in HEK293 cells and SH-SY5Y cells (a human 
neuroblastoma cell line) (Kuhn et al. 2010). They found that knocking-down ADAM9 
had no effect, ADAM17 caused a small reduction in APP processing in HEK293 cells but 
no affect in SH-SY5Y cells, whereas ADAM10 knock-down resulted in a reduction in 
APP processing and the production of sAPPα. This demonstrated ADAM10 is necessary 
for α-secretase activity in neurons and that ADAM9 and 17 cannot compensate for its 
loss. Interestingly, however, ADAM10 knock-out mice are embryonic lethal, due to a 
defect in notch signalling, however ADAM 9 and 17 are not affected and α-secretase 
activity is maintained (Hartmann et al. 2002). Similarly ADAM9 knock-out mice, 
although they show no developmental abnormalities, the α-secretase cleavage products 
are unchanged (Weskamp et al. 2002). This illustrates the necessity for not only one 
ADAM to act as the α-secretase, but rather multiple (9, 17 and 10) will act together to 
mediate α-secretase cleavage of APP.  
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1.7.3.3 Identification of the β-secretase 
As cleavage of APP by the β-secretase is considered the rate-limiting step in the 
production of Aβ a great deal of research focused on characterising this enzyme over the 
identification of the α- and γ-secretases. Many groups identified the transmembrane 
aspartic protease BACE1 (the β-site APP cleaving enzyme 1) as the β-secretase mainly 
due to it sharing the same characteristics. Vassar and colleagues were amongst the first 
groups to identify BACE1 (also known as Asp2) as the β-secretase utilising an expression 
cloning strategy whereby they found increased Aβ and C99 in HEK293 cells transfected 
with a BACE1 vector and overexpression of APP with the Swedish mutation (hAPPswe) 
(Vassar et al. 1999). Vassar and colleagues also showed high expression of BACE1 in the 
brain, predominantly in neurons and only low levels in glia, which is consistent with the 
β-secretase, a finding supported by other groups (Vassar et al. 1999; Zhao et al. 2007; 
Hussain et al. 1999). Others also confirmed BACE1 to share the same characteristics as 
the β-secretase and cleave APP at the same site using cloning and purification techniques 
(Sinha et al. 1999) and genomic screening of aspartic proteases (Hussain et al. 1999; Lin 
et al. 2000). Such characteristics include the structure and localisation of BACE1, as it is 
a type 1 transmembrane protein with an active site on the luminal side, which is where β-
secretase cleaves APP, and it is localised mainly to the golgi and the endosomes which is 
characteristic of the β-secretase (Vassar et al. 1999). In support of BACE1 being 
identified as the β-secretase it has further been shown that inhibition of BACE1 using 
antisense oligomers reduces Aβ release, levels of sAPPβ and C99, whilst increasing 
sAPPα levels (Yan et al. 1999). This reduction in β-secretase activity with a concomitant 
increase in α-secretase activity demonstrates the relationship between the two enzymes 
in which they compete for APP as a substrate and have opposing actions to one another. 
This is also observed when ADAM10 is overexpressed in neurons which results in 
enhanced α-secretase activity and reduced BACE1 cleavage (Postina et al. 2004). 
Interestingly, however, enzymes other than the α-secretase and BACE1 may account for 
a degree of APP processing as Kuhn et al found when both ADAM10 and BACE1 are 
inhibited in SH-SY5Y cells there is still APP secretion into the media (approximately 10-
15%) (Kuhn et al. 2010). Furthermore, BACE1 knock-out studies in mice have shown a 
deficiency in BACE1 results in reduced sAPPβ levels, increased sAPPα levels and Aβ 
secretion is abolished (Luo et al. 2001; Roberds et al. 2001; Cai et al. 2001). Such work 
validates BACE1 as the β-secretase and provides a potential target for therapeutic 
intervention in AD.  
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Soon after the identification of BACE1 as the β-secretase, a second aspartic protease 
BACE2 was discovered (Lin et al. 2000). The sequence and expression pattern of BACE2 
was analysed, revealing it shared a similar structure and 64% amino acid similarity to 
BACE1 (Bennett et al. 2000). Although BACE1 and BACE2 share similar homology they 
only share 40-44% similarity with other members of the pepsin family, presenting these 
two enzymes as a novel family of aspartic proteases. BACE2 also has the ability to cleave 
APP at the β-secretase site (Hussain et al. 2000), which raised the possibility of it also 
being the β-secretase. However, Bennett and colleagues found utilising northern blot 
analysis that BACE2 is expressed in most tissues with highest mRNA expression in adult 
tissues including the pancreas, kidney and stomach, however unlike BACE1, in the brain 
BACE2 expression is low (Bennett et al. 2000). Owing to the expression pattern in the 
brain is it unlikely that BACE2 acts as the β-secretase.  
1.7.3.4  Identification of the γ-secretase  
The γ-secretase has also been identified and studied as a potential therapeutic target in 
AD. However, the γ-secretase has many substrates other than just C99, including the 
notch receptor which controls cellular differentiation events, therefore modulation of this 
enzyme rather than inhibition provides a better therapeutic strategy. The γ-secretase has 
been identified as an enzymatic complex made up of four membrane proteins; presenilin 
1 or 2 (PS1/2), nicastrin, anterior pharynx-defective 1(Aph-1) and presenilin enhancer 2 
(Pen-2) (Wolfe 2008). Initially it was accepted that PS1 was responsible for γ-secretase 
activity, acting as the catalytic component, as Wolfe et al showed mutations of aspartate 
residues in PS1 reduce Aβ release (Wolfe et al. 1999). Similarly, Zhang and colleagues 
found knock-down of PS1 and PS2 in cells reduced Aβ levels (Zhang et al. 2000), arguing 
the presenilins are vital for γ-secretase mediated processing of APP. It was further found 
that other proteins interact with the presenilins to mediate γ-secretase cleavage, such as 
nicastrin which is a type 1 transmembrane glycoprotein which interacts with PS1 and 
plays a role in its mediation of APP processing (Yu et al. 2000). Latterly, Aph-1 and Pen-
2 were isolated and identified as novel presenilin enhancers which, like nicastrin, are 
necessary for γ-secretase activity (Francis et al. 2002). Although the identification of this 
protein complex as the γ-secretase has been found the precise structure and function is 
still relatively unknown and yet to be defined.  
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1.7.4 BACE1 characterisation 
Since its discovery as the β-secretase a large body of research has focussed on the 
characterisation of BACE1, in terms of its structure and regulation. BACE1 structurally 
consists of an N-terminal signal peptide sequence, a propeptide, a catalytic domain, a 
transmembrane domain and a cytoplasmic carboxy-terminal (Vassar et al. 1999). BACE1 
is a type 1 transmembrane protein of 501 amino acids, which is highly expressed in the 
pancreas and the brain. Studies utilising RT-PCR indicates 3 alternatively spliced BACE1 
transcripts are also present and expressed in the brain and pancreas involving deletions of 
25, 44 or 69 amino acids; creating BACE-457, BACE1-476 and BACE1-432 (Tanahashi 
& Tabira 2001). BACE1-501 is the mature form and has the greatest activity.  
It is well accepted within the literature that BACE1 responds to various cellular stresses 
and owing to this it is regulated predominately by posttranslational modifications. 
Consequently, substantial research has focussed on the trafficking of BACE1 and its 
regulation through these modifications. An immature form of BACE1; pro-BACE1, with 
a molecular weight of approximately 58kDa is synthesised in the ER, which rapidly 
undergoes maturation in the golgi apparatus (Vassar 2001). This stable and mature form 
of BACE1 runs on a gel at approximately 70kDa, which is a greater mass than predicted 
for the protein suggesting BACE1 undergoes glycosylation (Haniu et al. 2000; Capell et 
al. 2000). The maturation process of BACE1 involves cleavage of the propeptide once 
the protein exits the ER and is transported to the golgi and endosomes (Huse et al. 2000; 
Haniu et al. 2000). Usually aspartic proteases will shed the propeptide domain themselves 
via autocatalysis, however BACE1 contains a propeptide convertase (PC) cleavage site, 
in which a separate protease can remove the propetide domain (Benjannet et al. 2001). 
The main PC which promotes this reaction is Furin, which is localised in the golgi and 
has been to shown to be necessary for removal of the propeptide (Benjannet et al. 2001; 
Bennett, Denis, et al. 2000). Work by Benjannet and colleagues found by transfecting 
HEK 293 cells with a mutated form of BACE1 which lacks the propetide domain, that 
BACE1 remains in the ER, therefore the propeptide is essential for the exit from the ER 
and the beginning of the maturation process. Interestingly, this immature form has been 
shown to also have β-secretase activity, as Creemers et al found even upon removal of 
furin BACE1 activity was unaffected, showing the propeptide domain has some β-
secretase activity and Aβ could be produced in the ER (Creemers et al. 2001).  
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BACE1 contains four N-linked glycosylation sites, three of which undergo glycosylation, 
which has shown to be necessary for BACE1 activity (Huse et al. 2000; Haniu et al. 2000). 
This modification occurs within the ER and BACE1 is subsequently transported to the 
endosomal system. The requirement for glycosylation of BACE1 activity was 
demonstrated by Charlwood et al who utilised site directed mutagenesis to mutate the 4 
glycosylation sites in CHO cells and found reduced activity, confirming glycosylation is 
required for BACE1 activity (Charlwood et al. 2001). After glycosylation, BACE1 is 
recycled between the cell surface and the endosomes which, based on its long half-life 
(approximately 9 hours), is believed to occur many times. This was supported by work 
from Huse and colleagues who carried out staining on HeLa cells (a human epithelial cell 
line) transfected with BACE1 constructs and found BACE1 co-localised with endosomes 
and also present at the membrane (Huse et al. 2000). It is accepted that this trafficking of 
BACE1 to the endosomes occurs via internalisation at the cell surface. The process of this 
trafficking from the cell surface to the endosomes is, at least in part, under the control of 
Golgi-localised γ-adaptin ear containing ARF-binding (GGA) proteins (Tan & Evin 
2012). GGA3 in particular, which is processed during apoptosis, regulates BACE1 
activity by increased cleavage of GGA3 resulting in elevated BACE1 activity (Tesco et 
al. 2007). Furthermore, GGA3 as well as other GGA proteins have found to be reduced 
in AD brains, in turn correlating with increased BACE1 levels, highlighting the 
importance of the trafficking of BACE1 in AD progression (Tesco et al. 2007).  
The cytoplasmic tail of BACE1 is also crucial for its trafficking. Work by Capell and 
colleagues found that if BACE1 lacks this component of its structure it cannot be 
transported from the ER (Capell et al. 2000). Within the C-tail BACE1 contains six 
extracellular cysteine resides which form three disulphide bonds and a dileucine motif 
contributing to its unique structure and lack of homology with other pepsins (Vassar et 
al. 1999). Huse et al showed that deletions of the dielucine motif resulted in BACE1 
remaining at the membrane, therefore blocking endosomal trafficking (Huse et al. 2000), 
potentially via reduced internalisation. The C-tail is also targeted for posttranslational 
modifications. The cysteine residues present on BACE1 have been shown to be 
palmitoylated, in particular three of these sites (Benjannet et al. 2001), and it is believed 
that this process is necessary for trafficking. The generation of cysteine residue mutants, 
transfected in HEK 293 cells shows reduced palmitoylation (Benjannet et al. 2001). A 
small part of BACE can undergo ectodomain shedding, resulting in some soluble BACE 
and this is thought to be involved in amyloidogensis as overexpression of a soluble form 
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of BACE1 increased Aβ generation (Benjannet et al. 2001). Benjannet and colleagues 
also found that this generation of a soluble form of BACE is inhibited by palmitoylation, 
and the amount of shedded ectodomain released is reliant on the degree of palmitoylation.  
Another posttranslational modification involved in the regulation of BACE1, particularly 
at the C-tail, is phosphorylation. Walter et al found BACE1 undergoes phosphorylation 
exclusively at the C-tail end, and only to the mature form of BACE1 (Walter et al. 2001) 
Their studies also revealed that phosphorylation affected both the trafficking and 
localisation of BACE1, with phosphorylation occurring in the golgi, but a non-
phosphorylated form present at the endosomes. In close proximity to the dileucine motif 
is a serine 498 (ser498) site which has also been shown to undergo phosphorylation 
(Pastorino et al. 2002). Phosphorylation at this site also enhances GGA binding, 
mediating BACE1 for degradation (Wahle et al. 2005; Tesco et al. 2007). However, 
Pastorino and colleagues showed, using site directed mutagenesis, that this site doesn’t 
affect degradation, and BACE1 activity, whereas mutations of the dileucine motif 
increases BACE1 at the membrane suggesting this component of BACE1 regulates its 
internalisation.  
Lastly, BACE1 also undergoes acetylation during its regulation, specifically in the lumen 
of the ER (Costantini et al. 2007), which also affects its trafficking. Constantini and 
colleagues found BACE1 is acetylated on seven lysine residues within its N-terminal 
domain. Using CHO cells they also demonstrated that mutating these lysine residues, 
resulting in no acetylation, reduced transport from the ER, and observed the opposite with 
a constititutively acetylated form. As mentioned, this is exclusive to pro-BACE1 and is 
thought that deacetylation occurs in the golgi. 
The structure, trafficking and regulation of BACE1 mentioned above highlights its 
existence as a novel member of the pepsin family. Differences in structure to other 
members of the pepsin family is an important feature as such differences may affect 
substrate specificity of the enzyme. The role of posttranslational modifications in the 
trafficking and regulation of BACE1 are also important in allowing rapid responses to 
stress conditions and changes in this regulation may affect BACE1-mediated APP 
processing, resulting in elevated BACE1 levels and activity, and a concomitant increase 
in Aβ.  
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1.7.5 BACE1 in AD 
Owing to BACE1-mediated APP processing resulting in the release of Aβ, BACE1 is 
considered the rate-limiting step in Aβ production. Consequently, any elevations in 
BACE1 levels or activity is considered the primary causative factor for the symptoms 
associated with AD progression.  
In support of this, BACE1 mRNA, protein and activity have all been shown to be elevated 
in AD brains, in both human samples (Yang et al. 2003; Fukumoto & Cheung 2002; Li 
et al. 2004) and mouse models (Zhao et al. 2007). Importantly, this increase in BACE1 
correlates with increased Aβ42, and is thus considered causative of increased Aβ (Li et al. 
2004). Familial Alzheimer’s disease (FAD) also provides evidence for increased BACE1 
driving AD pathology as this form of AD is associated with the Swedish, APPswe, 
mutation which results in increased APP levels and elevated BACE1 cleavage (Vassar et 
al. 2009b). In addition, Tyler and colleagues found that a large proportion of sporadic AD 
brains have increased BACE1 activity, with a corresponding reduction of α-secretase 
activity below the normal level (Tyler et al. 2002). Interestingly, Harada et al showed 
BACE1 is specifically increased in surviving neurons in AD brains (Harada et al. 2006). 
In this study they found a reduction in staining of the neuronal marker MAP2 in AD 
brains, corresponding to the neuronal loss associated with AD, however observed an 
increase in the ratio of BACE1 to MAP2 suggesting increased BACE1 within individual 
neurons. Therefore increased BACE1 in surviving neurons may further drive AD 
progression.  
BACE1 appears to act as a cellular stress response protein, and elevations can occur due 
to many stress-related factors, which are in turn associated with AD. For example, 
oxidative stress is known to play a role in AD with oxidative species accumulating in AD 
brains. Furthermore it has been shown that oxidative stress products can modulate 
BACE1 (Tamagno et al. 2002). Tamagno and colleagues showed that neurons exposed to 
pro-oxidant stimuli increased BACE1 protein levels, particularly the mature form in 
which they found strong staining localised to the golgi. BACE1 may also be mediated by 
hypoxia, as the induction of hypoxic conditions in a neuroblastoma cell line expressing 
APP695 causes increased BACE1 protein and activity, with no change in α-secretase 
activity or APP levels (Zhang et al. 2007). In particular HIF-1 (hypoxia-inducible factor 
1), which is a transcription factor activated in response to hypoxia, may modulate BACE1 
activity. Zhang et al found neuron specific HIF-1 null mice showed reduced BACE1 in 
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the hippocampus and cortex; the two regions most affected by AD, and conversely 
reduced BACE1 levels were observed when cells where transfected with HIF-1 (Zhang 
et al. 2007). This study further revealed that there is a functional HIF-1 site within the 
mouse BACE1 promoter, suggesting HIF-1 has the ability to directly regulate BACE1 
activity. As well as oxidative stress and hypoxia, defective energy metabolism may also 
contribute to elevated BACE1 activity, as impaired glucose homeostasis is considered to 
be associated with AD (Vassar et al. 2009b). Work by Velliquette et al further supported 
this by demonstrating reduced energy metabolism in mice leads to increased BACE1 and 
Aβ levels (R. a Velliquette et al. 2005). Therefore disruptions in energy metabolism may 
also regulate BACE1 levels and contribute to AD pathogenesis.  
Events associated with a higher risk of developing AD such as stroke and traumatic brain 
injury (TBI) may also contribute to BACE1-mediated production of Aβ. Wen and 
colleagues generated a stroke model of transient cerebral ischaemia in rats and found that 
these animals showed a large elevation in BACE1 protein and activity (Wen et al. 2004). 
This study also demonstrated co-localisation between BACE1 and a TUNEL stain- 
utilised as a marker of apoptosis, in regions directly affected by the ischaemia. It has also 
been found that apoptosis alone, independent of stroke models, drives an increase in 
BACE1 activity (Tesco et al. 2007). Stroke is also associated with oxidative stress, thus 
this may also drive the large increase in BACE1 levels associated. Similarly following 
TBI, in rats, BACE1 mRNA is increased in the hippocampus and the cortex, and this 
increase is associated with BACE1 present in astrocytes rather than predominantly 
neurons (Blasko et al. 2004). Therefore, these types of chronic stress or traumatic events 
drive increases in BACE1 and thus this may account for their association in AD.  
Further evidence for BACE1 causing AD symptoms stems from work on DS tissue, which 
also shows a large increase in BACE1 protein levels in cortical regions (Sun et al. 2006). 
This is of particular interest as most DS patients develop AD due to abnormal APP 
processing. DS patients have two copies of the APP gene, as well as other alterations, on 
chromosome 21 resulting in increased sAPPβ and Aβ deposition giving rise to a 
phenotype alike that observed in FAD (Selkoe 1991). Sun and colleagues found that the 
ratio of mature to immature form of BACE1 is increased in DS brains and the mature 
form remains for an extended time in the golgi (Sun et al. 2006). This is suggestive that 
the increased Aβ detected in DS cortical regions and the association with AD may be in 
particular due to abnormal BACE1 trafficking.  
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This work provides evidence that BACE1 cleavage of APP is the causative factor for the 
symptoms observed in AD. The factors associated with increasing BACE1 levels, and 
thus contributing to AD progression, are also those associated with many other non-
communicable chronic disease states (e.g. obesity, T2DM and cardiovascular disease) 
and therefore creates greater risk of developing AD as a result of other co-morbidities.  
1.8 AD links with T2DM/obesity 
Obesity and T2DM are now widely considered to be risk factors for AD, with the diseases 
sharing many common features such as inflammation and insulin resistance (Yang & 
Song 2013).  
Population-based studies investigating BMI and dementia have demonstrated obesity as 
a risk factor for AD, with patients developing dementia presenting increased BMI 
(Gorospe & Dave 2007; Investigation 2015). Interestingly, however this has been shown 
to vary with age, with mid-life obesity increasing the risk of dementia, yet in late-life 
(>65 years) reduced BMI is actually a risk factor for AD (Fitzpatrick et al. 2009). This is 
supported by recent research suggesting obesity may actually be protective in regards to 
AD progression (Qizilbash et al. 2015). However, the precise reasons behind this are 
unknown, and could be due to changes in BMI occurring with age. Significantly, 
symptoms associated with obesity may be linked to AD years before the onset of clinical 
symptoms and a great deal of research still links obesity to AD. Diet-induced obesity has 
been shown to result in elevated Aβ40 and Aβ42 in triple transgenic AD mouse models 
(Julien et al. 2010). Additionally, APP has been found in abundance in adipose tissue, 
and is upregulated with obesity, along with the presence of Aβ40 and Aβ42 not only in the 
adipose tissue but also in ATMs (Lee et al. 2008). This expression correlates with pro-
inflammatory cytokines produced by the adipose tissue, as well as chemokines, which all 
contribute to the development of insulin resistance (Luchsinger & Gustafson 2009), and 
moreover, inflammation is an associated factor of AD. Wang and colleagues have shown 
that calorie restriction, utilised to reverse obesity and insulin resistance in Tg2576 mice, 
which develop amyloid pathology, prevents amyloid depositions in the brain and 
enhances α-secretase APP processing through increased ADAM10 levels (Wang et al. 
2005). Furthermore, a consequence of obesity is leptin resistance which may also be 
implicated in increasing BACE1 levels as under normal conditions leptin has been shown 
to reduce BACE1 expression (Marwarha, Dasari, Prabhakara, et al. 2010; G Marwarha et 
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al. 2014). Thus, in an obese-leptin resistant state this action of leptin may become 
impaired and BACE1 expression increase.  
People with AD are also at greater risk of having T2DM (Janson et al. 2004), with the 
two diseases sharing defects in insulin signalling, which can lead to cognitive impairment 
and neuronal death (Li & Hölscher 2007). Furthermore, insulin resistance associated with 
HFD in Tg2576 mice show increased Aβ levels and further cognitive impairments (Ho et 
al. 2004) Population-based studies in humans also demonstrate the link between AD and 
T2DM, with an increased prevalence of T2DM in patients with dementia (Biessels et al. 
2006). Insulin resistance is also associated with reductions in the insulin degrading 
enzyme (IDE) (Ho et al. 2004), which has been described to also target Aβ for 
degradation. This may be another potential mechanism linking T2DM to AD, as IDE 
deficient mice show reduced degradation of Aβ and a related increase in Aβ levels (Farris 
et al. 2003). Again, calorie restriction has been shown to attenuate this reduction in IDE 
associated with insulin resistance and enhance its expression (Wang et al. 2005).  
As mentioned, BACE1 is considered the primary causative factor in the progression of 
AD and elevations can occur via a number of stresses, including age, hypoxia, oxidative 
stress as well as factors associated with obesity and T2DM such as impaired glucose 
homeostasis and insulin resistance. Therefore these factors may elevate BACE1 leading 
to increased risk of AD, and specifically highlights the role of BACE1 in connecting 
obesity/T2DM with AD. Recent work from our lab supports this notion demonstrating 
that BACE1 deficient (BACE1-/-) mice have an improved metabolic phenotype (Meakin 
et al. 2012). Meakin et al found BACE1-/- mice are protected against DIO and have 
improved glucose homeostasis and insulin sensitivity. Furthermore, pharmacological 
inhibition of BACE1 on a skeletal muscle cell line has shown to enhance glucose uptake 
and insulin signalling (Meakin et al. 2012; Hamilton et al. 2014). This work provides the 
potential for BACE1 to be a novel therapeutic target for not only AD, but obesity and 
T2DM. However, the precise role of BACE1 in energy metabolism remains yet to be 
defined.  
The current literature highlights a clear link between AD and factors associated with 
metabolic disease. Worryingly the prevalence of such diseases as obesity and T2DM are 
increasing rapidly due to the more modern lifestyle many now live, and therefore there is 
a drastic need to investigate potential therapies for metabolic disease to prevent people 
entering old age with poorer health.  
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1.9 Project aims and hypotheses 
Taken together, there is a clear role of BACE1 not only in the processing of APP and 
progression of AD, but also in energy metabolism. Our hypothesis is that BACE1 may be 
acting as a sensor of metabolic stress in particular and once elevated acts to modify 
metabolic processes to enable the cell/tissue to recover to or withstand the initiating stress. 
Unfortunately, under chronic stress conditions the permanently raised BACE1 activity 
results in prolonged higher levels of Aβ, driving further increases in the initiating and 
other adverse stress events, such as oxidative and inflammatory stress, creating a vicious 
cycle. Thus, it is therefore crucial to investigate the role of BACE1 in whole body energy 
homeostasis, to define a potential physiological role outwith the actions of BACE1 
directly relating to AD.  
The main objective of this project was to therefore investigate the role of BACE1 in 
metabolic disease by studying the effects of pharmacological inhibition of BACE1 as a 
potential treatment strategy for obesity and T2DM. With this in mind, additionally the 
characterisation of BACE1 in the hypothalamus and its role in the neural circuitry 
regulating energy balance was investigated with regards to a role for BACE1 in whole 
body energy homeostasis.   
The knowledge from this research may allow for advancements in the treatment of obesity 
and T2DM, and provide the potential for BACE1 inhibitors to play a role in the 
therapeutic intervention of metabolic disease.  
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1.10 Objectives 
 Examine the effects of pharmacologically inhibiting BACE1 on obesity and 
T2DM 
o Treat diet-induced obese wild-type mice with BACE1 inhibitors and 
measure metabolic outcomes (body weight, food intake, body 
composition, glucose tolerance and insulin sensitivity). 
o Examine various tissues (hypothalamus, white adipose tissue, brown 
adipose tissue and skeletal muscle) using real-time PCR to investigate 
changes in gene expression of markers of leptin signalling, inflammation, 
and thermogenic programming following treatment with BACE1 
inhibitors. 
 Examine the effects of altering APP processing on metabolic disease 
o Challenge mice overexpressing a human APP mutation, which enhances 
BACE1-mediated processing, and wild-type littermates with a high-fat 
diet for 16 weeks and measure metabolic outcomes. 
o Treat wild-type mice, when challenged with a high-fat diet, with an α-
secretase (ADAM10) inhibitor and measure metabolic outcomes.  
 Characterise BACE1 expression in the hypothalamus 
o Use immunofluorescence staining to examine BACE1 expression in 
different regions of the hypothalamus.  
o Examine co-expression of BACE1 and known hypothalamic neuronal 
populations using immunofluorescence staining to determine the neuronal 
circuitry BACE1 is part of. 
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2.1 General 
2.1.1 Chemicals 
Ammonium persulfate (APS), bovine serum albumin (BSA), dimethyl sulphoxide 
(DMSO), ethylene glycol tetraacetic acid (EGTA), ethidium bromide, gluconic acid, 
glycerol, hydrogen peroxide (H202), methyl cellulose, β-mercaptoethanol, 
paraformaldehyde, phenylmethylsulphonyl fluoride (PMSF), sodium dodecyl sulphate 
(SDS), sodium orthovanadate, tetramethylethylenediamine (TEMED), TrisAcetate, 
Triton X-100 and Tween®20 were purchased from Sigma Aldrich. Chloroform, ethanol, 
glycine, hydrochloric acid, methanol, sodium chloride, sodium hyrodxide and sucrose 
were purchased from VWR. Bromophenol blue, D-glucose, isopropanol, n-butanol and 
tris(hydroxymethyl)aminomethane (TRIS) were purchased from Fisher. Citric acid was 
purchased from Fluka.  
2.1.2 Statistical analysis 
All data was expressed as mean  standard error of the mean. To make comparisons 
between groups standard unpaired two-tailed Student’s t-tests, one-sample Student’s t-
tests or repeated-measures two-way ANOVAs with Bonferroni post-tests were carried 
out, using GraphPad software (Prism5). A p0.05 value was considered statistically 
significant. Degree of significance was expressed as follows: *p0.05, **p0.01 and 
***p0.001. 
2.2 Animals 
2.2.1 Maintenance of animal lines 
All animal procedures were performed in accordance to Home Office guidelines under 
the project license PPL 60/4280 held by Michael Ashford and personal license PIL 
60/13320. Animals were maintained under a 12 hour light/dark cycle and at a controlled 
temperature (21°C), with free access to normal chow (NC) diet (7.5% fat, 75% 
carbohydrate and 17.5% protein by energy) (RM1 diet, Special Diet Services) and water. 
During high-fat feeding studies animals had free access to water and were fed a 45% high-
fat diet (HFD) (45% fat, 35% carbohydrate and 20% protein by energy) (824053; Special 
Diet Services) or a 60% HFD (58% fat, 25.5% carbohydrate and 16.4% protein by energy) 
(824054; Special Diet Service).  
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2.2.2 BACE1 knock-out mouse 
BACE1-/- mice were generated by GlaxoSmithKline and maintained on a C57BL/6J 
background in-house (Ninewells Hospital & Medical School, University of Dundee). 
Mice were generated where the β-galactosidase reporter gene (LacZ) is inserted within 
the BACE1 locus where it precludes BACE1 gene expression allowing identification and 
visualisation of BACE1 gene expression (Harrison et al. 2003).  
2.2.3 hAPPswe transgenic mouse 
Transgenic mice were generated to express all isoforms of the human amyloid precursor 
protein (APP) containing the Familial Alzheimer Disease (FAD) associated Swedish 
mutation K67ON/M671L (strain name: B6.129-Tg(APPsw)40Btla/Mmjax, stock 
number: 034831; Jackson Laboratories). Hemizygous mice have a two to three fold 
increase in endogenous APP levels. Mice were maintained on C57Bl/6J background.  
2.2.4 RIP-cre transgenic mouse 
Transgenic mice carrying the RIP-cre transgene which contains a 668bp fragment of the 
rat insulin II promoter, cre recombinase and a 2.1kb fragment from the human growth 
gene were generated (strain name: B6. Cg-Tg(Ins2-cre)25Mgn/J, stock number: 003573; 
Jackson Laboratories). The resulting transgene is expressed in the pancreatic beta cell and 
in areas of the hypothalamus. Mice were maintained on a C57BL/6J background in-house. 
RIP-Cre transgenic mice were crossed with Z/EG mice, expressing GFP upon cre-
mediated excision, allowing visualisation of RIP-cre expression. Whole brains were 
kindly provided by Dr. Mark Smith, Imperial College London. 
2.2.5 POMC-GFP transgenic mouse 
Mice were generated to express enhanced green fluorescent protein (EGFP) in the mouse 
POMC promoter/enhancer regions (strain name: C57BL/6J-Tg (POMC-EGFP)1Low/J, 
stock number: 009593; Jackson Laboratories). Fluorescence is detected in neurons within 
the hypothalamus, pituitary, medulla and in a proportion of cells in the dentate gyrus of 
the hippocampus. Mice were maintained on a C57Bl/6J background. Whole brains were 
kindly provided by Professor Lora Heisler, University of Aberdeen.  
2.2.6 Neuropeptide Y-GFP transgenic mouse 
Mice were generated expressing the tau (MAPT)-sapphire green fluorescent protein 
(GFP) under transcriptional control of the mouse NPY promoter (strain name: B6.Cg-Tg 
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(NPY-MAPT/Sapphire)1Rck/J, stock number: 008321; Jackson Laboratories). 
Fluorescence is detected in neuronal populations within the arcuate nucleus of the 
hypothalamus. Mice were maintained on a C57BL/6J. Coronal brain sections were kindly 
provided by Professor Lora Heisler, University of Aberdeen.  
2.2.7 GAD67 transgenic mouse 
Knock-in mice expressing EGFP under control of the glutamic acid decarboxylase 67 
(GAD67) promoter were generated (Tamamaki et al. 2003), with GAD67 utilised as a 
marker of γ-aminobutyric acid (GABA). GFP expression is found throughout the adult 
brain in GABAergic neurons. Heterozygous mice with the GAD67-GFP allele were 
maintained on a C57BL/6J background. Mice were kindly provided by Dr. Delia Belelli, 
Division of Neuroscience, University of Dundee.  
2.2.8 Vglut2-ires-cre transgenic mouse 
Knock-in mice were generated expressing cre recombinase in excitatory glutamatergic 
neuronal cell bodies (strain name: Slc17a6tm2(cre)Lowl/J, stock number: 016963; Jackson 
Laboratories). Cre expression is detected in areas including the thalamus, paraventricular 
nucleus and ventromedial hypothalamus. Mice were maintained on a C57BL/6J 
background. Vglut2-ires-cre mice were crossed with Z/EG mice, expressing GFP upon 
cre-mediated excision, allowing visualisation of Vglut2 expression. Whole brains were 
kindly provided by Dr. Mark Smith, Imperial College London.  
2.2.9 SF-1-cre transgenic mouse 
Transgenic mice were generated to express cre recombinase in steroidogenic factor-1 
neurons (strain name: Tg (Nr5a1-cre)7Lowl/J, stock number: 012462; Jackson 
Laboratories). Cre expression is detected in the ventromedial hypothalamus, the pituitary, 
gonad and adrenal tissue. Mice were maintained on a C57BL/6J background. SF-1-cre 
transgenic mice were crossed with Z/EG mice, expressing GFP upon cre-mediated 
exicision, allowing visualisation of SF-1 expression. Whole brains were kindly provided 
by Dr. Mark Smith, Imperial College London. 
2.2.10 Genotyping of animals by PCR 
Polymerase-chain reaction (PCR) amplification of DNA and relevant primers (Table 2.1 
and Table 2.3) was performed in order to genotype mouse lines. Once weaned mice were 
ear-notched for identification and the ear-notch collected for DNA extraction. DNA 
extraction was achieved by pre-mixing 100µl of extraction buffer (E7526; Sigma) with 
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25µl of tissue preparation solution (T3073; Sigma), with care taken to ensure the sample 
was fully submerged. Samples were vortexed and incubated for 10 minutes at room 
temperature, followed by a 3 minute incubation at 95°C. 100µl of neutralisation buffer 
(N3910; Sigma) was added, the sample vortexed and placed on ice. Extracted DNA was 
stored at -20°C until required for PCR. DNA was amplified using Novagen® KOD Hot 
Start Polymerase kit (71086; Merck Millipore), with relevant primers for the mouse line 
being genotyped (as detailed in Table 2.1 and Table 2.3). 
 
Primer Sequence 5’→3’ 
LacZ forward GAC CAG CCC TTC CCG GCT GTG CCG 
LacZ reverse GCC GAC CAC GGG TTG CCG TTT TCA 
BACE1-/- forward CGC TGC ACT GGC TCC TGC TAT GGG 
BACE1-/- reverse TCT CCA CAT AGT CCT GGC CGG 
Table 2.1 Primer sequences used for genotyping BACE1-/- mice. 
 
2.2.10.1 Genotyping of BACE1-/- mice 
Primer sequences (Sigma Aldrich) required for genotyping of BACE1-/- mice are shown 
in Table 2.1. Two PCR master-mixtures were prepared (Table 2.2) using the Novagen® 
KOD Hot Start Polymerase kit, one containing LacZ primers and one containing BACE1 
primers (Table 2.1). 5µl of extracted DNA and 45µl of PCR master-mix was added to 
two PCR tubes (Star Lab) and placed in a Veriti® 96-well Thermal Cycler machine 
(Applied Biosystems) using an approximately 45 minute cycle protocol shown in Table 
2.4. PCR products were mixed with loading dye (G2101; Promega) and ran on an 
ethidium bromide infused 1% agarose gel, with a DNA ladder (G1881; Promega) for 
reference. PCR products were ran at 120V for approximately 35-40 minutes in Tris-
acetate-EDTA (TAE) buffer (T9650; Sigma). The gel was imaged with a GeneFlash 
Imager (Syngene Bioimaging) by exciting the ethidium bromide stained DNA under a 
UV light. These two reactions allow detection of the LacZ gene (299 kDa band) and the 
BACE1 gene (200 kDa band) respectively, and the genotype of the animals is determined 
by the presence or absence of these bands. A wild-type (WT) mouse was identified by the 
absence of a LacZ band, a BACE1-/- mouse identified by the absence of a BACE1 band 
(BACE1 has been replaced by LacZ) and a heterozygote mouse identified by the presence 
of both bands present (only one BACE1 allele has been replaced by LacZ). 
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Component Volume (BACE1-/- mice) Volume (hAPPswe mice) 
KOD 10x buffer 5µl 5µl 
25 mM MgSO4 3µl 3µl 
dNTPS (2mM each) 5µl 5µl 
Nuclease-free water 29.5µl 26µl 
KOD Taq 1µl 1µl 
Primers BACE1 fwd 0.75µl Tg fwd 1.5µl 
LacZ fwd 0.75µl Tg rev 1.5µl 
BACE1 rev 0.75µl WT fwd 1µl 
LacZ rev 0.75µl WT rev 1µl 
Table 2.2 PCR master-mix components and volumes required for genotyping of 
BACE1-/- and hAPPswe mouse lines. 
 
2.2.10.2 Genotyping of hAPPswe mice 
Primer sequences required for genotyping hAPPswe mice (Jackson Laboratories) are 
shown in Table 2.3. A PCR master-mix was prepared (Table 2.2) using the Novagen® 
KOD Hot Start Polymerase kit, containing WT and transgenic (Tg) primers (Table 2.3). 
Using a similar methodology as described above, 5µl of extracted DNA and 45µl of PCR 
master-mix was added to PCR tubes and placed in a PCR machine. PCR protocol cycle 
performed is shown in Table 2.4. Obtained PCR products were ran on an agarose gel and 
visualised. The reaction detects a WT band at approximately 200kDa and a Tg band at 
approximately 84kDa molecular weight.  The WT band serves as a control and the 
presence of a Tg band indicates a transgenic hAPPswe mouse. 
 
Primer Sequence 5’→3’ 
oIMR6938 (Tg fwd) CTT CAC TCG TTC TCA TTC TCT TCC A 
oIMR6939 (Tg rev) GCG TTT TTA TCC GCA TTT CGT TTT T 
oIMR8744 (WT fwd) CCA ATG TTG CTT GTC TGG TG 
oIMR8745 (WT rev) GTC AGT CGA GTG CAC AGT TT 
Table 2.3 Primer sequences used for genotyping hAPPswe mice. 
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 BACE1-/- Mice hAPPswe Mice 
Step Temperature  Duration Temperature  Duration 
Polymerase 
activation 
95°C 2 min 95°C 180 sec 
Denaturation 95°C 20 sec x35 95°C 30 sec x35 
Annealing 62°C 15 sec 67°C 30 sec 
Elongation 70°C 7 sec 72°C 30 sec 
Terminal 
Elongation 
/ / 72°C 300 sec 
Hold 4°C ∞ 4°C ∞ 
Table 2.4 PCR cycle details for genotyping of BACE1-/- and hAPPswe mouse lines. 
 
2.2.11  Intracerebroventricular (ICV) surgery  
Osmotic minipumps connected to brain infusion kits (Alzet®) were utilised to centrally 
deliver inhibitors in diet-induced obese (DIO) WT C57BL/6J mice. Minipumps were 
primed by filling the pump using a syringe and blunt ended needle (provided in pump kit) 
with compound or vehicle at 37°C for 40 hours, to allow the pump to equilibrate and 
reach a steady pumping rate. The pump was then connected to the brain infusion assembly 
(a cannula connected to the pump via a catheter), ready for implantation.  
Mice were anaesthetised using a combination of 5% isoflurane (Abbott Laboratories) and 
medical oxygen (BOC gases) delivered at a flow rate of 1.5-2L/minute via standard 
Boyle’s Apparatus (Fluovac, Harvard Apparatus). The correct level of anaesthetic was 
confirmed by an absence of foot reflexes. Mice were fitted into a nose cone delivering a 
1.5-2% concentration of isoflurane in oxygen to maintain anaesthesia during surgery. 
Mice were shaved and placed in a stereotaxic frame (Harvard Apparatus), with bars 
inserted into the external auditory meatus to prevent lateral head movements. Once 
secured in the frame the mouse was wiped with ethanol for sterility and a mid-line incision 
was made through the scalp, the area exposed and the skull thoroughly dried. The canula 
was lowered and pushed directly through the skull using the stereotaxic apparatus to target 
the lateral ventricle and secured into place using glue. The original incision was cut to the 
back of the skull and hemostats were inserted, gently opening and closing, to create a 
pocket in the back of the mouse. The minipump was inserted into the pocket, leaving 
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room for the catheter to move slightly and the incision closed using sutures. Mice were 
monitored regularly following surgery.  
All ICV surgery was performed by Dr. Paul J Meakin. 
2.3 Metabolic studies 
2.3.1  Inhibitor studies  
Unless otherwise stated, studies testing compounds were performed on WT C57BL/6J 
male mice (aged 8-10 weeks) fed a HFD for a period of 20 weeks to induce obesity. 
Compounds (Table 2.5) were administered via oral gavage, using gavage needles, or 
delivered by osmotic minipump connected to a brain infusion kit, as previously described 
(section 2.2.11). All studies were performed for a period of 28 days, during which time 
body weight and food intake measurements were taken daily. Where possible further 
measurements were carried out, including glucose and insulin tolerance tests and 
assessments of body composition. Mice were maintained on a HFD during the course of 
these studies and had free access to water at all times. 
 
Compound Compound Type Vehicle Dose Route of 
Administration 
AZ4217 
(AstraZenaca) 
BACE1 inhibitor Gluconic 
Acid 
50mg/kg Oral gavage (daily) 
Merck-3  
(In-house) 
BACE1 inhibitor DMSO 10mg/kg, Osmotic minipump 
(ICV surgery) 
AZ3839  
(In-house) 
BACE1 inhibitor Gluconic 
Acid 
43mg/kg Oral gavage (daily) 
GI254023X (In-
house) 
ADAM10 inhibitor DMSO 10mg/kg Osmotic minipump 
(ICV surgery) 
Table 2.5 Compounds, corresponding vehicles, dose and route of administration 
used during in-vivo metabolic studies. 
 
2.3.2  Glucose tolerance test 
Mice were fasted overnight prior to glucose tolerance testing. Fasted blood glucose levels 
were measured using a glucometer by extracting blood from the tail vein onto a glucose 
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measuring strip (Contour®, Bayer). D-glucose was administered at either 2mg/kg or 
1mg/kg (in PBS) via intraperitoneal (i.p) injection and blood glucose levels measured at 
15, 30, 45, 60 and 120 minutes post-injection using a glucometer. 
2.3.3  Insulin tolerance test 
Mice were fasted for four hours prior to testing and fasted blood glucose levels were 
measured using a glucometer, as previously described. Human insulin (Actrapid®, Novo 
Nordisk) was administered at 0.75IU/kg (in PBS) via i.p injection and blood glucose 
levels measured at 15, 30, 60, 90 and 120 minutes post-injection using a glucometer. 
2.3.4  Echo MRI scanning 
Body composition was assessed using a magnetic resonance analyser (Echo MRI™, Echo 
Medical Systems). Mice were weighed and placed in a cylinder tube to be inserted into 
the machine. Three repeat scans were taken resulting in a measurement of fat and lean 
mass. Raw fat and lean mass levels were analysed, and measurements were calculated as 
a percentage of total body weight.  
2.3.5  Blood biochemistry 
Animals were sacrificed by cervical dislocation, the head removed and blood collected in 
EDTA-coated tubes (Startedt AG & Co.). Whole blood was centrifuged at 3500 rpm for 
15 minutes at 4°C to separate plasma. Plasma samples were stored at -80°C until required. 
2.3.5.1 Leptin ELISA 
To measure the leptin concentration in serum samples a Mouse Leptin Quantikine® 
ELISA (R&D Systems) was used according to the manufacturer’s instructions. In brief, 
all components of the kit were allowed to equilibrate to room temperature prior to 
carrying out the assay. Assay diluent RD1W (50µl) and 50µl of sample (each ran in 
duplicate) were added to the 96-well microplate. Working leptin standards provided were 
also ran in duplicate. Solutions were mixed by gently tapping the frame of the plate for 
approximately 1 minute prior to incubation for 2 hours at room temperature. Wells were 
washed (5x) in 400µl of wash buffer, ensuring all liquid was removed each time. Mouse 
leptin conjugate (100µl) was added to each well and incubated for 2 hours at room 
temperature followed by repeating the washing step. Substrate solution (100µl) was 
added to each well and incubated for 30 minutes at room temperature, covered to protect 
from light exposure. The reaction was stopped by adding 100µl of stop solution, initiating 
a colour change from blue to yellow, and mixed by gentle tapping. The absorbance was 
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measured within 30 minutes on an EnVision® 2104 Multilabel Plate Reader (Perkin 
Elmer), measuring the absorbance at 450nm and subtracting the absorbance at 
540nm/570nm. The means of the absorbance of each sample was calculated and using the 
leptin standards a standard curve was plotted of mean absorbance against concentration, 
which allowed the concentration of leptin in samples to be calculated. 
2.3.5.2 Insulin ELISA 
To measure the insulin concentrations in serum samples an Ultra Sensitive Rat Insulin 
ELISA Kit (90060; Crystal Chem Inc.) was used according to the manufacturer’s 
instructions. In brief, the 96-well antibody-coated microplate was allowed to equilibrate 
to room temperature and 95µl of sample diluent and 5µl of samples added to wells, with 
all samples ran in duplicate. Working insulin standards provided were also ran in 
duplicate. The plate was covered and incubated for 2 hours at 4°C followed by washing 
(5x) in 300µl of wash buffer, ensuring all liquid was removed each time. Anti-insulin 
enzyme conjugate (100µl) was added to each well and incubated for 30 minutes at room 
temperature, followed by washing (5x) as before. Enzyme substrate solution (100µl) was 
added to each well and incubated for 40 minutes at room temperature, covered to protect 
from light exposure. The reaction was stopped by adding 100µl of enzyme stop solution 
to each well and the absorbance measured within 30 minutes on an EnVision® 2104 
Multilabel Plate Reader (Perkin Elmer). The absorbance at 450nm was measured and the 
absorbance at 630nm subtracted. The means of the absorbance of each sample was 
calculated and using the insulin standards a standard curve was plotted of mean 
absorbance against concentration, which allowed the concentration of insulin in serum 
samples to be calculated.  
2.3.6 In vivo leptin treatment 
Age-matched adult animals, fed a NC chow diet, were dosed with 4mg/kg leptin (498-
OB; R & D Systems) via i.p injection following an overnight fast. Animals were 
sacrificed by CO2 1 hour post leptin injection, and perfused fixed with 4% 
paraformaldehyde (PFA) in PBS. For perfuse fixation mice were deeply sacrificed by 
CO2, dissected to expose the heart and slowly flushed with 10ml PBS via the apex of the 
heart, until all blood ran clear, followed by 10ml 4% PFA. Whole brains were removed 
and processed for imaging studies, or the brains dissected and snap frozen for Western 
blot analysis.  
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2.4 Gene expression studies 
2.4.1 Tissue preparation 
Mice were sacrificed by cervical dislocation and tissues harvested. Tissue was snap frozen 
in liquid nitrogen and stored at -80°C until further use. Frozen tissue was transferred from 
-80°C to a tight-fit glass homogenizer and homogenised in 1ml of TRI Reagent (T9424; 
Sigma Aldrich). Tissue was homogenized on ice until a solution formed, which was 
subsequently transferred to a 1.5ml eppendorf and kept on ice Samples were stored at -
80°C until further use. 
2.4.2 RNA extraction 
Homogenised samples were transferred from -80°C to a 1.5ml eppendorf and allowed to 
stand at room temperature for five minutes. For white adipose tissue, samples were 
additionally centrifuged at 13000 rpm for 15 minutes to remove any fatty layer present 
before continuing. For phase separation 0.2ml of chloroform was added to each sample 
and shaken vigorously by hand. Samples were allowed to stand at room temperature for 
15 minutes before centrifugation at 12000 rpm for 15 minutes. This step separates the 
RNA into an aqueous phase which can be isolated by transferring the clear phase to a 
fresh eppendorf and adding 0.5ml isopropanol, mixing by inverting the tube. This was 
allowed to stand at room temperature for 10 minutes before centrifugation at 12000 rpm 
for 10 minutes, resulting in the RNA forming a pellet. The supernatant was removed and 
the pellet washed in 1ml of 75% ethanol. Samples were vortexed and centrifuged at 12000 
rpm for 5 minutes and the pellets air-dried for 7 minutes in a fume hood. Pellets were 
dissolved in 30l of nuclease-free water (Ambion) by repeated pipetting at 55-60C for 
15 minutes. Once dissolved the purity and concentration of RNA was measured using a 
NanoDrop ND-8000 Spectrophotometer and NanoDrop 8000 V.2.3.2 Software. 
Nuclease-free water was used to blank the machine and to measure samples 1.5l of total 
RNA was loaded. The concentration of RNA was measured in ng/µl at an absorbance of 
260nm and a purity ratio of ≥1.7 from a reading of 260/280nm was considered useable.  
RNA was stored at -80C until further use.  
2.4.3 cDNA synthesis 
RNA samples were converted to first-strand cDNA using a SuperScriptTM II RT kit 
(Invitrogen by Life Technologies; 10864-014). In brief, a mixture of random primers 
(1µl), total RNA (1µg), 10mM dNTP mix (1µl) and nuclease-free water (to a final volume 
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of 13µl) was incubated for 5 minutes at 65°C, briefly chilled on ice and vortexed. 4µl of 
5x first-strand buffer and 2µl of 0.1M DTT were added to the mixture and mixed gently 
before adding 1µl of SuperScript™ II RT, gently mixing by pipetting. The mixture was 
incubated for 1 minute at room temperature, followed by a 50 minute incubation at 42°C 
and the reaction stopped by heating the mixture to 70°C for 15 minutes. cDNA was 
diluted (1:10) with nuclease-free water to give a final concentration of 1µg in 200µl and 
stored at -20°C until required.  
2.4.4  Real-time PCR 
Real-time PCR was performed using Taqman gene expression assays (Applied 
Biosystems) which uses reverse transcription-PCR (RT-PCR) to detect specific genes and 
measure relative expression. A fluorescent FAM™ reporter dye is connected to the 
Taqman® probe which becomes released during the RT-PCR reaction and the resulting 
fluorescence is detected, ultimately measuring relative levels of the probe. A PCR 
reaction mixture (Table 2.6) for each DNA sample and gene of interest was added to a 
1.5ml eppendorf and mixed. 17.5µl of the reaction mixture was added to a 96-well plate 
(Nunc) and 2.5µl of DNA. The plate was spun briefly in a Centrifuge 5810R (Eppendorf) 
to collect the contents of the wells at the bottom and placed in a real-time PCR machine 
(7900HT; Applied Biosystems). The PCR cycle protocol used is shown in Table 2.7. The 
PCR machine generates a copy number which is used to calculate mRNA expression 
levels and this is normalised against actin as an endogenous control. Details of all probes 
used to identify genes of interest are shown in Table 2.8. 
 
Component Volume 
cDNA 2.5µl 
Mastermix (Applied Biosystems) 10µl 
Primer/Probe (Life Technologies) 1µl 
Nuclease-free water 6.5µl 
Table 2.6 Components of PCR reaction mixtures. 
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Step Temperature  Duration 
Initial 95°C 10 min 
Denaturation 95°C 15 sec x40 
Annealing 60°C 1 min 
Elongation 60°C 1 min 
Table 2.7 Real-time PCR cycle details. 
 
Probe Name Specificity Code  
Actin Mouse 4352663 
Arg-1 Mouse Mm00475988m1 
Cartpt (CART) Mouse Mm0048906_m1 
Dio2 Mouse Mm00515664_m1 
Emr1 (F4/80) Mouse Mm00802529_m1 
IFN- Mouse Mm01168134_m1 
IL-10 Mouse Mm00439614_m1 
IL-6 Mouse Mm00446190_m1 
IL1 Mouse Mm00434228_m1 
Leptin Mouse Mm00434759_m1 
Leptin Receptor Mouse Mm00440181_m1 
MCP-1 Mouse Mm00441242_m1 
MIP-1α Mouse Mm00441259_g1 
MIP-1β Mouse Mm00443111_m1 
NOS2 Mouse Mm00440488_m1 
NPY Mouse Mm03048253_m1 
POMC Mouse Mm00435874_m1 
Ppargc1 (PGC1) Mouse Mm01208835_m1 
Prdm16 Mouse Mm00712556_m1 
PTP1β Mouse Mm00448431_m1 
RANTES Mouse Mm01302427_m1 
SOCS3 Mouse Mm00545913_s1 
TGFβ-1 Mouse Mm01178820_m1 
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TNFα Mouse Mm00443260_g1 
UCP1 Mouse Mm01244861_m1 
UCP2 Mouse Mm00627597_m1 
UCP3  Mouse Mm00494077_m1 
YM-1 Mouse Mm00657889_mH 
Table 2.8 Summary of all Taqman probes used in present studies. 
 
2.5 Western blotting 
2.5.1 Tissue preparation 
Mice were sacrificed by cervical dislocation and tissues harvested. Tissue was snap frozen 
in liquid nitrogen and stored at -80°C until further use. Frozen tissue was transferred from 
-80°C to a tight-fit glass homogenizer (Fisher) and homogenized, as previously described 
(section 2.4.1), in 100-500µl (depending on tissue size) of lysis buffer (Table 2.12) added. 
The lysate was vortexed and centrifuged at 4°C for 15 minutes at 13000 rpm. The 
resulting supernatant was removed and transferred to a fresh eppendorf and stored at -
20°C. 
2.5.2 Determining protein content 
The protein content of samples was measured using a Bradford Assay (Bradford 1976). 
This involves Coomassie Blue G-250 forming a complex with proteins which causes a 
shift in the absorbance maximum of the dye from 465nm to 595nm. The resulting 
absorbance can be measured and indicates the amount of protein present in a sample. In 
brief, 1µl of sample and 9µl of distilled water are added to a 96-well plate (Nunc), 
followed by the addition of 250µl of Bradford Reagent (B6916; Sigma Aldrich). The 
colour was allowed to develop for approximately 15 minutes at room temperature and the 
plate ran on an EnVision® 2104 Multilabel Plate Reader (Perkin Elmer), measuring the 
absorbance at 595nm. Serial dilutions of BSA standards were also ran so a standard curve 
of absorbance against protein content could be plotted allowing the lysate concentration 
to be calculated.  
2.5.3 SDS-Page gel system 
Proteins within lysates were separated according to their molecular weight using Sodium 
Dodecyl Sulphate Polyacrylamide Gel electrophoresis (SDS-PAGE). Lysates (containing 
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10-20µg of protein) were prepared by adding distilled water and sample buffer (Table 
2.12) containing SDS, to add negative charges to the proteins, and Bromophenol blue, to 
allow visualisation of proteins as they move through the gel. A molecular weight marker 
(SeeBlue Plus2 pre-stained protein standard; Life Technologies) run alongside samples 
to identify the weight of proteins of interest.  
Proteins were separated using self-poured gels with BioRad gel casting equipment. Lower 
gel (Table 2.9) was poured into the casting equipment, which comprised of two glass 
plates held together tightly with plastic clips (BioRad), and topped with a layer of 50:50 
(v/v) solution of distilled water and n-butanol to straighten the top of the lower gel. This 
was allowed to set for approximately 15-30 minutes and once set the water:butanol 
solution was discarded, the gels rinsed with water and a stacking gel (Table 2.9) poured 
on top. 10- or 15-well plastic combs were placed within the stacking buffer, which 
contained a pinch of bromophenol blue for visualisation, and allowed to set for 
approximately 15-30 minutes. When set the combs were removed and electrophoresis 
performed in gel running tanks (BioRad) filled with 10x Tris-Glycine running buffer 
(National Diagnostics) in distilled water. Electrophoresis ran for approximately 1-2 hours 
at 150V.  
 
 Lower Gel Stacking Gel 
Component Volume (10% gel) Volume (4% gel) 
dH2O 6.2ml 4.2ml 
0.5M Tris (pH 6.8) 4.7ml 1.9ml 
30% Acrylamide 5.6ml 1.25ml 
10% SDS 165µl 75µl 
TEMED 16.5µl 8µl 
20% APS 83µl 75µl 
Table 2.9 Components of SDS-PAGE gels. 
 
2.5.4 Transfer of proteins onto nitrocellulose membrane for 
immunoblotting 
Once electrophoresis was complete the gel casts were removed and prised apart leaving 
the gel remaining on one of the glass plates. A blotting ‘sandwich’ was assembled 
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comprising of blotting sponges, filter paper (Whatman), the protein gel and a 
nitrocellulose membrane (GE Healthcare Life Sciences), which were all pre-soaked in 
transfer buffer (Table 2.12) prior to the assembly of the transfer module. The transfer 
cassette was assembled by placing blotting sponges on the white facing of the blotting 
cassette, followed by soaked filter paper. The nitrocellulose membrane was carefully 
placed on top of the gel avoiding the introduction of air bubbles, which was then flipped 
over and placed onto the filter paper and the glass plate removed. This was topped with 
another piece of soaked filter paper, rolled to remove any bubbles and another blotting 
sponge placed on top. The black facing of the cassette was then closed and the assembled 
cassette placed in a transfer tank (BioRad), along with an ice pack, filled with transfer 
buffer. Electrophoresis was run for 1 hour at 100V. Once the transfer was complete the 
cassette was removed and the membrane placed in a blotting dish and rinsed with tris-
buffered saline-tween (TBST). The membrane was stained with Ponceau S Stain (Sigma 
Aldrich) to ensure complete transfer of proteins onto the membrane. Membranes were 
then washed in TBST to remove ponceau staining.  
2.5.5 Immunoblotting 
To reduce non-specific antibody binding membranes were blocked, prior to immuno-
blotting, with 10% dried milk (Marvel™) in TBST for 1 hour at room temperature on a 
rocking platform. Membranes were briefly washed in TBST to remove any remaining 
milk and incubated in primary antibody (Table 2.10) made up in 5% BSA in TBST 
overnight at 4°C on a rocking platform. Following primary antibody incubation the 
membrane was washed (5x 5 minutes) in TBST on a rocking platform and blocked, again, 
in 4% BSA in TBST for 20 minutes at room temperature. Membranes were incubated in 
secondary antibody (Table 2.11) made up in TBST for 1 hour at room temperature on a 
rocking platform, followed by washing (5x 5 minutes) in TBST on a rocking platform. 
Membranes were placed in fresh TBST and stored at 4°C until imaging.  
2.5.6 Analysis 
Membranes were imaged on a Licor Odyssey Infrared Scanner and densitometry analysis 
perfomed on Image Studie Lite Version 4.0 (Licor). All protein expression was 
normalised against actin as an endogenous control.  
66 
 
 
 
2.6 Imaging studies 
2.6.1 Tissue preparation 
Mice were sacrificed by CO2 and perfused fixed, as previously described (section 2.3.6). 
Tissues were removed and post-fixed overnight in 4% PFA at 4°C and for 
immunofluorescence (IF) this was followed by 30% sucrose in PBS until the tissue sank 
or for immunohistochemistry (IHC) transferred to 10% neutral buffered formalin (v/v) 
(4% Formaldehyde) (NHS Tayside Tissue Bank) until required. For IF brain studies, once 
fixed, tissue was placed in a plastic mould with M-1 embedding matrix (Thermo 
Scientific) and frozen on a bed of dry ice and isopropanol. Once frozen, moulds were 
wrapped in parafilm and stored at -80°C. For fluorescent in situ hybridization (FISH) 
mice were sacrificed by CO2 and perfused fixed with 4% PFA (with 2mM EGTA). Brains 
were post fixed as previously described, and whole brains washed (2x10 minutes) in PBS 
(with 2mM EGTA) with gentle agitation on an orbital shaker at room temperature. Brains 
were then frozen and stored as previously described. 
2.6.2 Tissue sectioning 
For IF and FISH whole brains were sectioned using a cryostat 5040 Microtome (Bright). 
Frozen embedded brains were removed from moulds and glued onto a cryostat chuck 
using cryo-embedding compound (Bright). The chuck was placed in the cryostat, sprayed 
with cryo-spray (Bright) to quick freeze the cryo-embedding compound and left for 
approximately 20 minutes to equilibrate to the cryostat temperature (approximately -
20°C). For IF, sections were cut using microtome blades (Feather) 15-30µm in thickness 
and collected serially, using a paintbrush, in PBS. Sections were stored at 4°C in PBS 
until used, and for long-term storage were kept at -20°C in cryo-protectant solution (Table 
2.12). For FISH, sections were cut as previously described, 30µm in thickness, and 
collected serially in 50% EtOH in PBS. Sections were washed (1x 10 minutes) in fresh 
50% EtoH followed by washes (2x 10 minutes) in 100% EtoH. Sections were stored at -
20°C in 100% EtoH until used. Brains for all studies were sectioned coronally (unless 
stated) in accordance with The Mouse Brain in Stereotaxic Coordinates (Paxinos & 
Franklin, Second Edition) focussing on bregmas (approximately -1.22mm to -1.96mm) 
from the hypothalamic region. For IHC on peripheral tissue (white adipose tissue), 
samples were removed from neutral buffered formalin and processed overnight on a Leica 
Peloris II processor using an 8 hour xylene standard protocol (NHS Tayside Standard 
Protocol). Tissue was embedded in paraffin wax using a Tissue-Tek embedding centre 
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(Sakura), ready for sectioning into 4µm thick sections using a microtome (Leica RM 
2135). Sections were collected onto Superfrost® glass microscopic pulse slides (VWR) 
and dried for 1 hour at room temperature, before staining.  
For IHC samples were processed by Tayside Tissue Bank. 
2.6.3 Immunofluorescence on free-floating sections 
Where necessary antigen retrieval was performed to un-mask epitopes hidden during 
protein cross-linking (occurring due to PFA fixation). This involved pre-heating 10mM 
citric acid (pH 6.0) in 24-well plates (Nunc) to 80-100°C in an oven (Genlab) and placing 
tissue sections (1 section/well) in the heated citric acid for 30 minutes. Sections were 
cooled to room temperature in the acid. Following a quick wash in PBS sections were 
permeabilised, to allow antibody penetration through the tissue in 0.1% triton X-100 in 
PBS (PBST) for 1 hour on an orbital shaker. Sections remained on an orbital shaker for 
gentle agitation for the remainder of the protocol. To prevent non-specific binding of 
antibodies sections were blocked in 5% BSA in PBST for 1 hour prior to primary antibody 
incubation. Primary antibodies (Table 2.10) were diluted in blocking solution and 
incubated with sections overnight at 4°C. Following removal of primary antibodies 
sections were washed (5x 5 minutes in PBST) and, for single-labelling experiments, 
incubated in secondary antibody (Table 2.11) in PBST for 1 hour at room temperature. 
Sections were washed again (5x 5 minutes in PBST), followed by a final wash in PBS, to 
remove any remaining detergent, before mounting. Tissue sections were mounted onto 
glass microscopes slides (VWR International) with Vectashield anti-fade medium 
containing the nuclear marker 4’,6-diamidino-2-phenylindole (DAPI) (H-1200; Vector 
Laboratories). Glass coverslips were placed over the sections and sealed with nail varnish. 
For dual-labelling experiments sequential staining was performed whereby following 
removal of the primary antibody and washes a second primary antibody of a different host 
species was applied for another overnight incubation. The same method was adopted for 
secondary antibody incubation steps, whereby following removal of the first secondary 
antibody and washes a second secondary antibody was applied. Sections were mounted 
as described above and slides stored at 4° in the dark until imaged. 
For pSTAT3 staining a 3,3’ diaminobenzidine (DAB) staining protocol was performed 
using a Vectastain®Elite®ABC kit (PK-6100 Series, Vector Laboratories), an 
avidin/biotin blocking kit (SP-2001; Vector Laboratories) and a liquid DAB and substrate 
chromogen system (K3468; DAKO), prior to IF. First, antigen retrieval and 
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permeabilisation were performed, as previously described (section 2.6.3). Sections were 
incubated in 0.6% H202 in PBST, to block endogenous peroxidases, for 30 minutes and 
washed again (5x 5 minutes in PBST) before blocking. Sections were blocked in PBST 
with avidin solution (100µl/ml) and serum (15µl/ml) (provided in kit) for one hour prior 
to primary antibody incubation. pSTAT3 antibody (Table 2.10) was diluted in a blocking 
solution containing biotin solution (100µl/ml) and serum (15µl/ml) in PBST and 
incubated with sections overnight at 4°C. Following removal of primary antibody sections 
were washed (5x 5 minutes in PBST) and incubated with a biotinylated secondary 
antibody (5µl/ml) (provided in kit) in PBST with serum (15µl/ml) for 1hour. Sections 
were washed (5x 5minutes in PBST) and incubated in an Avidin/Biotinylated enzyme 
complex, prepared by mixing 2 drops from both solutions A and B (provided in kit) per 
5ml of PBST, 30 minutes prior to use to allow the solutions to form a complex, for 2 
hours at room temperature. Following removal of the complex sections were washed (5x5 
minutes + 1x 10 minute in PBST) and developed in DAB stain prepared at a concentration 
of 1:50 of DAB + chromogen (provided in kit) in DAB + substrate buffer (provided in 
kit) for 4 minutes. The DAB stain was removed and sections washed (5x 5 minutes + 1x 
10 minutes in PBST). For dual-labelling, IF was performed on the sections as previously 
described from the blocking stage.  
2.6.4 Immunofluorescence on paraffin-embedded sections 
Sections were heated at 60°C, in an oven, for 45 minutes, to remove paraffin then cooled 
to room temperature for 10 minutes. Sections were submerged in Histo-Clear™ III 
histological clearing agent (HS-204; National Diagnostics) for 20 minutes, followed by 
100% ethanol for 10 minutes and subsequently fresh 100% ethanol for 5 minutes. 
Sections were washed in distilled water for 10minutes before undergoing antigen 
retrieval, which was performed as previously described (section 2.6.3). Sections were 
permeabilised in 0.5% PBST for 1 hour and blocked in 5% BSA in 0.5% PBST for 1 
hour, both at room temperature before primary antibody incubation. Primary antibodies 
(Table 2.10) were prepared in blocking solution and sections incubated overnight in a 
humidified chamber at 4°C. The humidified chamber was removed and sections were 
allowed to equilibrate to room temperature for 10 minutes, before washing (2 x 10 
minutes) in PBS. Excess buffer was drained from the sections and incubated in secondary 
antibody (Table 2.11) prepared in 0.1% PBST for 1 hour at room temperature. Sections 
were washed (2 x 10 minutes) in PBS followed by a distilled water wash for 10 minutes, 
before dehydrated through a series of ethanol steps; 70% for 2 minutes, 90% for 2 minutes 
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and 2 x 5 minutes in 100%. Sections were air dried for approximately 30 minutes at room 
temperature before mounting as previously described (2.6.3).  
2.6.5 Fluorescent in situ hybridization (FISH) 
All FISH protocols were provided by and performed under the supervision of Dr Kim 
Dale’s Lab (School of Life Sciences, University of Dundee).  
2.6.5.1 Probe generation 
Primer sequences for POMC (151-850bp, Genbank: NM_008895.4) and NPY (101-
501bp, Genbank: NM_023456.2) were chosen, amplified and cloned in a pBluescript II 
Sk(-) plasmid by Dundee Cell Products. To generate antisense cRNA probes the plasmid 
was linearised using a BamHI restriction enzyme for 1.5 hours at 37°C. To confirm the 
digestion was successful and the product was the correct size, linearised DNA was ran on 
a 1% agarose gel in TBE electrophoresis buffer (1X). Linearised DNA was purified using 
a QIAquick® PCR Purification kit (28104; Qiagen) according to the manufacturer’s 
instructions. In brief, samples were diluted 1:5 with buffer (provided in kit) and added to 
columns in 2ml collections tubes (provided in kit) Samples were centrifuged for 
approximately 1 minute and the flow-through discarded. DNA was washed in 750µl of 
buffer and centrifuged and the flow-through discarded again, to ensure all wash buffer 
was removed. DNA was eluted by adding 50µl of buffer EB (provided in kit) and 
centrifuged as described. To ensure the purification was successful DNA was ran on a 
1% agarose gel, as previously described. The concentration of DNA was measured using 
a Nanodrop spectrophotometer and an in vitro transcription (IVT) carried out to synthesis 
the RNA. In brief, the IVT involved mixing 1µg of DNA, 4µl of transcription optimised 
5X buffer (P118B; Promega) , 2µl DTT (P117B; Promega), 2µl digoxigenin (DIG)-
labelling mix (11277073910; Roche), 2µl T7 RNA polymerase (P207B; Promega), and 
1µl RNase inhibitor, made up to a final volume of 20µl with nuclease-free water, and 
incubating this for 2 hours at 37°C. After the IVT the template DNA was cut using DNase 
and RNase (04716728001; Roche) and incubated for 1 hour at 37°C. The RNA was 
purified using a Purelink™ RNA Mini Kit (12183018A; Ambion) according to the 
manufacturer’s instructions. In brief, lysis buffer was added to samples to protect the 
RNA from degradation prior to the protocol. EtoH (70%) was added to each sample and 
vortexed. Samples were transferred to collection tubes (provided in kit) and centrifuged 
at 12000 rpm for 15 seconds. Flow-through was removed and the initial steps repeated 
before washing in 700µl of wash buffer I (provided in kit) and centrifuged again. Samples 
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were washed in 500µl of wash buffer II (provided in kit) with ethanol and centrifuged. 
The flow-through was discarded and wash steps repeated. The collection tube was then 
centrifuged at 12000 rpm for 1 minute to dry the RNA, before adding nuclease-free water 
and incubating at room temperature for 1 minute. Finally, samples were centrifuged at 
12000 rpm for 2 minutes to elute the RNA. To ensure the IVT and purification was 
successful the RNA was run on a 1% agarose gel as previously described. RNA was 
stored at -80°C until further use.  
2.6.5.2 FISH  
Tissue sections were removed from -20°C and rehydrated in 50% EtoH/PBS-0.1% 
Tween®20 for 10 minutes on a rocking platform, followed by washing (2x 10 minutes) 
in PBS-0.1% Tween®20. Sections were dissected under a dissecting microscope (Leica) 
to cut out the arcuate nucleus of the hypothalamic region, and the remaining section 
disregarded. Hypothalamic sections were treated with proteinase K (Roche) in PBST 
(20mg/ml) for precisely 8 minutes, carefully removed and rinsed in PBS-0.1% Tween®20  
before post-fixing in 4% HCHO + 0.1% glutaraldehyde in PBS-0.1% Tween®20  for 30 
minutes. After post-fixation sections were washed (2x 10 minutes) in PBST on a rocking 
platform, followed by a 10 minute wash in 1:1 PBST/exonic hybridisation mix (Table 
2.12) at 65°C. Sections were rinsed twice with exonic hybridisation mix before incubation 
in fresh exonic hybridisation mix for 2 hours at 65°C. This solution was then replaced 
with pre-warmed (65°C) exonic hybridisation mix with DIG-labeled RNA probes 
(80µl/ml) and incubated overnight at 65°C. The plate containing sections was taped 
around the edges to avoid evaporation during the incubation period. All probes were 
recovered and stored at -20°C for re-use and sections were rinsed twice in pre-warmed 
(65°C) exonic hybridisation mix and transferred to 12-well plates (Nunc) to increase 
washing volume. Sections were washed (3x 1 hour) with pre-warmed (65°C) exonic 
hybridisation mix followed by a 15 minute wash in 1:1 exonic hybridisation mix/ TBST 
(1x TBS + 0.1% Tween®20) at 65°C. Sections were rinsed twice in TBST at room 
temperature on a rocking platform, followed by a 30 minute wash in fresh TBST before 
incubation in blocking solution. Blocking solution contained 2% blocking buffer reagent 
(11096176001; Roche) and 20% heat treated goat serum (Life Technologies) in TBST, 
and sections were blocked for 2 hours at room temperature on a rocking platform. 
Following blocking, sections were incubated in anti-Dig-HRP antibody (11207733910; 
Roche) diluted in blocking solution (1:200) overnight at 4°C on a rocking platform. 
Antibody was removed and sections were rinsed in TBST (3x) at room temperature 
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followed by washing (3x 1 hour) in TBST on a rocking platform. Fluorescence was 
achieved using a TSA™ Plus Cyanine 3 System (NEL744001KT; PerkinElmer) which 
involved transferring sections to 1.5ml eppendorf tubes and incubating in 0.25ml 1x 
amplification buffer (provided in kit) for 1 minute. Amplification buffer was removed 
and recovered to make Fluorescein-TSA solution (1:50) (provided in kit), which was 
added to sections (250µl/tube) and incubated for 90 minutes on a rocking platform, 
covered in foil to protect from light. The TSA-solution was removed and sections were 
transferred back into 12-well plates and washed (3x5 minutes) in TBST on a rocking 
platform. Sections were incubated in 1% H202 in TBST for 45 minutes and washed (3x 5 
minutes in TBST, and 2x 5 minutes in PBST) on a rocking platform. For dual-labelling, 
IF was carried out as previously described from the permeabilisation stage. 
2.6.6 Immunohistochemistry 
Antigen retrieval and de-paraffinisation were performed on sections using a DAKO 
EnVision™ Flex Target Retrieval solution (high pH) in a DAKO PT Link machine. 
Staining was subsequently performed on a DAKO Autostainer Link48 machine using 
DAB staining and a Vectastain® ABC Elite IgG kit (Vector Laboratories). Staining with 
the ABC kit was performed as previously described (section 2.6.3). Sections were 
blocked in 10% avidin solution in normal rabbit serum for 20 minutes at room 
temperature followed by primary antibody incubation. Primary antibodies (Table 2.10) 
were made up in 10% biotin solution in normal rabbit serum and incubated for 30 minutes 
at room temperature. Sections were then incubated in a biotinylated secondary antibody 
for 30 minutes at room temperature prior to a 30 minute incubation in Vectastain® Elite 
ABC solution. Sections were then incubated with a DAKO substrate working solution as 
a chromogenic agent (as previously described) twice for 5 minutes at room temperature 
then counterstained with EnVision™ Flex hematoxylin stain. Between all steps slides 
were washed briefly in tris-buffered saline (TBS). Sections were stored at room 
temperature until imaging.  
Immunhistochemistry was performed by Tayside Tissue Bank. 
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Primary Antibody Species Dilution Source 
Actin Rabbit 1:1000 Sigma Aldrich 
BACE1 Rabbit 1:250 (IF), 
 1:1000 (WB) 
Sigma Aldrich 
BACE1 Rabbit 1:250 (IF) Genetex 
CD68 Rat 1:100 (IHC) AbD Serotec 
Insulin Guinea-pig 1:100 (IF) Abcam 
F4/80 Rat 1:100 (IHC) AbD Serotec 
GFAP Chicken 1:500 (IF) Millipore 
GFP Rabbit 1:200 (IF) Abcam 
GFP Mouse 1:200 (IF) Abcam 
GFP Chicken 1:200 (IF) Abcam 
Glucagon Mouse 1:100 (IF) Sigma Aldrich 
Leptin Receptor Sheep 1:10 (IF) In-house 
NeuN Guinea-pig 1:500 (IF) Millipore 
Perilipin Goat 1:200 (IF) Abcam 
pSTAT3 Rabbit 1:8000 (IF) Cell Signalling 
Table 2.10 Summary of all primary antibodies and concentrations used in the 
present studies. 
 
Secondary 
Antibody 
Dilution Source 
Alexa 488 1:500 (IF) Life Technologies 
Alexa 568 1:500 (IF) Life Technologies 
Alexa 594 1:500 (IF) Life Technologies 
Alexa 647 1:500 (IF) Life Technologies 
Alexa Fluor 680 (IR 
dye 700) 
1:10000 (WB) Life Technologies 
Alexa Fluor 790 (IR 
dye 800) 
1:10000 (WB) Rockland Inc. 
Cy3 1:250 (IF) Jackson ImmunoResearch 
Table 2.11 Summary of all secondary antibodies and concentrations used in the 
present studies. 
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2.6.7 Confocal Microscopy 
Fluorescent images were acquired using a laser scanning confocal microscope (Leica 
TCS SP5 II). Sections were scanned sequentially using 405 diode, Argon, HeNe 543 
and/or HeNe 633 lasers. Scanning was performed bi-directionally at 400Hz, with 
resolution set at 1024 x 1024 pixels for all images. Unless stated, Z-stack images were 
taken, scanning 0.4μm steps, at either x40 or x63 magnification using an oil-objective 
lens on Leica Application Software (LAS). Necessary controls where included, where 
primary antibodies where omitted and minimal fluorescence was observed to take into 
account non-specific binding. 
2.6.8 Light Microscopy 
IHC images were acquired using a light microscope (Leica AF600). Images were taken 
at x10 magnification using a dry-objective lens on LAS. Necessary controls were 
included, where primary antibodies were omitted and minimal staining was observed to 
take into account non-specific binding.  
2.6.9 Analysis 
Images were processed on Volocity (Perkin Elmer) and Photoshop CS4 (Adobe). In 
Volocity single plane images from Z-stacks were merged to give maximally projected 
images (as representatives) and scale bars added. In some instances the ‘remove noise’ 
Volocity function was applied to images with a high background, and the contrast 
enhancement tool utilised to adjust brightness and contrast. Snapshots of final images 
were acquired and additional brightness and contrast adjustments made on Photoshop. 
For cell counting, Z-stack images were analysed in Fiji Imaging Software. Cells were 
counted manually using the multi-pointer tool, and a cell was considered ‘co-localised’ 
where staining from both fluorophores was present in the same pixels or same cell in the 
individual plane. The maximum resolution of the confocal microscope is 200nm in the X 
and Y planes and 700nm in the Z plane, therefore in cell counting experiments co-
localisation is defined as an association between the two stains, whereby the sources of 
the staining are within this maximal resolution range, for example less than 200nm apart. 
Cell counting was carried out from multiple sections from different animals and the mean 
of the total cell count for each population, from all animals, was calculated. 
Cell counting analysis was performed by Christopher McGinley (DCAT Summer Project 
Studentship). 
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Solution Components Volume 
Cryoprotectant solution 
(protocol from 
www.ihcworld.com) 
Sucrose 300g 
Polyvinyl-pyrrolidone 
(PVP-40) 
10g 
Ethylene glycol 300ml 
0.1M Phosphate buffer Fill to 1L 
Exonix hybridisation mix 
(solutions supplied and 
made by Dr. J Kim Dale’s 
Laboratory) 
Formamide 500ml 
20X Saline Sodium Citrate 
(pH 5.0) 
65ml 
0.5M EDTA (pH 8.0) 10ml 
tRNA (20mg/ml) 2.5ml 
Tween-20 2ml 
20% SDS 5ml 
Heparin (50mg/ml) 2ml 
Milli Q water Fill to 1L 
Lysis Buffer (5x stock) Tris HCL (pH 7.4) 125mM 
NaF 250mM 
NaCl 0.5M 
EDTA 5mM 
EGTA 25mM 
NaPPi 50mM 
Triton X-100 5% (v/v) 
Lysis Buffer (1x) 
(supplements added at time 
of use) 
Sucrose 92mg/ml 
β-mercaptoethanol 1μl/ml 
1mM Sodium 
orthovanadate (pre-heated 
at 95°C for 5 minutes) 
2μl/ml 
1mM Benzamidine 1μl/ml 
0.1mM PMSF 1μl/ml 
Sample Buffer (4x) 0.5M Tris (pH6.8) 4ml 
Glycerol 3.2ml 
20% SDS 3.2ml 
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β-mercaptoethanol 1.6ml 
Bromophenol blue Pinch 
TBE Electophoresis Buffer 
(10X) 
(solutions supplied and 
made by Dr. J Kim Dale’s 
Laboratory) 
Tris Base 121.1g 
Boric Acid 61.8g 
EDTA 7.4g 
RNAse-free water Fill to 1L 
Transfer Buffer Tris Base 11.62g 
Glycine 5.86g 
Methanol 400ml 
dH2O 1600ml 
Tris-buffered Saline-
Tween (TBST) 
1M Tris HCL (pH 7.4) 40ml 
4M NaCl 74ml 
Tween-20 1ml 
dH2O Fill to 2L 
Table 2.12 Components of commonly used solutions in the present studies
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Chapter 3 
 
 
 
Pharmacological reduction of BACE1 
improves an obese and diabetic phenotype 
in mice 
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3.1 Introduction 
BACE1-mediated APP processing is considered the primary causative factor for the 
symptoms associated with AD. There are numerous APP mutations which lead to familial 
AD (FAD) in particular, all of which occur close to or within the β-secretase cleavage site 
and increase Aβ levels. However, the Icelandic (A673T) mutation, which occurs adjacent 
to the BACE1-cleavage site, and in very close proximity to a mutation responsible for 
FAD, is proven to be protective against the development of AD (Jonsson et al. 2012). 
Jonsson et al found carriers of the A673T mutation had improved cognitive function and 
reduced BACE1-mediated processing of APP. Owing to this BACE1 has become a key 
target in the investigation of therapeutic strategies for AD.  
Consequently, a large body of research has focused on blocking (or reducing) BACE1 
activity, and in turn preventing Aβ production, as a therapeutic approach for AD. BACE1-
deficient rodent models have been widely used to investigate this and many mouse lines 
have been developed, which demonstrate complete ablation or drastic reductions in Aβ 
levels. BACE1-/- mice are generally reported to be healthy, viable, fertile and display no 
phenotypic or genetic abnormalities (Roberds et al. 2001; Luo et al. 2001). Owing to this, 
the investigation into the development of small molecule BACE1 inhibitors has become 
a focus for AD treatment. However, as yet, the production of effective compounds is 
proving challenging due to low stability, oral availability, and difficulty in developing 
molecules small enough to cross the BBB (Citron 2004; Vassar 2014). A major concern 
related to BACE1 inhibitors currently in clinical trials is the lack of knowledge of 
potential side effects and whether complete removal or inhibition may be linked to 
mechanism based toxicities, corresponding with more recent reports of adverse effect in 
BACE1-/- rodent models. BACE1-/- mice have since been described to exhibit mild 
behaviour and cognitive problems, including deficits in learning and memory tasks (Laird 
et al. 2005), showing a less explorative and more anxious behaviour than WT littermates 
(Harrison et al. 2003), and sharing many common symptoms associated with 
schizophrenia (Savonenko et al. 2008). As well as the reported cognitive impairments in 
BACE1-/- mice there has been studies describing biological changes. These include reports 
of altered synaptic plasticity and reduced synaptic function (Laird et al. 2005), as well as 
observed hypomyelination and markedly thinner myelin sheath in comparison to WT 
littermates (Hu et al. 2006). This proposes a potential role for BACE1, not only in 
behaviour, but in myelination and synaptic functions- which are tightly controlled 
biological events. More worryingly, one report has demonstrated that BACE1-/- mice have 
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increased mortality rates (Dominguez et al. 2005), however not all BACE1-/- mouse 
models report this, and therefore not all variants will encounter this problem. 
Nevertheless, taken together current knowledge suggests complete inhibition could cause 
detrimental side effects and may not be a successful therapeutic intervention. Conversely, 
partial inhibition may be a positive approach, as it has been shown that only a 50% 
reduction in BACE1 activity leads to a small, but effective, decrease in Aβ (McConlogue 
et al. 2007) and that reduced BACE1 expression via lentiviral knock-down also 
demonstrates dampened APP processing and Aβ production (Singer et al. 2005). Notably, 
individuals carrying one copy of the Icelandic A673T mutation also show reduced Aβ 
levels (approximately 20% reduction) and have lifelong protection against AD (Vassar 
2014). Therefore, a partial reduction in BACE1 activity appears a more beneficial 
therapeutic strategy for the treatment of AD. 
BACE1 levels and activity can become elevated due to a number of stresses including 
age, hypoxia (Zhang et al. 2007), oxidative stress (Tamagno et al. 2002) and apoptosis 
(Tesco et al. 2007), as well as metabolic stress, where disruptions in energy metabolism 
have been shown to raise BACE1 levels (Velliquette et al. 2005). Consequently, the 
factors associated with obesity and T2DM such as impaired glucose homeostasis and 
insulin resistance, may increase BACE1 levels/activity and furthermore metabolic disease 
could be linked to, and potentially drive, the pathological processes underlying AD. This 
is supported by the growing body of research describing obesity and T2DM as risk factors 
for AD (Gorospe & Dave 2007; Janson et al. 2004; Biessels et al. 2006), with these 
diseases linked by many common features such as inflammation and insulin resistance 
(Yang & Song 2013). 
Despite having established a link between AD, obesity and T2DM, the precise role of 
BACE1 in energy metabolism is unknown. Work from our lab investigating the BACE1-
/- mouse from a metabolic perspective have shown that these animals are lean and more 
insulin sensitive than WT littermates. Importantly, when challenged with a HFD BACE1-
/- mice display resistance to diet-induced obesity, improved glucose homeostasis and 
increased energy expenditure compared to high-fat fed WT littermates (Meakin et al. 
2012). Furthermore, pharmacological inhibition of BACE1 has also been shown to 
improve glucose homeostasis. In vitro BACE1 inhibition increased muscle glucose 
uptake and insulin signalling, with over-expression of BACE1 producing the opposite 
effect (Meakin et al. 2012; Hamilton et al. 2014). Meakin et al also demonstrated that 
BACE1+/- mice share the same beneficial effects as BACE1-/- mice (Meakin et al. 2012). 
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Additionally, recent work from our lab has tested a BACE1 inhibitor (Merck-3), in vivo, 
through peripheral administration in DIO mice over a 28 day period. This work showed 
Merck-3 reduces body weight and improves glucose homeostasis, although does not alter 
insulin sensitivity, over the course of treatment (unpublished data). Interestingly, these 
effects are only observed in DIO mice and not in mice fed a regular chow diet. 
Furthermore, peripheral treatment with Merck-3 also results in an elevated resting 
metabolic rate in DIO mice, increased expression of genes involved in thermogenic 
programming in both brown and white adipose tissue, and reduced high-fat diet driven 
inflammation. Taken together, this provides the potential for BACE1 inhibition to be a 
novel therapeutic strategy for not only AD, but obesity and T2DM. However, the precise 
role of BACE1 in energy homeostasis and the mechanism(s) responsible for its removal 
or reduction causing improvements in the metabolic disturbances associated with obesity 
and T2DM is unknown.  
The present studies aimed to investigate the effects of pharmacological inhibition of 
BACE1 in DIO mice. Different compounds and administration routes were investigated, 
examining various metabolic measurements, comparing the effects to those observed in 
BACE1-/- mice and peripheral Merck-3 treated mice. This chapter will also consider the 
potential mechanisms underlying the role of BACE1 in energy homeostasis, by 
examining peripheral and central tissues using real-time PCR to examine changes in gene 
expression that may allude to the potential mechanism(s) occurring. The knowledge from 
this research may provide insight into the role of BACE1 in energy homeostasis whilst 
providing potential for a novel therapeutic target for the treatment of obesity and T2DM.  
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3.1.1 Objectives 
 Test BACE1 inhibitors in vivo in DIO mice  and measure the following metabolic 
outcomes: 
o Changes in body weight and body composition 
o Changes in food intake 
o Changes in glucose homeostasis 
o Changes in insulin sensitivity 
 Test structurally different, peripherally acting, BACE1 inhibitors; AZ4217 and 
AZ3839 in DIO mice via oral gavage  
o AZ4217 is tested to directly compare to previous Merck-3 studies as both 
compounds have been reported to target BACE1 however are structurally 
different. AZ4217 is an orally active BACE1 inhibitor which has been 
shown to reduce Aβ levels in the plasma after a single dose and amyloid 
burden in the brain following repeated dosing in mice, with no reported 
adverse side effects (Eketjäll et al. 2013). 
o AZ3839 is tested as this compound completed a Phase 1 clinical trial for 
AD. AZ3839 is an orally active BACE1 inhibitor which reportedly crosses 
the BBB and reduces Aβ (Jeppsson et al. 2012).  
 Examine the effects of centrally inhibiting BACE1 in DIO mice using Merck-3 
(previously tested via peripheral administration) via central infusion through an 
osmotic minipump and brain infusion kit 
o Merck-3 is tested to investigate if BACE1 is acting via a central 
mechanism and it has been shown to cross the blood brain barrier 
(unpublished data). Merck-3 reportedly inhibits sAPPβ, increases sAPPα 
and reduces Aβ40/42 following central infusion (Sankaranarayananet al. 
2008). 
 Examine peripheral and central tissues following treatment with BACE1 
inhibitors to investigate changes in gene expression associated with: 
o White adipose tissue leptin expression 
o Hypothalamic leptin signalling 
o Thermogenic programming in brown and white adipose tissue and skeletal 
muscle 
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o Central (hypothalamic) and peripheral (white adipose tissue) 
inflammatory programming 
3.2 Methods Summary 
Wild-type adult mice (8 weeks of age) were fed a 45% HFD for a period of 20 weeks to 
be considered DIO. Animals were then administered BACE1 inhibitor (via oral gavage 
or central infusion directly into the lateral ventricle) for a period of 28 days. Throughout 
the study body weight and food intake measurements were taken daily. A glucose 
tolerance test was performed on day 14 of the study, following an overnight fast, and an 
insulin tolerance test was performed on day 21 following a four hour fast. An assessment 
of fat and lean mass was conducted at the beginning and end of the study. Throughout the 
study animals were maintained on the 45% HFD. Following 28 days of treatment mice 
were fasted overnight and tissue harvested for gene and protein expression studies and 
blood collected for leptin and insulin measurements.  
3.3 Results 
3.3.1  Peripheral inhibition of BACE1 in vivo reduces body 
weight and improves glucose homeostasis 
Initially the effects of the orally active BACE1 inhibitor, AZ4217 (AstraZeneca), were 
investigated. DIO mice were treated with either AZ4217 (50mg/kg; Starting body weight: 
43.79 ± 1.37g; n=10) or vehicle (Gluconic acid; Starting body weight: 45.23 ± 1.04g; 
n=9) (control mice) daily, via oral gavage, for up to 28 days.  
3.3.1.1 Treatment with AZ4217 reduces body weight in diet-induced 
obese mice 
Over the course of treatment AZ4217 resulted in a reduction in body weight, which was 
significant after day 16, compared to control mice (Day 25: Control; -2.4% vs. AZ4217; 
-9.3%, p<0.01, n=9-10, Figure 3.1A). The percentage change in body weight 
corresponded to a significant reduction in actual mass, measured in grams (Control; -1.17 
± 0.51g vs. AZ4217; -3.60 ± 0.76g, p<0.01, n=9-10, Figure 3.1B). The observed loss of 
body weight is more specifically a reduction in adiposity, as AZ4217 treated mice display 
a reduction in fat mass (Control; -0.99 ± 0.77% vs. AZ4217; -6.78 ± 1.80%, p<0.01, n=9-
10, Figure 3.1C), with lean mass between the two groups unaltered. To determine if the 
reduced fat mass was associated with circulating leptin levels, leptin was measured in the 
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serum of these mice upon termination of the study (day 28). AZ4217 treatment caused a 
reduction in circulating leptin levels compared to control mice (Control; 73.51 
±9.46ng/ml vs. AZ4217; 44.60 ± 7.18ng/ml, p<0.05, n=9-10, Figure 3.1D), which 
correlates with the observed reduction in fat mass. Taken together these data show 
BACE1 inhibition with AZ4217 reduces adiposity in DIO mice, which is associated with 
decreased circulating leptin levels. 
To determine if these effects were attributable to changes in food consumption, daily food 
intake was measured over the course of the study. There was no difference in cumulative 
food intake between AZ4217 treated mice and control mice (Figure 3.2A), with both 
groups consuming the same amount throughout the study. As total food intake was 
unchanged relative food intake in relation to body weight was measured as a ratio of the 
amount of food consumed and body weight. At days 1 and 16 of treatment there was no 
difference in relative food intake between AZ4217 treated mice and control mice (Figure 
3.2B), however by day 24 AZ4217 treatment caused an increase in relative food intake 
compared to control mice (Day 24: Control; 0.08 ± 0.002 vs. AZ4217; 0.09 ± 0.007, 
p<0.05, n=9-10, Figure 3.2B). This increase in relative food intake in AZ4217 treated 
mice indicates these animals have relative hyperphagia in relation to body weight.  
 
  
83 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Treatment of diet-induced obese mice with AZ4217 for 28 days reduces 
body weight and circulating leptin levels. 
(A) Treatment with AZ4217 causes a significant reduction in percentage body weight 
from day 16 of treatment (p<0.01, n=9-10). (B) Actual weight loss, at the end of the study, 
is significantly reduced in mice treated with AZ4217 (p<0.01, n=9-10). (C) Echo MRI 
data demonstrating a significant reduction in fat mass in mice treated with AZ4217, with 
no change in lean mass (p<0.01, n=9-10). (D) Reduction in fat mass is associated with a 
significant reduction in circulating serum leptin levels in AZ4217 treated mice (p<0.05, 
n=9-10). 
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Figure 3.2 Treatment of diet-induced obese mice with AZ4217 for 28 does not affect 
total food intake, however increases relative food intake. 
(A) Cumulative food intake was unchanged with AZ4217 treated (n=9-10). (B) Relative 
food intake, described as the ratio between food intake and body weight, was significantly 
increased at the end of the study (day 24) with AZ4217 treatment, but showed no 
difference at day 1 and 16 (p<0.05, n=9-10). 
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3.3.1.2 Treatment with AZ4217 improves glucose homeostasis in diet-
induced obese mice 
To examine the diabetic phenotype of DIO mice treated with AZ4217 and vehicle, 
glucose and insulin tolerance tests were carried out on day 14 and 21 of treatment 
respectively. Following an overnight fast AZ4217 treated mice displayed increased 
glucose clearance compared to control mice (AUC: control; 2196 ± 150.5 vs. AZ4217; 
1848 ± 119.2, p<0.05, n=9-10, Figure 3.3A and B). AZ4217 treated mice also showed a 
reduction in fasting blood glucose levels compared to control mice (Control; 4.78 ± 
0.25mmol/l vs. AZ4217; 4.16 ± 0.17mmol/l, p<0.05, n=9-10, Figure 3.3C). These data 
demonstrate that AZ4217 treatment causes an overall improvement in glucose tolerance. 
Following a four hour fast an insulin tolerance test was carried out and no difference in 
blood glucose levels throughout the course of the test (15-120 minutes) was observed 
between AZ4217 treated mice and control mice (Figure 3.4A). Circulating insulin levels 
were also examined, following an overnight fast at the end of the study, and there was a 
trend towards a reduction in insulin levels in the serum of AZ4217 treated mice compared 
to control mice, however this was not a significant effect (Figure 3.4B). Taken together 
these results show AZ4217 treated mice have improved glucose homeostasis, compared 
to control mice, however insulin sensitivity is unaltered. 
3.3.2  Treatment with AZ4217 modifies white adipose tissue 
leptin expression in diet-induced obese mice 
Having shown that inhibition of BACE1 causes a reduction in circulating leptin levels we 
asked the question whether this was due to a direct effect on white adipose tissue (WAT). 
Initially, BACE1 expression in WAT was examined and if this expression was affected 
by HFD. Using immunofluorescence (IF) WAT from WT mice fed a NC or HFD were 
double-stained for BACE1 (red) and perilipin (green), which is a protein associated with 
lipid droplets and utilised to indicate adipocytes. Representative confocal images show 
BACE1 is co-localised with perilipin, indicating BACE is present in adipocytes, and 
BACE1 staining is stronger in high-fat fed animals (Figure 3.5). These data show BACE1 
is present in WAT and is elevated following a HFD.  
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Figure 3.3 Treatment of diet-induced obese mice with AZ4217 significantly 
improves glucose homeostasis. 
(A) Glucose tolerance test profile showing AZ4217 treatment improves glucose disposal. 
(B) Quantification of area under the curve (AUC) for glucose response shown in (A), 
demonstrating significant improvement in glucose disposal with AZ4217 treatment 
(p<0.05, n=9-10). (C) Treatment with AZ4217 significantly reduces fasting blood glucose 
levels (p<0.05, n=9-10). 
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Figure 3.4 Treatment of diet-induced obese mice with AZ4217 for 28 days does not 
alter insulin sensitivity. 
(A) Insulin tolerance test profile displaying no significant effect of AZ4217 treatment on 
insulin sensitivity (n=9-10). (B) AZ4217 treatment caused no significant effect on 
circulating serum insulin levels (n=9-10). 
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Figure 3.5 BACE1 expression is elevated in white adipose tissue when mice are fed 
a high-fat diet for 20 weeks. 
Confocal images taken at x40 magnification, showing BACE1 (red), adipocyte marker 
perilipin (green) and merged channels within white adipose tissue. Representative images 
from (A) mice fed a normal chow (NC) diet and (B) mice fed a high-fat diet (HFD) for a 
period of 20 weeks. All scale bars 50µm. 
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Having observed BACE1 is increased following a HFD in WAT, it was investigated if 
BACE1 inhibition affects WAT directly and whether this may be responsible for the 
observed reduction in circulating leptin levels. The expression of leptin in WAT was 
examined, using real-time PCR, and AZ4217 treated mice displayed reduced leptin 
expression in comparison to control mice (Control; 1.00 ± 0.23 vs. AZ4217; 0.54 ± 0.07, 
p<0.001, n=9-10, Figure 3.6A). AZ4217 treated mice also showed reduced levels of the 
long form of the leptin receptor, ObRb, in WAT compared to control mice (Control; 1.00 
± 0.18 vs. AZ4217; 0.77 ± 0.10, p<0.05, n=6-10, Figure 3.6B). Taken together these data 
suggest BACE1 may be involved in the high circulating levels of leptin present in obesity, 
and that increased BACE1 levels/activity may be required for the resulting leptin 
resistance, which primarily targets the hypothalamus. Consequently, reducing BACE1 
levels/activity may be associated with reduced WAT leptin and circulating leptin levels, 
thus improving leptin sensitivity in DIO mice, and reversing hypothalamic leptin 
resistance.  
3.3.3  Treatment with AZ4217 alters hypothalamic leptin 
signalling in diet-induced obese mice 
Having found BACE1 inhibition causes a large reduction in circulating leptin levels, 
whether this and the associated reduction in body weight is driven by a direct effect on 
leptin signalling was investigated. The hypothalamic expression of key anorexigenic and 
orexigenic neuropeptides involved in leptin signalling were measured in AZ4217 treated 
and control mice. The hypothalamus was extracted and analysed following an overnight 
fast, examining the expression of the anorexigenic neuropeptides, pro-opiomelanocortin 
(POMC) and cocaine- and amphetamine- regulated transcript (CART) and the orexigenic 
neuropeptides, neuropeptide Y (NPY) and agouti- related protein (AgRP). Treatment with 
AZ4217 caused a reduction in POMC expression compared to control mice (Control; 1.00 
± 0.32 vs AZ4217; 0.53 ± 0.12, p<0.01, n=9-10, Figure 3.7A), however the compound 
had no effect on CART expression (Figure 3.7B). Treatment with AZ4217 also had no 
effect on orexigenic hypothalamic peptide expression, with no difference between groups 
observed for NPY or AgRP expression (Figure 3.7C and D). To assess if the expression 
of orexigenic neuropeptides changed in relation to anorexigenic expression the ratios of 
NPY/POMC and AgRP /POMC were calculated. AZ4217 treatment resulted in a slight, 
but non-significant, increase in the ratios of NPY/POMC and AgRP/POMC (Figure 3.7E 
and F), suggesting AZ4217 may promote orexigenic signalling. Owing to AZ4217 having 
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little effect on the key neuropeptides involved in leptin signalling, the expression of 
negative regulators of leptin signalling, which are thought to elicit leptin resistance, were 
measured in the hypothalamus. SOCS3 and PTP1B levels were examined as they have 
been reported to contribute to leptin resistance (Münzberg & Myers 2005; Bjorbaek et al. 
1998; Zabolotny et al. 2002). Hypothalamic SOCS3 mRNA was reduced in AZ4217 
treated mice relative to control mice (Control; 1.00 ± 0.16 vs. AZ4217; 0.80 ± 0.08, 
p<0.05, n=9-10, Figure 3.8A). As SOCS3 blocks leptin signalling the observed reduction 
may indicate improved hypothalamic leptin sensitivity/signalling. However, PTP1B 
levels were unchanged between AZ4217 treated mice and controls (Figure 3.8B and C), 
indicating reduced PTP1B levels may not be responsible for the observed improvement 
in leptin sensitivity. 
3.3.4 Treatment with AZ4217 does not alter thermogenic 
programming in diet-induced obese mice 
Having shown an improvement in the metabolic state of DIO mice treated with AZ4217, 
a possible mechanism explaining this outcome is increased energy expenditure through 
increased thermogenesis. It has previously been shown that BACE1-/- mice have increased 
energy expenditure and elevated levels of uncoupling proteins in brown adipose tissue 
(BAT) and skeletal muscle (Meakin et al. 2012), indicating increased thermogenesis. 
Thus, thermogenic programming was examined in BAT and skeletal muscle of AZ4217 
treated and control mice. In BAT the thermogenic factors uncoupling protein 1 (UCP1), 
peroxisome proliferator-activated receptor-γ, coactivator 1-α (PGC1α), type 2 deiodinase 
(DIO2) and the zinc finger transcription factor Prdm16 mRNA levels were measured as 
markers of the switching on of thermogenic programming. AZ4217 treatment had no 
effect on UCP1, DIO2 or Prdm16 mRNA levels in BAT relative to control mice (Figure 
3.9A, C and D), and reduced PGC1α levels compared to control mice (Control; 1.00 ± 
0.2 vs. AZ4217; 0.70 ± 0.06, p<0.01, n=9, Figure 3.9B). These data show AZ4217 does 
not impact thermogenic programming in BAT, and increased energy expenditure via this 
tissue is unlikely to be responsible for the improved metabolic phenotype observed. 
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Figure 3.6 AZ4217 treatment significantly reduces leptin mRNA expression in white 
adipose tissue. 
Histograms showing relative mRNA expression of (A) leptin and (B) the long form of the 
leptin receptor (ObRb) in white adipose tissue. (A) AZ4217 treatment causes a significant 
reduction in leptin (p<0.001, n=9-10) and (B) ObRb (p<0.05, n=6-10).  
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Figure 3.7 AZ4217 treatment reduces anorexigenic, but does not affect orexigenic, 
neuropeptide hypothalamic gene expression. 
Histograms showing relative mRNA expression of (A) POMC, (B) CART, (C) NPY, (D) 
AgRP, (E) NPY/POMC and (F) AgRP/POMC in the hypothalamus. (A) AZ4217 treatment 
causes a significant reduction in hypothalamic POMC mRNA expression (p<0.01, n=9-
10) but no significant effect on CART mRNA expression (n=7-8). (C and D) AZ4217 had 
no significant effect on orexigenic neuropeptides NPY or AgRP (n=9-10). (E and F) 
Representative hypothalamic ratios of NPY/POMC (n=9) and AgRP/POMC (n=9-10) 
display no significant difference with AZ4217 treatment. 
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Figure 3.8 AZ4217 treatment significantly reduces SOCS3 gene expression, but does 
not alter PTP1B gene expression in the hypothalamus. 
Histograms showing relative mRNA expression of (A) SOCS3 and (B) PTP1B in the 
hypothalamus. (A) AZ4217 treatment causes a significant reduction in hypothalamic 
SOCS3 expression (p<0.05, n=9-10). (B) AZ4217 treatment has no significant effect on 
PTP1B (n=8-9).  
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Figure 3.9 AZ4217 treatment significantly reduces PGC1α but does not affect other 
markers of thermogenic programming in brown adipose tissue. 
Histograms showing relative mRNA expression of (A) UCP1, (B) PGC1α, (C) DIO2 and 
(D) Prdm16 in brown adipose tissue.(B) AZ4217 treatment causes a significant reduction 
in PGC1α (p<0.01, n=9), but causes no significant effect on (A) UCP1, (C) DIO2 or (D) 
Prdm16 (n=9).  
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Skeletal muscle in mice was also examined. It is reported that UCP1 expression is low in 
skeletal muscle, which was found in the BACE1-/- mouse, however increased levels of the 
uncoupling proteins 2 and 3 (UCP2/3) could be measured (Meakin et al. 2012). Thus, 
UCP2 and UCP3 levels were examined in skeletal muscle of AZ4217 treated and control 
mice. AZ4217 treatment caused no change in UCP2 and UCP3 mRNA levels in skeletal 
muscle relative to control mice (Figure 3.10A and B), which is consistent with no change 
in thermogenic programming detected in BAT. 
Markers of BAT cell-selective genes, such as Prdm16, have also been shown to be present 
in WAT, with this gene in particular driving the ‘browning’ of white adipocytes to brown 
or ‘brite’ adipocytes (Seale et al. 2011). This is also indicative of raised thermogenesis 
and decreased metabolic efficiency. To examine whether any such changes occurred in 
WAT of AZ4217 treated and control mice the thermogenic genes analysed in BAT were 
measured. In WAT, AZ4217 treatment caused a reduction in PGC1α (Control; 1.00 ± 
0.26 vs. AZ4217; 0.75 ± 0.11, p<0.01, n=9, Figure 3.11B) and Prdm16 (Control; 1.00 ± 
0.22 vs. AZ4217; 0.56 ± 0.08, p<0.001, n=9, Figure 3.11D) levels relative to controls, 
suggesting a reduction in ‘browning’ of WAT. However, UCP1 and DIO2 were 
unchanged between AZ4217 treated and control mice (Figure 3.11A and C). Taken 
together these data show there is no effect on thermogenic programming in WAT, 
consistent with the BAT and skeletal muscle data, and AZ4217 is unlikely to be increasing 
energy expenditure via raised thermogenesis to result in the improved metabolic 
phenotype observed. 
3.3.5  Treatment with AZ4217 modifies high-fat diet-mediated 
inflammatory programming in diet-induced obese mice 
HFD drives increased pro-inflammatory cytokine expression both centrally, in the 
hypothalamus (De Souza et al. 2005), and peripherally (Gregor & Hotamisligil 2011), as 
well as increasing the accumulation of macrophages in peripheral tissues such as WAT 
(Caruso et al. 2010). Furthermore, work in our lab has recently shown that BACE1-/- mice 
have a reduced number of inflammatory cells in WAT and liver (unpublished data) and 
therefore may be resistant to HFD-induced inflammation. To examine this further WAT 
of WT and BACE1-/- mice, fed a HFD for a period of 20 weeks, were stained for 
macrophage markers F4/80 and Cd68. Representative light microscopy images show 
there is an increase in macrophage staining in WAT of WT mice in comparison to BACE1-
/- mice, with the adipocytes displaying a more irregular and larger morphology (Figure 
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3.12). These data show there is increased inflammation associated with diet-induced 
obesity, however in the absence of BACE1 there is no inflammatory response.  
As we observed reduced numbers of macrophages in WAT of BACE1-/- mice, in AZ4217 
treated mice we next investigated markers of the inflammasome, which are elevated in 
obesity (Vandanmagsar et al. 2011) and activate inflammatory processing (Guo et al. 
2015), as well as levels of pro- and anti-inflammatory cytokines. The expression of 
inflammatory markers were examined in the hypothalamus and WAT of AZ4217 treated 
and control mice. In the hypothalamus pro-inflammatory cytokines; TNFα and IL-6, 
markers of the inflammasome; IL-1β, NLRP3 and caspase 1, and F4/80, as a marker of 
total macrophage number, were studied. AZ4217 treatment reduced TNFα levels 
compared to controls (Control; 1.00 ± 0.41 vs. AZ4217; 0.35 ± 0.17, p<0.001, n=6-9, 
Figure 3.13A), however AZ4217 had no effect on IL-6 levels (Figure 3.13B). 
Unexpectedly, AZ4217 treatment drives a non-significant increase in IL-1β levels (Figure 
3.13C) and causes no change in NLRP3 or caspase 1 levels (Figure 3.13D and E). Total 
macrophage number is also unaltered in AZ4217 treated mice compared to control mice 
indicated by no change in F4/80 levels (Figure 3.13F). Taken together these data suggest 
AZ4217 causes a reduction in hypothalamic inflammation through reduced TNFα 
expression, however markers of the inflammasome and total macrophage levels are 
unchanged, therefore AZ4217 treatment does not appear to greatly alter HFD-mediated 
hypothalamic inflammation.  
In WAT, pro-inflammatory cytokines; inducible nitric oxide synthase (NOS2), INFγ, IL-
1β, TNFα and IL-6, anti-inflammatory cytokines; IL-10, YM-1 and Arg-1, and F4/80 were 
studied. Alike the hypothalamus, AZ4217 treatment induced a large reduction in TNFα 
levels relative to controls (Control; 1.00 ± 0.62 vs. AZ4217; 0.39 ± 0.06, p<0.001, n=7-
10, Figure 3.14D), however did not alter NOS2, IFNγ, IL-1β or IL-6 compared to controls 
(Figure 3.14A, B and C). Anti-inflammatory cytokines IL-10, YM-1 and Arg-1 were also 
unaltered following AZ4217 treatment (Figure 3.14F, G and H), although F4/80 levels 
were reduced following AZ4217 treatment in comparison to controls (Control; 1.00 ± 
0.47 vs. AZ4217; 0.66 ± 0.09, p<0.01, n=7-10, Figure 3.14I), indicating a reduced number 
of macrophages in WAT following BACE1 inhibition. Taken together these data suggest 
AZ4217 treatment reduces HFD-mediated WAT inflammation, however this is not a large 
change and may not be the main driver for the improved metabolic phenotype observed 
with reduced BACE1.   
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Figure 3.10 AZ4217 treatment does not alter uncoupling proteins expression in 
skeletal muscle. 
Histograms showing relative mRNA expression of (A) UCP2 and (B) UCP2 in skeletal 
muscle. AZ4217 treatment causes no significant effect on (A) UCP2 or (B) UCP3 
expression (n=9-10). 
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Figure 3.11 AZ4217 treatment significantly reduces PGC1α and Prdm16, but does 
not affect other markers of thermogenic programming in white adipose tissue. 
Histograms showing relative mRNA expression of (A) UCP1, (B) PGC1α, (C) DIO2 and 
(D) Prdm16 in white adipose tissue. (A and C) AZ4217 treatment causes no significant 
effect on UCP1 (n=9) or DIO2 (n=7-10). (B and D) AZ4217 treatment causes a 
significant reduction in PGC1α (p<0.05, n=6-10) and Prdm16 (p<0.001, n=7-10).  
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Figure 3.12 BACE1-/- mice do not display diet-induced inflammation in white 
adipose tissue following 20 weeks on a high-fat diet. 
Light microscopy images taken at x10 magnification showing macrophage markers F4/80 
and Cd68 staining in white adipose tissue. Representative images from (A) wild-type 
(WT) mice and (B) BACE1-/- mice fed a high-fat diet for a period of 20 weeks. Arrows 
indicate areas of macrophage infiltration. All scale bars 100µm.  
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Figure 3.13 AZ4217 treatment significantly reduces central TNFα expression, but 
does not alter other inflammatory markers in the hypothalamus. 
Histograms showing relative mRNA expression of pro-inflammatory cytokines (A) TNFα 
, (B) IL-6, (C) IL-1β, markers of the inflammasome (D) NLRP3, (E) Caspase 1 and 
macrophage marker (F) F4/80 in the hypothalamus.(A) AZ4217 treatment causes a 
significant reduction in (A) TNFα (p<0.01, n=6-9), however has no significant effect on 
(B) IL-6 (n=6). (C) AZ4217 treatment causes a trend towards a significant increase in (C) 
IL-1β (p=0.05, n=5) but has no significant effect on (D) NLRP3 or (E) Caspase 1 (n=5). 
(F) AZ4217 treatment has no significant effect on total macrophage number indicated by 
(F) F4/80 expression (n=7-10).  
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Figure 3.14 AZ4217 treatment significantly reduces TNFα and F4/80 expression, but 
does not alter other inflammatory markers in white adipose tissue. 
Histograms showing relative mRNA expression of pro-inflammatory cytokines (A) 
NOS2, (B) IFNγ, (C) IL-1β, (D) TNFα, (E) IL-6, anti-inflammatory cytokines (F) IL-10, 
(G) YM-1, (H) Arg-1 and macrophage marker (I) F4/80 in white adipose tissue. (D) 
AZ4217 treatment causes a significant reduction in TNFα expression (p<0.001, n=7-10), 
but has no significant effect on other pro-inflammatory cytokines (A) NOS2 (n=7-10), 
(B) IFNγ (n=7-9), (C) IL-1β (n=7-9) or (D) IL-6 (n=5-9).(F-H) AZ4217 treatment has no 
significant effect on anti-inflammatory cytokines (F) IL-10 (n=7-10), (G) YM-1 (n=7-10) 
and (H) Arg-1 (n=5-9). (I) AZ4217 treatment significantly reduces total number of 
macrophages, measured by F4/80 expression (p<0.01, n=7-10).  
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An important response to chronic inflammation is the recruitment of macrophages by 
chemokines, particularly to WAT, which is associated with insulin resistance and obesity. 
As we observe a reduced number of macrophages in WAT we examined whether altered 
chemokine expression may account for this. In WAT levels of chemotactic cytokines; 
monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins 1α and 
1β (MIP-1α and MIP-1β), and regulated upon activation, normal T cell expressed and 
secreted (RANTES), which are responsible for the migration of inflammatory cells into 
sites of inflammation, in particular monocytes and lymphocytes, and in some instance 
neutrophils, were measured (Surmi & Hasty 2010). AZ4217 treatment resulted in a 
reduction in MCP-1, MIP-1α and MIP-1β levels in comparison to control mice (MCP-1: 
Control; 1.00 ± 0.13 vs. AZ4217; 0.83 ± 0.09, p=0.08, MIP-1α: Control; 1.00 ± 0.18 vs. 
AZ4217; 0.66 ± 0.09, p<0.01, MIP-1β: Control; 1.00 ± 0.16 vs. AZ4217; 0.58 ± 0.11, 
p<0.05, n=5-9, Figure 3.15A, B and C), suggesting BACE1 inhibition reduces the number 
of immune cells being attracted to WAT, due to reduced HFD-mediated inflammation. 
However, AZ4217 treatment had no effect on RANTES expression compared to control 
mice (Figure 3.15D). Transforming growth factor β1 (TGFβ-1), which is secreted by 
activated macrophages and has been shown to act as a chemoattractant for neutrophils 
(Reibmant et al. 1991), was also examined in WAT. This growth factor is associated with 
obesity, with increased levels found in adipose tissue of obese mice (Samad et al. 1997), 
however AZ4217 did not alter the expression of this cytokine (Figure 3.15E).  
Taken together these data show BACE1 may be involved in HFD-mediated inflammatory 
programming and inhibition of BACE1 reduces a degree of inflammation in WAT as well 
as the accumulation of macrophages at this site and this could drive, in part, the improved 
obese/diabetic phenotype of DIO mice observed following reduction of BACE1.  
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Figure 3.15 AZ4217 treatment significantly reduces MIP-1α and MIP-1β expression 
in white adipose tissue, but does not alter expression of other chemokines. 
Histograms showing relative mRNA expression of chemokines (A) MCP-1, (B) MIP-1α, 
(C) MIP-1β, (D) RANTES, and pro-inflammatory cytokine (E) TGFβ-1 in white adipose 
tissue. (A) AZ4217 treatment causes a non-significant reduction in MCP-1 (p=0.08, n=5-
9) and causes a significant reduction in (B) MIP-1α (p<0.01, n=5-9) and (C) MIP-1β 
(p<0.05, n=5-6) but has no significant effect on (A) MCP-1 (n=5-9), (D) Rantes (n=4-8) 
or (E) TGFβ-1 (n=7-9) expression.  
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3.3.6  Treatment with a structurally different BACE1 inhibitor 
does not mimic AZ4217 treatment 
A second structurally different BACE1 inhibitor was examined, AZ3839, and the same 
metabolic measurements recorded as previously discussed (section 3.3.1). DIO mice were 
treated with AZ3839 (43mg/kg; Starting body weight: 49.56 ± 2.72g; n=5) or vehicle 
(Gluconic acid; Starting body weight: 49.94 ± 2.41g; n=5) (control mice) via oral gavage 
for up to 28 days, No change in body weight was observed following AZ3839 treatment 
(Figure 3.16A), which was associated with no observed difference in cumulative food 
intake between groups (Figure 3.16B). As BACE1 inhibition (with AZ4217 and 
peripheral Merck-3) reduces leptin levels, and as previously mentioned, the beneficial 
effects of inhibiting BACE1 may be dependent on reducing leptin levels, the circulating 
levels were measured in serum from AZ3839 treated mice. AZ3839 did not affect leptin 
levels in comparison to controls (Figure 3.16C), which suggests AZ3839 is not reducing 
leptin levels sufficiently and therefore not allowing for the subsequent reduction in body 
weight. As described in the AZ4217 study (section 3.3.1.2), the diabetic phenotype of 
these mice was examined. AZ3839 treatment had no effect on glucose clearance relative 
to control mice (Figure 3.17A and B) and did not alter fasting blood glucose levels (Figure 
3.17C), consistent with no change in body weight. Blood glucose levels were also 
unaltered with AZ3839 treatment during all time points (15-120 minutes) of an ITT 
(Figure 3.17D). Collectively these results show AZ3839 was not effective in improving 
the impaired metabolic state of DIO mice and in mimicking the phenotype of AZ4217 
treated mice, peripheral Merck-3 treated mice and BACE1-/- mice. 
3.3.7  Central inhibition of BACE1 in vivo reduces body weight 
and improves glucose homeostasis in diet-induced obese 
mice 
Peripheral treatment of AZ4217 produced many, but not all, of the outcomes observed in 
BACE1-/- mice and mice treated with peripheral Merck-3 (Meakin et al. 2012, unpublished 
data), whereas peripheral AZ3839 treatment appeared to have no effect on body weight 
and glucose homeostasis. One issue regarding this reduced and lack of effectiveness of 
peripherally applied compounds were their ability to cross the BBB sufficiently to reach 
levels that would reduce BACE1 activity and drive central actions. This led us to question 
how much of the outcomes associated with reduced BACE1 are owing to central rather 
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than peripheral actions. DIO mice were treated with Merck-3 (10mg/kg; 28 days; Starting 
body weight: 47.65 ± 1.37g; n=10) or vehicle (DMSO/PBS; Starting body weight: 48.69 
± 1.48g; n=9) through central administration directly into the brain.  for 28 days, and the 
metabolic measurements carried out for the AZ4217 study, as previously described 
(section 3.3.1), were performed to compare the effects of central and peripheral BACE1 
inhibition.  
3.3.7.1  Central inhibition of BACE1 reduces body weight in diet-
induced obese mice 
Central treatment with Merck-3 caused a significant reduction in percentage body weight 
over the course of the study in comparison to vehicle treated (control) mice (Control; 
0.6% vs. Merck-3; -7.6%, n=7-9, Figure 3.18A), although body weight began to rebound 
towards the end of the study. At the end of the study, there was still an overall decrease 
in body weight (Control; -1.17 ± 0.51g vs. Merck-3; -3.60 ± 0.76g, p<0.05, n=7-9, Figure 
3.18B). It could not be determined if this reduction in body weight was due to a reduction 
in adiposity as these mice could not be placed in the Echo MRI scanner due to the ICV 
brain infusion kit implanted. In an attempt to address this issue, circulating leptin levels 
in the serum of these mice (obtained at the end of the study) were measured. There was a 
trend towards a reduction in circulating leptin levels in central Merck-3 treated mice 
(Figure 3.18), however this was not a significant effect. This may be due to the loss of 
body weight in central Merck-3 treated mice recovering towards the end of the study. 
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Figure 3.16 Treatment of diet-induced obese mice with AZ3839 for 28 days does not 
affect body weight or circulating leptin levels. 
(A) Treatment with AZ3839 causes no change in percentage body weight over the course 
of 28 days (n=5). (B) Cumulative food intake is unchanged with AZ3839 treatment 
throughout the study (n=5). (C) AZ3839 treatment causes no significant difference in 
circulating serum leptin levels (n=5). 
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Figure 3.17 Treatment of diet-induced obese mice with AZ3839 for 28 days does not 
alter glucose homeostasis. 
(A) Glucose tolerance test profile showing AZ3839 treatment does not affect glucose 
disposal (n=5). (B) Quantification of area under the curve (AUC) for glucose responses 
shown in (A). (C) Treatment with AZ3839 does not affect fasted blood glucose levels 
(n=5). (D) Insulin tolerance test profile shows there is no significant effect of AZ3839 
treatment on insulin sensitivity in comparison to controls (n=5).  
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Figure 3.18 Central treatment of diet-induced obese mice with Merck-3 for 28 days 
significantly reduces body weight, but does not alter circulating leptin levels.  
(A) Central Merck-3 treatment causes a significant reduction in percentage body weight 
from day 7 to day 17 of treatment (p<0.05, n=7-9). (B) Actual weight loss, at the end of 
the study, is significantly reduced in mice treated centrally with Merck-3 (p<0.05, n=7-
9). (C) Histogram of circulating plasma leptin levels displays no significant effect with 
central Merck-3 treatment (n=8). 
Data collection was carried out in collaboration with Dr. Paul J Meakin and Karolina 
Parmionova (Masters Student).  
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As with AZ4217 treatment, changes in food consumption was examined. There was no 
difference in cumulative food intake between central Merck-3 treated mice and control 
mice (Figure 3.19A), demonstrating both groups of mice consume the same over the 
course of the study. Therefore, changes in total food intake is not responsible for the 
observed reduction in body weight. Central Merck-3 treatment caused a significant 
increase in relative food intake (in relation to body weight) by day 16 of treatment, 
(Control; 0.09 ± 0.00 vs. 0.11 ± 0.01, p<0.05, n=7-8, Figure 3.19B), although no change 
was observed on day 1 of the study. By day 24 of treatment this effect was absent, with 
no significant difference displayed between central Merck-3 treated mice and control 
mice. These data suggest at the point in the study where loss in body weight is greatest 
central Merck-3 treated mice may be hyperphagic in relation to body weight.  
3.3.7.2  Central inhibition of BACE1 improves glucose homeostasis in 
diet-induced obese mice 
The diabetic phenotype of these mice was investigated by carrying out glucose tolerance 
(day 14) and insulin tolerance (day 21) tests. Following an overnight fast there was an 
increase in glucose clearance with Merck-3 treatment in comparison to control mice 
(AUC: control; 1299 ± 81.76 vs. Merck-3; 1020 ± 66.91, p<0.05, n=7-8, Figure 3.20A 
and B), while fasting blood glucose levels were unaltered (Figure 3.20C). 
Following a four hour fast an ITT was carried out and central Merck-3 treatment caused 
no difference in blood glucose levels throughout the test (15-120 minutes) (Figure 3.21A). 
Circulating insulin levels were also measured in the serum of these mice following an 
overnight fast, at the end of the study (day 28). A trend towards a reduction in circulating 
insulin levels was found in central Merck-3 treated mice in comparison to control mice, 
however this was not a significant effect (Figure 3.21B). Taken together these data show 
central treatment with Merck-3 results in improved glucose tolerance, an effect observed 
at day 14 when weight loss in these animals is at its greatest. However, central Merck-3 
treatment does not affect insulin sensitivity, mimicking the effects of AZ4217 treatment.  
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Figure 3.19 Central treatment of diet-induced obese mice with Merck-3 for 28 days 
does not affect food intake, however increases relative food intake. 
(A) Cumulative food intake was unchanged with central Merck-3 treatment (n=7-9). (B) 
Relative food intake, described as a ratio between food intake and body weight, was 
significantly increased at day 16 of the study, but had no effect at day 1 or day 24 (p<0.05, 
n=9-10). 
Data collection was carried out in collaboration with Dr. Paul J Meakin and Karolina 
Parmionova (Masters Student).  
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Figure 3.20 Central treatment of diet-induced obese mice with Merck-3 for 28 days 
improves glucose homeostasis. 
(A) Glucose tolerance test profile showing central Merck-3 treatment improves glucose 
disposal. (B) Quantification of the area under the curve (AUC) for the glucose responses 
shown in (A), demonstrating a significant reduction in glucose disposal with central 
Merck-3 treatment (p<0.05, n=7-8). (C) Central Merck-3 treatment does not affect fasted 
blood glucose levels (n=7-9). 
Data collection was carried out in collaboration with Dr. Paul J Meakin and Karolina 
Parmionova (Masters Student). 
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Figure 3.21 Central treatment of diet-induced obese mice with Merck-3 for 28 days 
does not alter insulin sensitivity. 
(A) Insulin tolerance test profile displaying no significant effect of central Merck-3 
treatment on insulin sensitivity (n=9-10). (B) Central Merck-3 treatment caused no 
significant effect on circulating serum insulin levels (n=7-10).  
Data collection was carried out in collaboration with Dr. Paul J Meakin and Karolina 
Parmionova (Masters Student). 
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3.3.7.3  Central inhibition of BACE1 alters splenic weight, but does not 
impact other organs 
Upon termination of the study tissue weights of spleen, heart, liver and brain were 
measured in all mice as an indication of the health of these tissues and as a crude measure 
of lean mass. Central Merck-3 treatment caused an increase in actual splenic size and 
spleen weight represented as a percentage of total body weight, compared to control mice 
(Actual weight: Control; 0.12 ± 0.01g vs. Merck-3; 0.18 ± 0.01g, % of body weight: 
Control; 0.27 ± 0.02% vs. Merck-3; 0.43 ± 0.05%, p<0.01, n=7-9, Figure 3.22A and B). 
However, no effect was observed on heart, liver or brain weights. Taken together these 
data show central BACE1 inhibition only affects splenic weight and does not impact other 
organ size or weights.  
3.3.8  Central inhibition of BACE1 modifies white adipose tissue 
leptin expression in diet-induced obese mice 
Having observed a reduction in body weight and a trend towards a reduction in circulating 
leptin levels following central Merck-3 treatment, the relative expression of leptin in 
WAT was examined. Central Merck-3 treatment resulted in decreased leptin in 
comparison to control mice (Control; 1.00 ± 0.14 vs. Merck-3; 0.52 ± 0.14, p<0.05, n=8, 
Figure 3.23A). ObRb relative levels were unaltered between Merck-3 treated mice and 
controls (Figure 3.23B), demonstrating, although there is a reduction in leptin levels, 
receptor expression remains the same. Collectively, these data show that, although 
circulating leptin levels are not significantly reduced central BACE1 inhibition is 
reducing leptin WAT expression, which is consistent with results from genetic and 
pharmacological reduction in BACE1 (unpublished data, section 3.3.2).  
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Figure 3.22 Central treatment of diet-induced obese with Merck-3 mice alters spleen 
weight but does not impact other organs.  
(A) Central treatment with Merck-3 results in a significant increase in spleen weight 
(p<0.01) but has no effect on heart, liver or brain weights (n=7-9). (B) Actual weights 
represented as a percentage of total body weights. 
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Figure 3.23 Central Merck-3 treatment significantly reduces leptin mRNA 
expression in white adipose tissue. 
Histograms showing (A) leptin and (B) the long form of the leptin receptor (ObRb) in 
white adipose tissue. (A) Central Merck-3 treatment causes a significant reduction in 
leptin (p<0.05, n=8), however causes no significant effect on (B) ObRb (n=7-8).  
Data collection was carried out in collaboration with David Allsop (PhD Student). 
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3.3.9 Central inhibition of BACE1 alters hypothalamic leptin 
signalling in diet-induced obese mice 
As with peripheral AZ4217 treatment, the expression of key neuropeptides involved in 
leptin signalling were examined in the hypothalamus (section 3.3.3) to assess the direct 
effect of leptin signalling. Central Merck-3 treatment reduced CART expression in 
comparison to controls (Control; 1.00 ± 0.11 vs. Merck-3; 0.80 ± 0.08, p<0.05, n=7-8, 
Figure 3.24B), however had no significant effect on POMC expression (Figure 3.24A), 
although a trend towards an increase in comparison to controls was observed. Central 
Merck-3 treatment did not affect NPY or AgRP expression (Figure 3.24C and D), however 
resulted in a non-significant increase in the ratios of both NPY/POMC and AgRP/POMC 
(NPY/POMC: p=0.08, Figure 3.24E and F). Taken together these data indicate that central 
Merck-3 treatment may alter hypothalamic leptin signalling through reduced 
anorexigenic CART expression and promotion of orexigenic signalling.  
Central Merck-3 treatment had no effect on the negative regulator of leptin signalling 
SOCS3 expression (Figure 3.25A). Unexpectedly, central Merck-3 treatment resulted in 
a slight, but significant, increase in the negative regulator PTP1B levels in comparison to 
control mice (Control; 1.00 ± 0.05 vs. Merck-3; 1.16 ± 0.06, p<0.05, n=7-9,Figure 3.25B), 
an effect not observed with peripheral BACE1 inhibition. Collectively these data 
demonstrate central Merck-3 administration does not largely impact the negative 
regulation of hypothalamic leptin signalling, and therefore alterations in hypothalamic 
leptin signalling may not be directly responsible for the observed effects. However, 
measurements of actual leptin sensitivity in these animals has not been tested.  
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Figure 3.24 Central Merck-3 treatment reduces anorexigenic neuropeptide 
expression and promotes orexigenic signalling in the hypothalamus. 
Histograms showing relative mRNA expression of (A) POMC, (B) CART, (C) NPY, (D) 
AgRP, (E) NPY/POMC and (F) AgRP/POMC in the hypothalamus. (A and B) Central 
Merck-3 treatment causes a trend towards a reduction in hypothalamic POMC mRNA 
expression (n=7-9) and a significant reduction in CART mRNA expression (p<0.05, n=7-
8). (C and D) Central Merck-3 treatment had no significant effect on orexigenic 
neuropeptides NPY (n=7-9) or AgRP (n=7-8). (E and F) Representative hypothalamic 
ratios of NPY/POMC (n=7-9) and AgRP/POMC (n=6-9) display a slight, but non-
significant, increase.Data collection was carried out in collaboration with Karolina 
Parmionova (Masters Student). 
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Figure 3.25 Central Merck-3 treatment significantly increases PTP1B gene 
expression, but does not alter SOCS3 expression in the hypothalamus. 
Histograms showing relative mRNA expression of (A) SOCS3 and (B) PTP1B in the 
hypothalamus. (A) Central Merck-3 treatment has no significant effect on SOCS3 (n=7-
9). (B) Central Merck-3 treatment causes a significant increase in hypothalamic PTP1B 
expression (p<0.05, n=7-9). 
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3.3.10 Central inhibition of BACE1 alters thermogenic 
programming in diet-induced obese mice 
Having observed central Merck-3 largely mimicking the in-vivo effects of peripheral 
BACE1 inhibition, which may be due in part to alterations in thermogenic programming, 
the expression of genes involved in thermogenesis were also examined. In BAT, central 
Merck-3 treatment did not alter UCP1 expression levels compared to control mice (Figure 
3.26A), although other markers indicating up-regulation of thermogenic programming in 
BAT were elevated following central Merck-3 treatment. PGC1α was significantly 
increased (Control; 1.00 ± 0.12 vs. Merck-3; 2.00 ± 0.38, p<0.05, n=9, Figure 3.26B), 
DIO2 displayed a non-significant increase (p=0.07, Figure 3.26C) and Prdm16 displayed 
a trend towards an increase (Figure 3.26D). These data show, although UCP1 expression 
is not altered, other genes involved in thermogenic programming are upregulated 
following central Merck-3 treatment, indicating thermogenesis may be initiated; an effect 
not observed following peripheral AZ4217 treatment.  
The skeletal muscle of central Merck-3 treated mice was also examined, but unlike 
AZ4217 treatment, central Merck-3 treatment caused an unexpected decrease in UCP2 
levels in skeletal muscle (Control; 1.00 ± 0.31 vs. Merck-3; 0.65 ± 0.15, p=0.06, n=7-8, 
Figure 3.27A). However, no change in UCP3 mRNA levels was observed (Figure 3.27B). 
These data are consistent with the lack of strong evidence for increasing thermogenesis 
in BAT or muscle.  
Having observed increased expression of genes involved in thermogenesis in BAT, the 
presence of increased energy expenditure via ‘browning’ of WAT was examined. In WAT 
central Merck-3 treatment displayed a trend towards a small increase in UCP1 expression 
(Figure 3.28A), however did not alter PGC1α, DIO2 or Prdm16 expression in comparison 
to control mice (Figure 3.28C, D and E). These data indicate that central Merck-3 does 
not affect enhanced thermogenesis in WAT. Although there is an effect on BAT, 
collectively these data suggest increased thermogenesis may not be the main factor 
driving the improved metabolic phenotype caused by central inhibition of BACE1.  
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Figure 3.26 Central Merck-3 treatment significantly increases PGC1α but does not 
alter other markers of thermogenic programming in brown adipose tissue. 
Histograms showing relative mRNA expression of (A) UCP1, (B) PGC1α, (C) DIO2 and 
(D) Prdm16 in brown adipose tissue. (A) Central Merck-3 treatment causes no significant 
effect on (A) UCP1 (n=8). (B) Central Merck-3 treatment causes a significant increase in 
PGC1α (p<0.05, n=9) relative expression and a non-significant trend towards an increase 
in (C) DIO2 (p=0.07, n=8) and (D) Prdm16 (n=9) relative expression.  
Data collection was carried out in collaboration with Dr. Gemma Montagut. 
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Figure 3.27 Central Merck-3 treatment alters UCP2 expression, but not UCP3, in 
skeletal muscle. 
Histograms showing relative mRNA expression of (A) UCP2 and (B) UCP2 in skeletal 
muscle. Central Merck-3 treatment causes a decrease in (A) UCP2 expression (p=0.06, 
n=7-8), however has no effect on (B) UCP3 expression (n=8). 
Data collection was carried out in collaboration with Christopher McGinley (DCAT 
Summer Project Studentship). 
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Figure 3.28 Central Merck-3 treatment does not alter thermogenic programming in 
white adipose tissue. 
Histograms showing relative mRNA expression of (A) UCP1, (B) PGC1α, (C) DIO2 and 
(D) Prdm16 in white adipose tissue. (A) Central Merck-3 treatment causes a trend 
towards an increase in UCP1 (n=7-8) relative expression. (B-D) Central Merck-3 
treatment causes no significant effect on (B) PGC1α (n=8), (C) DIO2 (n=8) or (D) 
Prdm16 (n=8) relative expression.  
Data collection was carried out in collaboration with Dr. Gemma Montagut. 
  
123 
 
 
 
3.3.11 Central inhibition of BACE1 modifies high-fat diet-
mediated inflammatory programming in diet-induced 
obese mice 
Having observed that peripheral inhibition of BACE1 (AZ4217 treatment) reduced WAT 
inflammation we next examined whether central inhibition would cause the same effect. 
In the hypothalamus pro inflammatory cytokines, markers of the inflammasome and total 
macrophage expression were measured, as described previously for the AZ4217 study 
(section 3.3.5). In the hypothalamus central Merck-3 treatment caused no effect on TNFα 
expression (Figure 3.29A) however reduced IL-6 expression (Control; 1.00 ± 0.12 vs. 
Merck-3; 0.80 ± 0.07, p<0.05, n=7-9, Figure 3.29B) compared to control mice. IL-1β, 
NLRP3 and Caspase 1 levels were reduced following central Merck-3 treatment relative 
to DIO controls (IL-1β: Control; 1.00 ± 0.16 vs. Merck-3; 0.63 ± 0.12, p<0.05, NLRP3: 
Control; 1.00 ± 0.14 vs. Merck-3; 0.68 ± 0.04, p<0.001, Caspase 1: Control; 1.00 ± 0.11 
vs. Merck-3; 0.69 ± 0.10, p<0.05, n=7-9, Figure 3.29C, D and E), however F4/80 
expression, as an indication of total macrophage levels, was not altered (Figure 3.29F). 
Taken together these data show central Merck-3 treatment reduces hypothalamic 
inflammation through a large reduction in IL-1β and markers of the inflammasome, 
suggesting reduced central inflammatory programming may drive a proportion of the in-
vivo changes observed in our mice. 
In WAT pro- and anti-inflammatory cytokines, previously described for AZ4217 
treatment (section 3.3.5), as well as F4/80 expression were measured. Central Merck-3 
treatment drove a reduction in NOS2 expression (Control; 1.00 ± 0.10 vs. Merck-3; 0.67 
± 0.13, p<0.05, n=7-8, Figure 3.30A), but did not alter IFNγ, IL-1β or TNFα compared to 
controls (Figure 3.30B, C and D). Interestingly, central Merck-3 treatment caused a trend 
towards an increase in IL-6 expression compared to control mice (Control; 1.00 ± 0.10 
vs. Merck-3; 1.76 ± 0.36, p=0.07, n=8, Figure 3.30E). Central Merck-3 treatment also 
drove a large increase in anti-inflammatory cytokines IL-10, YM-1 and Arg-1 compared 
to control mice (IL-10: Control;1.00 ± 0.27 vs. Merck-3; 1.43 ± 0.15, p<0.05, YM-1: 
Control; 1.00 ± 0.13 vs. Merck-3; 2.69 ± 0.63, p<0.05, Arg-1: Control; 1.00 ± 0.15 vs. 
Merck-3; 1.69 ± 0.21, p<0.05, n=6-8, Figure 3.30F, G and H), and a slight trend towards 
an increase in F4/80 expression compared to control mice (p=0.07, Figure 3.30I). 
Collectively these data, in particular the large increase in anti-inflammatory cytokines, 
suggests central BACE1 inhibition is modifying inflammatory programming in WAT. 
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Figure 3.29 Central Merck-3 treatment significantly reduces pro-inflammatory 
cytokines and markers of the inflammasome, but does not affect F4/80 expression in 
the hypothalamus. 
Histograms showing relative mRNA expression of pro-inflammatory cytokines (A) TNFα 
, (B) IL-6, (C) IL-1β, markers of the inflammasome (D) NLRP3, (E) Caspase 1 and 
macrophage marker (F) F4/80 in the hypothalamus.(A) Central Merck-3 treatment causes 
no significant effect on TNFα expression (n=7-9). (B) Central Merck-3 treatment causes 
a significant reduction in (B) IL-6 expression (p<0.05, n=7-9).(C) Central Merck-3 
treatment causes a significant reduction in IL-1β expression (p=0.05, n=7-9, and a 
significant reduction in other markers of the inflammasome (D) NLRP3 (p<0.001, n=7-
9) and (E) Caspase 1 (p<0.05, n=7-8) expression. (F) Central Merck-3 treatment results 
in a non-significant trend towards an increase in total macrophage number measured by 
F4/80 expression (n=7-9). 
Data collection was carried out in collaboration with Dr. Paul J Meakin and Karolina 
Parmionova (Masters Student).  
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Figure 3.30 Central Merck-3 treatment increases anti-inflammatory signalling in 
white adipose tissue. 
Histograms showing relative mRNA expression of pro-inflammatory cytokines (A) 
NOS2, (B) IFNγ, (C) IL-1β, (D) TNFα, (E) IL-6, anti-inflammatory cytokines (F) IL-10, 
(G) YM-1, (H) Arg-1 and macrophage marker (I) F4/80 in white adipose tissue.(A) 
Central Merck-3 treatment causes a significant reduction in NOS2 expression (p<0.05, 
n=7-8). (B-D) Central Merck-3 treatment caused no significant effect on pro-
inflammatory cytokines IFNγ, IL-1β and TNFα expression (n=8), although showed a trend 
towards an increase in (E) IL-6 (p=0.07, n=8) expression. (F-H) Central Merck-3 
treatment caused a significant increase in anti-inflammatory cytokines IL-10 (p<0.05, 
n=7-8), YM-1 (p<0.05, n=8) and Arg-1 (p<0.05, n=6-8). (I) Total number of macrophages 
are unchanged, indicated by (I) F4/80 expression (n=8).  
Data collection was carried out in collaboration with David Allsop (PhD Student).  
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Macrophage infiltration of WAT was also examined via measuring levels of chemotactic 
cytokines; MCP-1, MIP-1α and MIP-1β, and RANTES, as previously described for 
AZ4217 treatment (section 3.3.5). Central Merck-3 treatment had no effect on MCP-1, 
MIP-1α or RANTES (Figure 3.31A, B and D), and raised MIP-1β levels (Control; 1.00 ± 
0.10 vs. Merck-3; 1.75 ± 0.29, p<0.05, n=7-8, Figure 3.31C) relative to controls. TGFβ-
1 levels were also unaltered following Merck-3 treatment, compared to control mice 
(Figure 3.31E). These data suggest that central Merck-3 treatment does not affect 
chemokine expression, and therefore macrophage migration and/or infiltration of WAT.  
Taken together these data (supported by results from BACE1-/- mice and mice treated with 
peripheral Merck-3 (unpublished data)) demonstrate that BACE1 may play a role in HFD 
mediated inflammatory programming, with central inhibition of BACE1 reducing 
inflammation both centrally (hypothalamus) and peripherally (WAT), and this could 
drive, in part, the improved obese/diabetic phenotype of mice with reduced BACE1 
levels.  
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Figure 3.31 Central Merck-3 treatment significantly increases MIP-1β expression in 
white adipose tissue, but does not alter the expression of other chemokines. 
Histograms showing relative mRNA expression of chemokines (A) MCP-1, (B) MIP-1α, 
(C) MIP-1β, (D) Rantes, and (E) TGFβ-1 in white adipose tissue. (A and B) Central 
Merck-3 treatment does not cause a significant effect on MCP-1 (n=7-8), or MIP-1α (n=6-
8) expression. (C) Central Merck-3 treatment causes a significant increase in MIP-1β 
expression (p<0.05, n=7-8). (D and E) Central Merck-3 treatment causes no significant 
effect on Rantes (n=7-8) or (E) TGFβ-1 (n=7-8) expression.  
Data collection was carried out in collaboration with David Allsop (PhD Student).  
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3.4 Discussion 
3.4.1 Summary 
Within this chapter we set out to investigate the effects of treating DIO mice with BACE1 
inhibitors and comparing the results to the previously reported metabolic phenotype of 
the BACE1-/- mouse. The results from these studies are summarised in Table 3.1. Overall, 
we found both peripherally and centrally inhibiting BACE1 (using AZ4217 and Merck-
3) improved all metabolic outcomes in DIO mice (excluding insulin sensitivity), however 
AZ3839 had no effect. Through studies utilising real-time PCR, to examine changes in 
gene expression, we found both peripheral and central BACE1 inhibition alters the 
expression of genes involved in hypothalamic leptin signalling, and may promote 
orexigenic signalling. Real-time PCR studies demonstrated no clear effect on 
thermogenesis following peripheral and central BACE1 inhibition, with a lack of 
consistent changes in the expression of genes involved in thermogenic programming. 
Lastly, both peripheral and central BACE1 inhibition altered a degree of high-fat diet 
driven inflammation, through changes in gene expression of cytokines and chemokines 
in both the hypothalamus and WAT, generally driving a reduction in pro-inflammatory 
cytokine expression following treatment. These results, and the potential underlying 
mechanisms, will be further discussed in the following sections. 
Metabolic 
Outcome 
BACE1-/- AZ4217 AZ3839 Merck-3 
(central 
infusion) 
Body weight ↓ ↓ - ↓ 
Fat mass ↓ ↓ - / 
Food intake - - - - 
Leptin levels ↓ ↓ - ↓ 
Glucose 
tolerance 
↑ ↑ - ↑ 
Insulin 
sensitivity 
- - - - 
Table 3.1 Summary of results for metabolic outcomes measured during inhibitor 
studies and previously reported BACE1-/- studies.  
Symbols as follows: ↓, reduced. ↑, improved. -, unchanged. /, could not be measured. 
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3.4.2  Pharmacological inhibition of BACE1 improves an 
obese/diabetic phenotype 
Herein we have demonstrated that pharmacological inhibition of BACE1 (with peripheral 
AZ4217 and central Merck-3 treatment) in DIO mice improves an obese/diabetic 
phenotype. This was observed through improvements in a variety of metabolic markers 
and the results mimic the effects of genetically reducing BACE1 (Meakin et al. 2012) or 
pharmacologically inhibiting BACE1 with Merck-3 administered peripherally 
(unpublished data). Overall, the weight loss and glucose homeostasis effects measured in 
the BACE1-/- mouse are emulated with both peripheral and central inhibition of BACE1, 
shown by a large reduction in body weight, specifically due to a reduction in fat mass in 
AZ4217 treated mice (this could not be measured in centrally treated mice), over the 
course of treatment. Unlike AZ4217 treatment, it was observed that with central Merck-
3 treatment there was a rebound in body weight after day 14 of treatment, where treated 
animals began to slowly re-gain weight. This may be due to compensatory mechanisms 
being initiated as the reduction in body weight following initial administration of the drug 
was dramatic and these mice lost more weight in the first two weeks of the study than 
those treated peripherally. A re-bound in body weight is often observed following rapid 
and large weight loss regimes in humans (Blomain et al. 2013). As mentioned, the 
compound utilised in the central inhibitor experiments has previously been tested 
peripherally (unpublished data) and in the current studies we utilised the same dose. 
Sankaranarayanan and colleagues reported that Merck-3 poorly penetrates the BBB 
(Sankaranarayanan, Price, Wu, M. Crouthamel, et al. 2008) when administered 
peripherally. In contrast to these results, our lab found that Merck-3 does enter the brain, 
reaching concentrations of 250pmol/g (wet brain) (unpublished data). Therefore, when 
Merck-3 is delivered directly into the lateral ventricle the central concentration may be 
very high, causing a rapid and dramatic loss of body weight, and so engaging alternative 
compensatory weight-gain mechanisms. Future studies would be required to examine the 
amount of Merck-3 that is present in the brain, following central administration, using 
mass spectrometry of brain samples from treated mice to determine if the concentration 
is indeed far higher than when Merck-3 is administered peripherally.  
In line with the correlation between circulating levels of leptin and fat mass (Maffei et al. 
1995) we also observe a large reduction in plasma leptin levels in AZ4217 treated mice. 
This suggests inhibition of BACE1 is causing a reduction in the high circulating levels of 
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leptin which develop in obesity (Considine et al. 1996), and as a result is reversing the 
resulting leptin resistance. It has formerly been reported that BACE1-/- mice also display 
increased leptin sensitivity, even when challenged with a HFD (unpublished data), 
supporting the concept that a reduced degree of adiposity or resistance to diet-induced 
obesity is the result of increased hypothalamic leptin sensitivity. Interestingly, these 
effects are dependent on leptin. In the genetically obese ob/ob and db/db mouse models 
BACE1 inhibition does not elicit beneficial effects (unpublished data), demonstrating that 
reduction of BACE1 not only increases leptin sensitivity, but requires intact leptin 
signalling to produce metabolic effects. The requirement for intact leptin signalling is 
suggestive of a centrally acting mechanism driving the observed effects as the signalling 
form of the leptin receptor is predominantly expressed in the hypothalamus (Fei et al. 
1997; Lee et al. 1996), and the hypothalamus, primarily the ARC, is the main site of leptin 
resistance (Enriori et al. 2007). Unfortunately, we do not observe a significant reduction 
in leptin levels in centrally treated mice, although there is a trend towards a reduction, 
which may be due to the observed re-bound in body weight. Leptin levels were measured 
at the end of the study when the mice had re-gained weight, thus there is likely an 
associated rise in leptin levels. It would be beneficial to measure leptin levels when mice 
have been treated centrally with a lower dose of Merck-3, or alternatively if the duration 
of the study was modified to a time point where mice were maintaining steady weight 
loss (i.e terminate the study at day 14). Additionally, it is important to highlight that in all 
studies we have not definitively measured leptin sensitivity. It is necessary to examine 
changes in food intake and body weight and/or pSTAT3 in response to exogenous leptin 
treatment following short-term treatment with peripherally administered Merck-3, to give 
a precise assessment of the effect of BACE1 inhibition on leptin sensitivity. A measure 
of leptin sensitivity has been carried out in BACE1-/- mice (unpublished data) by 
continuous daily injections of leptin to attain plasma levels higher than observed for DIO. 
Interestingly, BACE1-/- mice do not develop obesity when challenged with a HFD, 
demonstrating that not only is intact leptin signalling required for the effects of BACE1 
inhibition, but there is a reciprocal requirement of a minimum level of BACE1 to cause 
the development of leptin resistance. 
In models of obesity a reduction in body weight can often be linked to a concomitant 
reduction in food intake. Within our studies we observed that BACE1 inhibition (central 
and peripheral) does not alter food intake, thus mice are not consuming less to account 
for their reduced body weight. Conversely, we observed that these mice have relative 
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hyperphagia in relation to body weight. This is an effect observed at the end of the study 
in AZ4217 treated mice, and at day 16 for central Merck-3 treated mice, indicative of the 
point at which weight loss is greatest. Moreover, BACE1-/- mice also display hyperphagia 
in response to fasting, in comparison to WT littermates (unpublished data). As no change 
in daily food intake is observed when BACE1 is reduced, however mice are relatively 
hyperphagic, we assume the loss of body weight is caused by increased energy 
expenditure. In support of this, BACE1-/- mice reportedly have an increased resting 
metabolic rate (Meakin et al. 2012), a result also observed in mice treated peripherally 
with Merck-3, however no change in locomotor activity is observed (unpublished data). 
Unfortunately, these measurements could not be attained in the BACE1 inhibitor treated 
mice described in these studies due to technical issues; therefore no change in actual 
energy expenditure can be definitively concluded. As all metabolic changes found in these 
mice mimic those recorded in peripheral Merck-3 treated and BACE1-/- mice, it can be 
hypothesised that AZ4217 and central Merck-3 treatment will also cause increased resting 
metabolic rate with no alterations in locomotor activity. Taken together, it is hypothesised 
that mice treated with a BACE1 inhibitor are not exercising more and consequently the 
increased energy expenditure may be by means of upregulated thermogenic 
programming.  
Within this chapter we have shown that inhibition of BACE1 (peripheral and central) 
improves glucose homeostasis, through increased glucose disposal and fasted blood 
glucose levels during a GTT. These data suggest increased glucose uptake by peripheral 
tissues (Hamilton et al. 2014) and reversal of impaired glucose handling observed in 
obese mouse models (Bray & York 1979; Winzell & Ahren 2004). Again, this was an 
effect which mimicked findings from BACE1-/- mice (Meakin et al. 2012) and peripheral 
Merck-3 treated mice (unpublished data). Furthermore, BACE1 overexpression in vitro, 
in skeletal muscle cells, has been shown to decrease glucose uptake (Hamilton et al. 
2014). Only mild improvements in glucose homeostasis are observed in NC fed animals 
given Merck-3 peripherally (unpublished data), indicating this beneficial effect only 
occurs in an obese state when BACE1 levels are elevated. Noteworthy, is that we 
performed GTTs on day 14 of the studies, at which point central Merck-3 treated mice 
show the greatest reduction in body weight, therefore, it is unsurprising that we observe 
effects on glucose handling. In support of an improved diabetic phenotype, insulin 
sensitivity was also measured in these studies and only modest improvements were 
observed. This was not unique to our studies, as this is also observed with peripheral 
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Merck-3 treatment (unpublished data). Due to the retention of leptin sensitivity and 
improved glucose homeostasis it was hypothesised that BACE1 inhibition may also 
reverse insulin resistance, although this was not demonstrated in our studies. BACE1-/- 
mice show increased insulin sensitivity (Meakin et al. 2012) and BACE1 inhibition in 
vitro, on skeletal muscle cells, show enhanced insulin signalling (Hamilton et al. 2014). 
Therefore, a lack of effect in our study may be due to the length of treatment and possibly 
a longer period of inhibition would be required to evoke changes in insulin tolerance and 
serum insulin levels. As the development of insulin resistance can be considered, at least 
in part, to be due to central effects as insulin receptors are also present in the 
hypothalamus, it may be interesting to focus on central inhibitor studies to address this. 
Noteworthy, is that during central inhibitor studies the ITT was conducted during the re-
bound of body weight and this may mask any changes so it would be beneficial to re-test 
insulin sensitivity with a lower dose of Merck-3 or before substantial weight is re-gained.  
Interestingly, AZ3839 (a structurally different BACE1 inhibitor) did not induce the same 
metabolic effects as the previously tested compounds; causing no change in body weight, 
food intake, or glucose homeostasis in DIO mice. In addition, treatment of DIO mice with 
AZ3839 did not reduce circulating levels of leptin, which has been found to be one of the 
larger effects observed with BACE1 inhibition utilising other compounds. If it is assumed 
reducing BACE1 improves an obese phenotype by increasing leptin sensitivity and this 
effect is necessary to cause the resulting metabolic changes, AZ3839 may not reduce 
circulating leptin levels sufficiently to see any subsequent body weight and glucose 
tolerance changes. This inability of AZ3839 to replicate the effects of previously tested 
BACE1 inhibitors may be due to the route of administration, which was via oral gavage. 
Compounds administered through the oral route tend to have a slower onset of action and 
can have reduced absorption, mainly due to the first-pass effect of the liver which results 
in a reduced concentration of compound entering the general circulation (Turner et al. 
2011). It is necessary to measure the concentration of AZ3839 centrally and in the plasma 
to further clarify this. Additionally, dose and/or route of delivery (i.e peripheral 
administration via osmotic minipump) of AZ3839 may need to be adjusted for further 
testing. It is important to note that the benefit and reason for utilising orally active 
compounds is to reflect the administration of the drug if it were to be transitioned to 
humans. Furthermore, we also do not have a measure, in any of our inhibitor studies, of 
the magnitude to which the compounds tested reduce BACE1 activity. It has been shown 
that following peripheral treatment with Merck-3 that BACE1 protein levels are reduced 
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in the hypothalamus and WAT (unpublished data) and it can be assumed the compounds 
tested in these experiments will elicit the same effects. However, it is necessary to reliably 
measure BACE1 activity and this could be achieved by measuring sAPPβ levels by 
ELISA. This would provide the knowledge of the magnitude in which BACE1 activity is 
reduced following treatment with a BACE1 inhibitor, and potentially demonstrate 
AZ3839 does not reduce BACE1 activity adequately. Due to time constraints and animal 
numbers repeated testing of AZ3839 could not be conducted, and as we have shown two 
structurally different compounds result in the same metabolic effects it was not deemed 
necessary to validate the effects of BACE1 inhibition further.  
3.4.3 Inhibition of BACE1 alters hypothalamic leptin signalling 
Data within this chapter demonstrate that inhibition of BACE1 not only reduces 
circulating serum leptin levels but also leptin and ObRb mRNA levels in WAT, 
supporting the notion that BACE1 inhibition is reversing diet-induced leptin resistance. 
These data suggest that BACE1 may directly affect adipocytes to alter transcription of 
leptin and the levels of protein made. Additionally, these data propose a role for leptin 
signalling and that inhibiting BACE1 may modify the hypothalamic circuits involved in 
retaining leptin responsiveness. This is consistent with an observed reduction in 
anorexigenic neuropeptides, and a concomitant trend towards an increase in 
orexigenic/anorexigenic transcript ratios in inhibitor treated mice (central and peripheral) 
which echoes results reported from peripheral Merck-3 treated animals (unpublished 
data). These data suggest that reducing BACE1 may promote orexigenic signalling in the 
hypothalamus, which is consistent with the relative hyperphagia exhibited in these mice 
and is also suggestive of altered energy expenditure.  
In addition, negative regulators of leptin signalling are altered following inhibition of 
BACE1, providing a possible explanation for the observed reversal of leptin resistance. 
Notably, SOCS3 mRNA is reduced following AZ4217 treatment, supportive of a reversal 
of leptin resistance as SOCS3 inhibits leptin signalling and is reported to be a mediator 
of leptin resistance (Bjorbak et al. 2000; Banks et al. 2000). Conversely, PTP1B transcript 
levels are unchanged with AZ4217 treatment. These effects were not observed following 
central inhibition of BACE1 with Merck-3, with no changes found in SOCS3 mRNA and 
unexpectedly PTP1B transcript levels were increased. PTP1B also inhibits leptin (and 
insulin) signalling and is increased centrally in high-fat fed animals (Zabolotny et al. 
2002; White et al. 2009), so we would expect levels to decrease in our mice as leptin 
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sensitivity is enhanced. This is observed in BACE1-/- mice that display reduced PTP1B 
levels in comparison to WT littermates. Furthermore, following a HFD PTP1B levels are 
increased in WT littermates, however this response is diminished in BACE1-/- mice 
(unpublished data). The reported PTP1B expression in our studies is transcript levels 
only, therefore it is necessary to measure protein levels before assuming the increase in 
PTP1B in centrally treated mice, or lack of response in AZ4217 treated mice, is of 
physiological relevance. Accordingly, a role for PTP1B in re-sensitising BACE1 inhibitor 
treated mice to leptin should not be ruled out and future work investigating this, primarily 
through Western blotting for PTP1B in the hypothalamus of inhibitor treated mice should 
be conducted. Particularly owing to the fact neuronal PTP1B KO mice display a similar 
phenotype to our inhibitor treated mice and BACE1-/- mice (Bence et al. 2006). 
Conversely, we may conclude that although BACE1 inhibition reduces WAT leptin 
expression, and circulating leptin levels, a direct action on hypothalamic leptin signalling 
is not necessarily responsible for this outcome. 
3.4.4  The effects of inhibition of BACE1 on thermogenic 
programming 
As previously considered the relative hyperphagia, but lack of change in total food intake, 
observed in BACE1 inhibitor treated mice alludes to the fact there is increased energy 
expenditure. This is not due to changes in locomotor activity (measured in BACE1-/- mice 
and peripherally Merck-3 treated mice) and therefore it may be through heat loss. Markers 
of thermogenic programming (UCP1, PGC1α, DIO2 and Prdm16), are upregulated in 
BAT indicating switching on of thermogenesis, and can also be detected in WAT 
representing ‘brite’ adipocytes, indicative of enhanced thermogenesis (Seale et al. 2011; 
Cao et al. 2011). These markers were examined in the current study and interestingly we 
observed no change in thermogenic programming in both BAT and WAT of AZ4217 
treated mice; opposing findings from BACE1-/- mice and peripheral Merck-3 treated mice. 
Only PGC1α transcript levels changed in both tissues and Prdm16 showed reduced 
expression in WAT, suggestive of reduced adaptive thermogenesis in WAT as the 
upregulation of thermogenic genes in WAT is thought to be correlated with levels of 
Prdm16 (Seale et al. 2011). Central Merck-3 treated mice showed an upregulation in 
thermogenic genes (PGC1α, DIO2 and Prdm16) in BAT which may indicate enhanced 
thermogenic programming, although UCP1 levels were unchanged. These data suggest 
that central Merck-3 treatment alters thermogenic programming in BAT, indicative that 
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this mechanism is centrally driven. Furthermore, we hypothesise that this would be a more 
striking effect if tissue had been examined when weight loss was at its peak. Many 
centrally acting signals have been implicated in the regulation of BAT thermogenesis and 
the browning of WAT, including fibroblast growth factor 21 (FGF21), TGFβ and brain 
derived neurotrophic factor (BDNF) (Schulz & Tseng 2013), therefore it would be of 
interest to measure hypothalamic levels of these factors in inhibitor treated mice to 
examine their contribution to the enhanced adaptive thermogenesis. Thermogenic genes 
in WAT showed no changes in central Merck-3 treated mice although, as mentioned, this 
may be due to the time point at which the tissue was examined as there is a trend towards 
an increase in UCP1 levels suggestive of browning of WAT occurring. Additionally, no 
change was observed in UCP2 and UCP3 gene expression in skeletal muscle from 
AZ4217 or central Merck-3 treated mice. Collectively, these data suggest that alterations 
in thermogenic programming may occur through a central mechanism with central 
Merck-3 treatment showing greater effects than AZ4217 treatment. Although, overall our 
results indicate that thermogenesis is unlikely to be the main factor driving reduced 
obesity in BACE1 inhibitor treated mice. This is contradictory to results from peripheral 
Merck-3 treated and BACE1-/- mice where UCP1 expression in BAT, and UCP2 and 
UCP3 expression in muscle is enhanced, as well as an upregulation of thermogenic 
markers in WAT (unpublished data). However, AZ4217 is structurally different from 
Merck-3 and therefore unsurprisingly may act differently on target tissues. Additionally, 
the route of delivery of AZ4217 in our studies and Merck-3 from previous work are 
different, with AZ4217 delivered via oral gavage and Merck-3 through an osmotic 
minipump placed subcutaneously. Consequently, AZ4217 plasma and central levels may 
not be sufficient to reduce BACE1 adequately to reproduce all the effects observed with 
the concentration of Merck-3 utilised, which we believe is inhibiting BACE1 adequately. 
Taking this into consideration, as well as the fact increases in thermogenic genes in BAT, 
WAT and skeletal muscle are upregulated in BACE1-/- mice (Meakin et al. 2012, 
unpublished data), and more recent data establishing BACE1-/- mice have a higher body 
temperature (unpublished data) suggest, although increased thermogenesis may not be 
the mechanism whereby AZ4217 elicits its effects, it may still be a driving factor for the 
phenotype observed with reduced BACE1.  
3.4.5  Inhibition of BACE1 alters inflammatory programming 
We have shown that treatment with AZ4217 does not impact thermogenic programming, 
leaving the mechanism responsible for the improved metabolic phenotype undetermined. 
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Another contributor to leptin resistance is inflammation (Zhou & Rui 2013) which is 
associated with and caused by diet-induced obesity. As changes in leptin sensitivity, 
associated with reduced BACE1, are observed in the hypothalamus and leptin mRNA is 
reduced in WAT, in the present study, these tissues were examined regarding 
inflammatory status. Enhanced expression of pro-inflammatory cytokines can be 
observed as early as a few days post HFD in the hypothalamus (Thaler et al. 2012). In the 
present study mice have been fed a HFD for 20 weeks prior to BACE1 inhibitor treatment, 
therefore it is hypothesised that these mice will have increased pro-inflammatory cytokine 
expression. If this is assumed, this effect is attenuated with AZ4217 treatment which 
causes a large reduction in transcript levels of the pro-inflammatory cytokine TNFα. 
Although, other pro-inflammatory cytokines and markers of the inflammasome are 
unchanged. Collectively, these data indicate AZ4217 treatment does not impact 
hypothalamic inflammation. Peripheral inflammation, in WAT, has been found to be 
reduced in BACE1-/- mice and peripheral Merck-3 treated mice, through reduced 
expression of pro-inflammatory cytokines and raised expression of anti-inflammatory 
cytokines (unpublished data). Furthermore, BACE1-/- mice also demonstrate reduced 
immune cell number, notably macrophages. Alike the hypothalamus, TNFα transcript 
levels are reduced in WAT following AZ4217 treatment, as well as reduced F4/80 mRNA 
levels utilised as an indication of total macrophage expression. However, all other pro-
inflammatory cytokines examined remain unchanged, as do anti-inflammatory cytokines 
analysed, suggesting reduced peripheral inflammation is not the main contributor for the 
improved obese phenotype in these mice. Although no change in inflammatory 
programming is observed with AZ4217 treatment in both central and peripheral tissues, 
a reduction is seen in chemokine (MCP-1, MIP-1α and MIP-1β) expression in WAT 
which is suggestive of a reduction in the recruitment and infiltration of macrophages to 
the WAT (Surmi & Hasty 2010). This is supportive of the fact MIP-1α and MIP-1β in 
WAT are elevated in obesity (Surmi et al. 2010; Surmi & Hasty 2008) Further validation 
of the protein levels of both MIP-1α and MIP-1β are required, as the present data represent 
transcript expression only. Taken together, these data demonstrate moderate effects of 
AZ4217 treatment on peripheral HFD-induced inflammation and the accumulation of 
macrophages at peripheral tissue. As with the collected thermogenesis data, these results 
are not comparable to the effects observed in peripheral Merck-3 treated or BACE1-/- 
mice, presumably due to structural differences in AZ4217 and its efficacy of reducing 
BACE1 in central and peripheral tissues.  
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Our study revealed that central Merck-3 treatment diminished hypothalamic 
inflammation arising from diet-induced obesity, causing reductions in pro-inflammatory 
cytokines (IL-6 and IL-1β) and markers of the inflammasome (NLRP3 and caspase 1). 
An associated reduction in NOS2 and a concomitant increase in anti-inflammatory 
cytokines (IL-10, YM-1, and Arg-1) is also observed in the WAT from central Merck-3 
treated mice. Furthermore, upon termination of the study it was noted that spleen size 
from these mice was increased. An increased spleen is generally associated with 
inflammation and increased neutrophils within the circulation, thus we may observe a 
greater splenic mass due to the re-bound in weight resulting in an increase in 
inflammatory processing. Alternatively, this may be a physiological response and the 
greater splenic size could represent an increased number of immune cells, such as anti-
inflammatory M2-like macrophages, that do not exacerbate the inflammatory state but 
are required to deal with chronic diet-induced inflammation. Taken together, these data 
demonstrate a drive towards reduced central and peripheral inflammation, which was not 
observed with AZ4217 treatment, however correlates with the reported inflammatory 
phenotype of BACE1-/- mice and peripheral Merck-3 treated mice. This indicates a central 
mechanism likely drives the altered inflammatory profile observed following reduced 
BACE1. To determine the mechanisms behind this further, it would be interesting to study 
the brains of inhibitor treated mice, utilising IF, staining for astrocytes and microglia as 
these cells are a central source of cytokines when activated in response to stress (Avila-
Muñoz & Arias 2014; Choi et al. 2014). For example, in AD Aβ activates astrocytes and 
microglia resulting in the secretion of cytokines and exacerbation of the disease 
(Johnstone et al. 1999). We would hypothesise that BACE1 inhibition would reduce the 
number of activated microglia and astrocytes driven by chronic nutrient excess, thus 
reducing the secretion of cytokines. Additionally, of interest would be to co-stain for 
astrocytes and microglia with BACE1 to observe if BACE1 is expressed in these cell 
types in DIO mice, to determine if BACE1 acts directly on these cells to alter 
inflammatory processing. It may be hypothesised that BACE1 does elicit its effects 
through direct action on immune cells, as low BACE1 expression is observed in vitro in 
bone marrow derived macrophages (BMDMs), and this is elevated when BMDMs are 
stimulated with palmitate (modelling the effects of high-fat feeding in vivo) (unpublished 
data). To examine this further it would be of interest to remove BACE1 exclusively from 
immune cells using a conditional BACE1-/- mouse with loxed alleles crossed with a mouse 
line with cre expression specifically in immune cells. Furthermore, to investigate if 
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BACE1 is affecting the macrophages by interacting with other tissues it will also be 
necessary to remove BACE1 exclusively in WAT and more interestingly, as we assume 
a central mechanism is involved, in neurons, utilising the same cre lox technology.  
In both central and peripheral tissues F4/80 expression, utilised as a crude measurement 
of total macrophage expression, is unchanged with central Merck-3 treatment implying 
total numbers of macrophages are unaffected. However, to solidify this result a more 
direct measure would need to be carried out such as utilising flow cytometry to quantify 
absolute macrophage numbers, as F4/80 transcript levels do not represent actual 
macrophage numbers. This has been performed in BACE1-/- mice and peripheral Merck-
3 treated mice, and both show reduced actual macrophage numbers (unpublished data). 
Unlike peripheral AZ4217 treatment, central inhibition of BACE1 did not alter 
chemokine levels (MCP-1, MIP-1α, RANTES and TGFβ-1) in WAT. Importantly, 
transcript levels of these chemokines, as with F4/80 expression, is only a guide 
measurement, and the levels of these transcripts will not demonstrate the actual ability of 
the macrophages to respond to chemotaxis signals. Of benefit would be to examine 
protein levels of these chemokines to determine if changes in transcript levels relate to 
functional changes. Furthermore, to definitively examine the effects of BACE1 on 
macrophage migration and chemotaxis we would need to employ in vitro models utilising 
migration chambers to study the ability of macrophages to migrate in the presence of high 
BACE1 levels or when BACE1 is reduced. Interesting future work would also be to 
examine ER stress markers in central and peripheral tissues, as diet-induced inflammation 
is associated with increased ER stress, and leptin resistance is particularly associated with 
central, hypothalamic ER stress (Zhou & Rui 2013; Ozcan et al. 2004). In addition, 
BACE1-/- mice reportedly show reduced expression of ER stress related genes in the 
hypothalamus even when exposed to a HFD (unpublished data). Therefore, we 
hypothesise BACE1 inhibition may reduce central ER stress associated with obesity, and 
this will contribute to the improved leptin sensitivity in BACE1 inhibitor treated DIO 
mice. 
3.4.6  Concluding Remarks 
The data presented within this chapter, with recent work from our lab, provide evidence 
that BACE1 inhibition could be a novel therapeutic strategy for the treatment of metabolic 
disease. We have shown that partial reduction of BACE1 improves an obese/diabetic 
phenotype in DIO mice by reducing body weight and improving glucose homeostasis. 
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The data presented herein implicate modifications in thermogenic and inflammatory 
programming to mediate the metabolic changes observed following BACE1 inhibition, 
and that this may be in large part due to a centrally acting mechanism. Further work is 
necessary to examine the precise mechanisms whereby BACE1 inhibition increases 
energy expenditure through thermogenesis and alters inflammatory processing to reduce 
diet-induced inflammation. It would be of benefit to test the metabolic effects of a 
clinically tested BACE1 inhibitor with the knowledge from this research allowing for 
future work to repurpose BACE1 inhibitors currently trialled for AD treatment for the 
treatment of obesity and T2DM. 
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Chapter 4 
 
 
 
The role of APP processing on an obese and 
diabetic phenotype 
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4.1 Introduction 
In the previous chapter it was demonstrated that inhibition of BACE1 improves an 
obese/diabetic phenotype, mimicking the effects observed utilising a previously tested 
BACE1 inhibitor and the phenotype of BACE1-/- mice. The data alluded to the notion that 
this improvement may be predominantly due to a centrally acting mechanism, affecting 
inflammation and/or thermogenic programming. However, as yet the precise mechanism 
is still unknown. This is a difficult concept to unpick as BACE1 has a number of 
substrates other than APP, and as yet many are unidentified (Vassar 2014). The majority 
of BACE1 substrates are type 1 transmembrane proteins and many have centrally acting 
roles (Hemming et al. 2009). Those identified include neureglin-1 type III (NRG1) which 
is involved in myelination (Hu et al. 2006), a neural cell adhesion molecule; CHL1, 
involved in axonal growth and ventricle development (Heyden et al. 2008) and Jagged 1 
(JAG1) which is involved in notch signalling to control cell differentiation (Hu et al. 
2013). In addition, substrates involved in immune cell function, primarily immune cell 
adhesion and activation, have also been described for BACE1. These include the type II 
transmembrane protein, TGN-resident β-galactoside α2,6-sialytransferase (ST6Gal1) 
(Kitazume et al. 2001) and P-selectin glycoprotein ligand-1 (PSGL-1) which is also a 
substrate for the α-secretase (Lichtenthaler et al. 2003), as well as the interleukin 1 
receptor II (IL-1R2) proposed as a potential substrate (Kuhn et al. 2007). Owing to the 
number of BACE1 substrates and the various functions of each it is challenging to 
decipher the precise role of BACE1 and which substrate it cleaves to mediate metabolic 
actions. 
The most characterised and studied substrate for BACE1, although it is in fact a relatively 
poor substrate, is APP. The majority of APP mutations giving rise to AD are due to 
increased BACE1-mediated APP processing (Vassar 2014; Jonsson et al. 2012). Thus, 
BACE1 may utilise APP as it’s substrate in regards to its functions in energy homeostasis, 
and if so, this knowledge would allow for a better understanding of the role of BACE1 in 
energy metabolism. The FAD associated Swedish mutation K67ON/M671L is a double 
mutation of APP localised to the N-terminus of the β-secretase cleavage site (Mullan et 
al. 1992). This mutation strengthens APP as a substrate for BACE1, whereby BACE1 
cleaves APP up to approximately 100-fold more efficiently than under normal 
circumstances, and accordingly results in increased Aβ levels (Vassar et al. 2009; Vassar 
2004). This mutation demonstrates BACE1-mediated processing of APP is implicated in 
the development of AD.  
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Under normal circumstances APP is a stronger substrate for the ADAMs; identified as 
the α-secretase. As a result the non-amyloidogenic pathway exists as the dominant 
pathway in regards to APP processing and α-secretase cleavage of APP occurs far more 
readily than BACE1 cleavage. In fact, BACE1 and the α-secretase compete for APP as a 
substrate, and blockage of one pathway gives rise to enhanced processing down the 
opposing route (Yan et al. 1999; Postina et al. 2004). This balance, which favours α-
secretase mediated processing of APP, is vital for cellular health, as sAPPα has been 
found to play physiological roles in synapse formation (Morimoto et al. 1998), neurite 
growth and neuronal survival (Araki et al. 1991). Furthermore, elevations in BACE1 lead 
to increased β-secretase cleavage, Aβ production and subsequently neuronal dysfunction 
and cell death (Hardy & Higgins 1992). Consequently, instances where the accessibility 
of BACE1 to utilise APP as a substrate over the α-secretase is detrimental, for example 
in the presence of high cholesterol (Marquer et al. 2011).  
Cholesterol metabolism is closely linked with APP and associated with AD, in particular 
through the ApoE gene which is present in plaques and tangles (Strittmatter et al. 1993). 
Specifically, the E4 allele of the ApoE gene is associated with high cholesterol (Sing & 
Davignon 1985) and this allele is strongly linked to FAD (Strittmatter et al. 1993). 
However, when cholesterol levels are depleted in neurons levels of Aβ are reduced 
(Simons et al. 1998), and furthermore when cholesterol is reduced in cells overexpressing 
ADAM10 there is an increase in sAPPα (Kojro et al. 2001). Consequently, enhancing α-
secretase cleavage is believed to beneficial in preventing AD progression. This is further 
supported by work showing overexpression of ADAM10; the predominant α-secretase in 
neurons (Kuhn et al. 2010), in mouse models of AD prevents plaque formation, whereas 
expression of a catalytically inactive form gives rise to plaque deposition (Postina et al. 
2004). Furthermore, mutations in ADAM10 are found in families with late-onset AD and 
reportedly cause attenuation of α-secretase activity and reduced sAPPα, accompanied 
with increased Aβ levels (Kim et al. 2009). Therefore, the non-amyloidogenic pathway is 
crucial for precluding Aβ production and may be a target of therapeutic intervention for 
AD. However, how alterations in α-secretase affect energy homeostasis is unknown, and 
if BACE1-mediated APP processing is pivotal for the role of BACE1 in metabolism is 
yet to be defined. 
In the present studies we aimed to investigate if disturbances in normal APP processing, 
resulting in elevated BACE1, would give rise to defects in energy metabolism. To do so, 
mice harbouring the double Swedish mutation implicated in FAD were challenged with 
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a HFD diet and various metabolic measurements taken. In addition, α-secretase activity 
was blocked in mice challenged with a HFD, and metabolic measurements examined. 
Both approaches alter the balance between non-amyloidogenic and amyloidogenic APP 
processing, causing increased BACE1-mediated APP processing. It was hypothesised 
that, if BACE1 is utilising APP as its substrate in regulating energy homeostasis, 
following increased BACE1 activity mice would demonstrate accelerated obesity and 
metabolic impairments associated with high-fat feeding. The knowledge from this 
research may provide information on the substrate BACE1 processes to contribute to 
energy metabolism and its overall role in energy homeostasis, as well as examining the 
role of α-secretase APP processing in the control of energy balance.  
  
144 
 
 
 
 
4.1.1 Objectives 
 Examine if elevated BACE1 activity, using two models (overexpression of a 
human APP mutation and blocking α-secretase processing), will drive metabolic 
disease when challenged with a HFD measuring the following metabolic 
outcomes: 
o Changes in body weight and body composition 
o Changes in food intake 
o Changes in glucose homeostasis 
o Changes in insulin sensitivity 
 Challenge mice overexpressing all isoforms of human APP containing the FAD 
associated Swedish mutation K67ON/M671L (hAPPswe mice) and littermates 
with a HFD for a period of 16 weeks 
o hAPPswe have approximately 2-3 fold increase in endogenous APP levels, 
increased β-secretase cleavage and Aβ levels, with a concomitant 
reduction in α-secretase cleavage (Lamb et al. 1997). 
 Block α-secretase processing in mice challenged with a HFD using an ADAM10 
inhibitor; GI254023X, for 28 days 
o ADAM10 is the predominant enzyme responsible for constitutive activity 
and basal α-secretase activity in neurons (Kuhn et al. 2010)GI254023X 
reportedly reduces sAPPα in vitro on SH-SY5Y cells (Tippmann et al. 
2009) and in vivo in mice (Powers et al. 2012), and is selective for 
ADAM10 over other ADAM members. 
4.2 Methods Summary 
For hAPPswe studies, adult (8 weeks of age) hAPPswe mice and WT littermates were 
challenged with a 60% HFD. 60% HFD was utilised to attempt to accelerate a DIO 
phenotype. Animals were weighed weekly throughout the duration of the study, at the 
same time each week. Glucose tolerance tests were carried out during weeks 5 and 10, 
following an overnight fast, and insulin tolerance tests were carried out during weeks 6 
and 11 following a four hour fast. An assessment of fat and lean mass was conducted at 
the beginning and end of the study. Throughout the study animals were maintained on the 
60 % HFD. Following 16 days of high-fat feeding mice were fasted overnight and tissue 
harvested. 
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For ADAM10 inhibitor studies, WT adult (8 weeks of age) mice were placed on a 45% 
HFD for one week. Following one week of high-fat feeding animals were treated with an 
ADAM10 inhibitor; GI254023X (ADAM10i) via central infusion directly into the lateral 
ventricle for 28 days. Throughout the study body weight and food intake measurements 
were taken daily. Glucose tolerance tests were performed on day 14 and day 28 of the 
study, following an overnight fast, and an insulin tolerance test was performed on day 21 
following a four hour fast. Throughout the study animals were maintained on the 45% 
HFD. Following 28 days of treatment mice were fasted overnight and tissue harvested. 
4.3 Results 
4.3.1  The effects of overexpressing hAPPswe in diet-induced 
obesity 
Owing to the increased β-secretase cleavage, hAPPswe mice were utilised as a model of 
enhanced BACE1 activity in order to study the interaction between increased BACE1 
activity and high-fat feeding. Due to reports of increased mortality in young homozygote 
mice, hemizygous mice were used in these studies. Hemizygous mice show a 7-8 fold 
increase in global Aβ1-42, however they do not display amyloid pathology as early as 
homozygote mice (Lamb et al. 1999). 
4.3.1.1  Overexpression of hAPPswe does not affect body weight gain on 
a high-fat diet 
hAPPswe mice (Starting body weight: 22.87 ± 0.67g; n=7) and WT littermates (Starting 
body weight: 23.19 ± 0.48g; n=16) were challenged with a 60% HFD to accelerate diet-
induced obesity. Mice were monitored over a 16 week period and body weight assessed 
by weighing mice weekly over the course of the study. hAPPswe mice did not exhibit any 
differences in body weight compared to WT littermates throughout the period of high-fat 
feeding; week 1 to 16, as presented by absolute (Figure 4.1A) and percentage change in 
body weight (Figure 4.1B). Taken together these data show hAPPswe overexpression 
does not result in exacerbated obesity when challenged with a HFD. 
4.3.1.2  Overexpression of hAPPswe does not alter glucose homeostasis 
in diet-induced obesity 
Although no change in body weight was observed when challenged with a HFD, the 
diabetic phenotype of hAPPswe mice was examined at 5-6 and 10-11 weeks of the study, 
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using glucose and insulin tolerance tests, to determine if a glucose-handling defect was 
present. At an early stage (5 weeks) no change in glucose disposal following an overnight 
fast was observed between hAPPswe mice and WT littermates (Figure 4.2A and B). At 
this time point there is also no impact on fasted blood glucose levels (Figure 4.2C). To 
determine whether this time point was too early to assess defects in glucose homeostasis 
a second glucose tolerance test, at a later stage (10 weeks), when a greater degree of 
obesity was achieved, was conducted. At 10 weeks there was still no difference in glucose 
disposal between hAPPswe mice and WT littermates (Figure 4.2D and E) or fasted blood 
glucose levels (Figure 4.2F); levels remained comparable to measurements taken at 5 
weeks.  
At both an early (week 6) and late (week 11) stage, following a four hour fast, no 
difference in blood glucose levels over all time points (15-120 minutes) of an ITT was 
observed between hAPPswe mice and WT littermates (Figure 4.3A and B). Taken 
together these data indicate hAPPswe overexpression does not alter glucose disposal or 
insulin sensitivity when challenged with a HFD and enhancing APP processing through 
the β-secretase route in this instance does not induce exacerbated metabolic syndrome.  
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Figure 4.1 Overexpression of hAPPswe does not affect body weight gain in mice 
challenged with a high-fat diet. 
(A) Overexpression of hAPPswe  causes no significant effect in body weight change over 
the course of 16 weeks challenged with a high-fat diet (n=7-16). (B) Body weight gain 
represented as a percentage change in body weight, displaying no significant effect of 
hAPPswe overexpression. 
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Figure 4.2 Overexpression of hAPPswe has no effect on glucose homeostasis in mice 
following 5 or 10 weeks on a high-fat diet. 
(A and D) Glucose tolerance test profiles showing hAPPswe overexpression has no effect 
on glucose disposal following 5 or 10 weeks on a high-fat diet (n=7-16). (B and E) 
Quantification of area under the curve for glucose responses shown in (A and D), 
demonstrating no significant change in glucose disposal. (C and F) hAPPswe 
overexpression causes no significant effect on fasted blood glucose levels (n=7-16).   
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Figure 4.3 Overexpression of hAPPswe does not alter insulin sensitivity in mice 
challenged with a high-fat diet. 
(A) Insulin tolerance test profile showing no significant difference in insulin sensitivity 
with hAPPswe overexpression following 6 weeks on a high-fat diet (n=7-15). (B) Insulin 
tolerance test profile showing there is still no significant effect on insulin sensitivity 
following 11 weeks on a high-fat diet (n=7-16).  
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4.3.1.3  Overexpression of hAPPswe does not impact organ weight 
following a high-fat diet 
Although no in-vivo phenotype was observed in hAPPswe mice following high-fat 
feeding, upon termination of the study tissue weights of spleen, heart, liver and brain were 
collected to provide an indication of tissue health and a crude measure of lean mass. For 
all tissues, actual size was noted as well as organ weight as a percentage of total body 
weight. No effect was observed for the spleen, heart, liver or brain (Figure 4.4A and B) 
between hAPPswe mice and WT littermates. Taken together these data show hAPP 
overexpression does not affect organ weights. 
4.3.2  The effects of inhibiting α-secretase APP processing on 
diet-induced obesity 
Having observed no metabolic phenotype as a result of global overexpression of hAPP 
the effects of increasing BACE1 activity on energy homeostasis was yet to be examined. 
In the hAPPswe model upregulation of α-secretase activity still occurs through mouse 
APP processing and presumably to a degree through hAPP processing, so total sAPPα in 
the brains of these mice may still be relatively high. Therefore, selective reduction of α-
secretase-mediated processing may provide a better model for studying the effects of 
increased BACE1 activity, sAPPβ and Aβ levels. Reduction of ADAM10 will result in 
reduced basal α-secretase-mediated processing and thus it is assumed this will cause a 
concomitant increase in BACE1-mediated processing of APP and production of sAPPβ. 
Consequently, we examined the effects of altering the balance of APP processing down 
the α-secretase versus the β-secretase pathway through central inhibition of ADAM10 
activity in mice challenged with a HFD. It was hypothesised that this would result in a 
worsening of the metabolic phenotype associated with diet-induced obesity.  
Age-matched, male WT mice were treated with a potent ADAM10 inhibitor; GI254023X 
(ADAM10i) or vehicle. Due to the large effect of central inhibition of BACE1 on energy 
homeostasis in DIO mice, mice in these studies were also treated through central 
administration directly into the lateral ventricle. Central administration of the compound 
or vehicle was delivered for 28 days, with the same metabolic measurements carried out 
during BACE1 inhibitor studies (section 3.2.1) performed to compare the effects of 
reducing and enhancing BACE1 activity.  
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4.3.2.1 Inhibition of ADAM10 does not significantly affect body weight 
gain following high-fat feeding 
Central treatment with ADAM10i (10mg/kg; Starting body weight: 27.10 ± 0.37g; n=9) 
caused a slight, but non-significant, increase in percentage body weight over the course 
of the study in comparison to vehicle (DMSO/PBS; Starting body weight: 26.74 ± 0.46g; 
n=9) treated (control) mice (Figure 4.5A). Although this was a non-significant effect, 
actual change in body weight at the end of the study displayed a trend towards increased 
weight gain with central ADAM10i treatment (Figure 4.5B). It could not be determined 
if changes in adiposity were present in these animals, as the mice could not be placed in 
the Echo MRI scanner due to the ICV brain infusion kit implanted. Taken together, these 
data show central inhibition of ADAM10 results in a modest increase in body weight.  
As with BACE1 inhibitor studies, changes in food consumption were examined. There 
was no difference in cumulative food intake over the course of the study between 
ADAM10i treated mice and control mice (Figure 4.5C), indicating that both groups of 
mice consume the same. Thus, a change in total food intake is not responsible for the 
slight change in body weight observed in ADAM10i treated mice. As the observed change 
in body weight is small, as expected relative food intake in relation to body weight of 
these mice was also unchanged (data not shown). 
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Figure 4.4 Overexpression of hAPPswe does not alter organ weights following high-
fat feeding. 
(A) Overexpression of hAPPswe has no significant effect on spleen, heart, liver or brain 
weights (n=7-16). (B) Actual weights represented as a percentage of total body weight. 
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Figure 4.5 Central ADAM10i treatment for 28 days causes a modest increase in body 
weight but does not alter food intake following high-fat feeding. 
(A) Central ADAM10i treatment causes a slight increase in percentage body weight over 
the course of the study (n=9). (B) Actual weight change from starting body weight, at the 
end of the study (day 27), shows a trend towards an increase in mice treated centrally with 
ADAM10i (n=8). (C) Cumulative food intake was unchanged with central ADAM10i 
treatment (n=8). 
Data collection was carried out in collaboration with Dr. Paul J Meakin.  
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4.3.2.2 Inhibition of ADAM10 exacerbates a diabetic phenotype 
following high-fat feeding 
The diabetic phenotype of these mice was also investigated by performing a GTT (day 
14) and ITT (day 21). Following an overnight fast there was a small decrease in glucose 
clearance with ADAM10i treatment in comparison to control mice (AUC: control; 1429 
± 49.21 vs. ADAM10i; 1555 ± 47.66, p=0.09, n=8-9, Figure 4.6A and B), however fasting 
blood glucose levels were unaltered (Figure 4.6C). As a slight impairment in glucose 
handling was observed, although not significant, a second GTT on day 28 was carried out 
to assess if this was due to the length of treatment and/or the duration of high-fat feeding. 
By day 28, glucose tolerance was further compromised with ADAM10i treatment, 
displaying a trend towards impaired glucose homeostasis in comparison to control mice 
(AUC: control; 1368 ± 90.24 vs. ADAM10i; 1840 ± 194.6, p=0.06, n=3-4, Figure 4.6D 
and E). Again, fasting blood glucose levels in these mice were unaltered on day 28 (Figure 
4.6F). 
Following a four hour fast an ITT was carried out and ADAM10i treatment caused a 
significant impairment in insulin sensitivity 60 minutes into testing (p<0.05, n=8-9, 
Figure 4.7A). Taken together, these data show central treatment with ADAM10i results 
in impaired glucose tolerance, an effect observed at day 14 and further worsened at day 
28, when weight gain is beginning to increase in comparison to control mice. Insulin 
sensitivity is also reduced following ADAM10i treatment, displaying an overall worsened 
diabetic phenotype and contrasting the effects of reducing BACE1 levels.  
4.3.2.3 Inhibition of ADAM10 does not impact organ weights following 
a high-fat feeding 
Upon termination of the study tissue weights of spleen, heart, liver and brain were 
measured in all mice, as an indication of the health of these tissues and as a crude measure 
of lean mass. For all tissues, actual size was measured as well as organ weight as a 
percentage of total body weight. ADAM10i treatment caused no effect on the spleen, 
heart or brain compared to control mice (Figure 4.8A and B), however ADAM10i 
treatment caused a significant increase in liver weight as a percentage of body weight 
(Control; 3.54 ± 0.12% vs. ADAM10i; 4.08 ± 0.05%, p<0.01, n=4-5, Figure 4.8). Taken 
together these data show ADAM10 inhibition does not affect raw organ weights. 
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Figure 4.6 Central ADAM10i treatment impairs glucose homeostasis following 14 
and 28 days on a high-fat feeding. 
(A and D) Glucose tolerance test profiles showing central ADAM10i treatment impairs 
glucose disposal following 2 weeks (n=8-9) and 4 weeks (n=3-4) on a high-fat diet. (B 
and E) Quantification of area under the curve for glucose responses shown in (A and D), 
demonstrating an increase in glucose disposal with central ADAM10i treatment (Week 
2; p=0.09, n=8-9, Week 4; p=0.06, n=3-4). (C and F) Central ADAM10i treatment causes 
no significant effect on fasted blood glucose levels at 2 weeks (n=8-9) or 4 weeks (n=3-
4). 
Data collection was carried out in collaboration with Dr. Paul J Meakin.  
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Figure 4.7 Central ADAM10i treatment impairs insulin sensitivity following 21 days 
on a high-fat diet. 
Insulin tolerance test profile displaying significant effect of central ADAM10i treatment 
on insulin sensitivity at 60 minutes (p<0.05, n=8-9). 
Data collection was carried out in collaboration with Dr. Paul J Meakin.  
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Figure 4.8 Central ADAM10i treatment for 28 days does not alter raw organ 
weights. 
(A) Central ADAM10i treatment has no significant effect on spleen, heart, liver or brain 
raw weights. (B) Actual weights represented as a percentage of total body weight 
demonstrates increased liver weight with central ADAM10i treatment (p<0.01, n=4-5).  
Data collection was carried out in collaboration with Dr. Paul J Meakin. 
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4.4 Discussion 
4.4.1 Summary 
Within this chapter we set out to investigate if altering the balance between non-
amyloidogenic and amyloidogenic APP processing to favour BACE1-mediated cleavage 
would drive an obese/diabetic phenotype. Herein, with the two models utilised we did not 
observe a drastic exacerbation of obesity when challenged with a HFD. hAPPswe mice 
did not differ from WT littermates in their responses to all metabolic outcomes measured 
when challenged with a HFD. However, ADAM10 inhibition in mice fed a HFD resulted 
in a modest increase in body weight and small impairments in glucose tolerance and 
insulin sensitivity. These results, and the potential underlying mechanisms, will be further 
discussed in the following sections. 
4.4.2 Overexpression of hAPPswe does not worsen an 
obese/diabetic phenotype 
In the previous chapter we demonstrated that a reduction in BACE1 improves an 
obese/diabetic phenotype through enhanced leptin sensitivity and reduced HFD-induced 
inflammation. To address if increasing BACE1 levels exacerbates an obese state we 
sought to alter the balance between α-secretase and BACE1-mediated APP processing. 
This was initially examined utilising an AD transgenic mouse model carrying the human 
APPswe mutation that results in increased BACE1-cleavage of APP. It was hypothesised 
that hAPPswe mice would have increased body weight gain when challenged with a HFD 
and impaired glucose homeostasis owing to elevated BACE1 levels and consequently 
enhanced β-secretase cleavage of both native and human APP. However, in the present 
study, when challenged with a HFD no metabolic phenotype was observed in hAPPswe 
mice, as demonstrated by no change in body weight gain and glucose homeostasis (GTT 
and ITT) in comparison to littermate controls; opposing our hypothesis. These mice also 
showed no change in organ weight, indicative of a lack of inflammation and no change 
in lean mass. 
The lack of phenotype observed in hAPPswe mice may be due to the AD model utilised 
which overexpresses human APP globally. Although the presence of the hAPPswe 
mutation results in more BACE1-mediated APP processing the mouse APP gene is still 
present and unaffected, thus α-secretase mediated APP processing still occurs. Mouse 
APP is processed favouring the α-secretase pathway which produces protective effects, 
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as sAPPα has neuroprotective functions (Araki et al. 1991; Meziane et al. 1998; Stein et 
al. 2004). Therefore, this may compensate for and mask the effects of the elevated 
BACE1-mediated processing. Moreover, sAPPα has been shown to act like an insulin 
sensitizer; stimulating glucose uptake and glucose oxidation in neuronal SH-SY5Y cells 
(John Findlay PhD Thesis) and primary cortical synaptosomes (Mattson et al. 1999), as 
well as in skeletal muscle (C2C12) cells (Hamilton et al. 2014). Furthermore, sAPPα may 
mediate some protective effects through activation of the PI3K pathway (Jimenez et al. 
2011) which promotes cell survival. This is supported by data from our lab showing that 
the stimulatory effects of sAPPα on glucose uptake and oxidation are dependent on PI3K 
signalling (Hamilton et al. 2014, John Findlay PhD Thesis). Accordingly, if sAPPα is 
behaving as an insulin sensitizer through the PI3K pathway it is possible it may also act 
on the hypothalamus as a leptin sensitizer, as leptin also utilises the PI3K pathway. If this 
is the case, sAPPα may have the ability to re-sensitise hypothalamic neurons to leptin 
preventing leptin resistance associated with high-fat feeding. This could account for the 
lack of phenotype observed in our studies as the PI3K-dependent cell survival action of 
sAPPα may compensate for the effects of HFD, and delay the onset of metabolic 
dysfunction.  
In the present studies, it would be interesting to examine sAPPβ and Aβ levels, as well as 
sAPPα levels, in our animals to measure the degree of which BACE1 activity is increased, 
as in our model BACE1 activity may not be elevated to the level at which other stressors 
cause. An additional stressor that elevates BACE1 levels may be required to observe 
significant effects. This is supported by data from our lab demonstrating that aged 
hAPPswe mice (>12 months old) show a non-significant increase in body weight and 
impaired glucose homeostasis, whereas no phenotype is observed when mice are fed a 
NC diet (unpublished data). In addition, work utilising a triple transgenic mouse model 
(3xTgAD) with mutations in APP, PS1 and tau show no initial change in body weight 
when challenged with a HFD however, show increased fat mass from 7 months onwards 
(Knight et al. 2014), indicative of an altered metabolic response to high-fat feeding. Aging 
is associated with elevated BACE1 levels and midlife obesity has been shown to be 
associated with increased AD risk (Fitzpatrick et al. 2009). Moreover, Mody et al found 
that ageing alone does not exacerbate obesity in AD transgenic models with a double 
transgenic (APP/PSEN1) mouse model and a single PS1 mutation mouse model both 
showing no change in body weight in comparison to WT littermates during the ageing 
process when fed a NC diet (Mody et al. 2011). This further supports the notion that a 
160 
 
 
 
greater enhancement of BACE1 may be required, through a combination of stresses, to 
elicit metabolic effects. In addition, Mody and colleagues found that APP/PSEN1 mice 
were more susceptible to obesity, displaying greater body weight gain, following 8 weeks 
on a HFD, accompanied by impaired glucose homeostasis and insulin signalling, in 
comparison to mice with a single AD mutation and WT littermates (Mody et al. 2011). 
Cao et al also utilised double transgenic AD mice and found that replacing their water 
with sucrose-sweetened water, representing increased calorific intake, increased body 
weight, impaired glucose homeostasis and increased circulating insulin levels (Cao et al. 
2007). These data suggest our mouse model may represent a mild AD model, which is 
supported by an absence of plaque pathology observed at 16 months (unpublished data). 
Therefore, it would be interesting to examine our mice further following a longer duration 
of high-fat feeding or utilising a more severe AD mouse model. In the models described, 
whereby double or triple mutations are incorporated and metabolic dysfunction is 
observed, it would be of interest to treat these mice with a BACE1 inhibitor (as previously 
carried out in chapter 3) or cross these mice with a BACE1-/- mouse to reduce BACE1 
levels by 50%, and examine if the observed effects are BACE1 dependent. We would 
hypothesise that reducing BACE1 levels in these mice would reverse the obese 
phenotype, suggesting BACE1 is utilising APP as a substrate in regards to its metabolic 
actions.  
Conversely, opposing the data described above, groups have shown that single mutation 
AD mouse models incorporating the same APP mutation as our mouse line do show 
metabolic defects following HFD (Kohjima et al. 2010; Ho et al. 2004). Kohjima and 
colleagues found mice with a single APP mutation (Tg2576 mice) are obese and insulin 
resistant, displaying increased body weight, fat mass, food intake and impaired glucose 
homeostasis and insulin sensitivity following 16 weeks on a HFD (Kohjima et al. 2010). 
In this study it was also found that Aβ levels were elevated at an earlier time point than 
previously reported for this mouse model and that this increase may be directly due to 
increased food intake and body weight. These data implicate Aβ as the potential driver 
for metabolic dysfunction, as opposed to sAPPβ. Noteworthy, is the fact Kohjima and 
colleagues conducted their GTT at 16 weeks, whereas we performed a GTT at only 10 
weeks and consequently may be missing a defect. This is unlikely to be the sole reason 
for the lack of phenotype observed as Kohjima et al show clear body weight changes at 
4 weeks and 12 weeks; effects we do not observe. The data from Ho et al also demonstrate 
that Tg2576 mice challenged with a HFD show increased circulating insulin levels, body 
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weight and fat mass, accompanied by impaired glucose homeostasis (Ho et al. 2004). 
Again, the time points slightly differ to our study whereby the effects observed by Ho and 
colleagues are demonstrated after 5 months on a HFD, whereas our studies where 
terminated at four months. Although the mutations in the Tg2576 mouse and the 
hAPPswe mouse are the same, the models differ slightly and this may account for the 
differences observed when challenged with a HFD. In the Tg2576 mouse the FAD 
mutation is driven by the hamster prion protein promoter (Elder et al. 2010) whereas in 
our model the mutation is driven by the mouse APP promoter. Furthermore, in Tg2576 
mice expression of human APP is over five times higher than mouse APP expression and 
consequently plaque pathology can be observed from 11-13 months of age (Elder et al. 
2010). Alternatively, the mouse model utilised in our studies reportedly overexpress 
human APP only 2-3 fold in relation to mouse APP levels and, as mentioned, do not 
develop plaques. This further supports the notion that our model may represent a 
relatively mild AD model. Nonetheless, our model itself may not be the sole reason we 
observe no altered metabolic phenotype and other factors within our study design may 
contribute.  
The interesting observation from our study is that both groups (WT and hAPPswe mice) 
did not gain substantial weight when placed on the HFD. In previous studies we utilise 
DIO mice, considered to be obese when they reach a weight of over 40g which is achieved 
following approximately 20 weeks on a 45% HFD. Herein, we find neither group of mice 
achieve DIO status even when challenged with a 60% HFD for 16 weeks. A diet of 60% 
fat was utilised in these studies with the aim of inducing obesity at an earlier time point. 
This would suggest the diet has had a major effect on our study and it is possible that it is 
less palatable than the 45% diet and therefore mice are consuming less. Unfortunately, 
food intake could not be measured in these mice owing to the consistency of the 60% diet 
and the fact mice were group housed, thus we cannot definitively conclude if changes in 
food intake may account for the lack of weight gain. It would be more advantageous to 
repeat these studies utilising 45% HFD, which has been shown to induce diet-induced 
obesity by 20 weeks of high-fat feeding, and conduct the study for a longer duration. 
4.4.3  Altering APP processing through inhibition of the α-
secretase pathway on an obese/diabetic phenotype 
Within this chapter we have shown that blockage of the α-secretase pathway may produce 
the opposite phenotype observed in BACE1 inhibitor treated mice (chapter 3), by 
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worsening an obese/diabetic phenotype. We demonstrated this through central ADAM10 
inhibition causing a slight increase in body weight and impaired glucose and insulin 
tolerance over the course of treatment. These effects were somewhat mild which may be 
due to the dose and duration of the study, as the greatest effects occurred at the end of the 
study with a greater defect in glucose handling observed at day 28 in comparison to day 
14, and impaired insulin tolerance observed at day 21. This correlates with changes in 
body weight, as inhibitor treated mice do not begin to gain weight faster than control mice 
until approximately day 20 of treatment, consequently the glucose handling defect may 
be a direct consequence of increased body weight. Of particular interest, is that between 
glucose tolerance tests the response of vehicle treated mice is unaltered, suggesting the 
compound is accelerating the effects of diet-induced obesity. This is supported by data 
showing that α-secretase inhibition in vitro on SH-SY5Y cells reduced glucose uptake, 
and over-expression of BACE1 caused the opposite effect (John Findlay PhD Thesis). 
Conversely, fasting blood glucose levels increase in both groups of mice suggesting basal 
glucose levels are a result of the diet and not the treatment. Alike BACE1 inhibitor treated 
mice, we observe no change in food intake, and therefore the mild increase in body weight 
is not owing to animals consuming more. Furthermore, these animals are not relatively 
hyperphagic suggesting that the neuronal circuitry controlling food intake is not altered 
following ADAM10 inhibition. Nonetheless, if the length of treatment was extended we 
would possibly observe more severe changes in body weight and consequently feeding 
behaviour. It is also necessary to measure circulating leptin levels in these mice, which 
we would have initially hypothesised to be elevated (indicative of leptin resistance), 
however owing to only mild effects on body weight this may not occur. Interestingly, 
insulin tolerance was affected in inhibitor treated mice at day 21 of treatment, before even 
mild changes in body weight are detected. This is intriguing as it suggests insulin 
resistance is occurring independently of body weight changes, and notably we do not 
observe changes in insulin tolerance following inhibition of BACE1 (section 3.2.1.2 and 
3.2.7.2). This is supportive of the notion that ADAM10 inhibition is accelerating the 
effects of high-fat feeding, driving insulin resistance at a time point in which BACE1 
inhibition cannot reverse this. The change in insulin tolerance with ADAM10 inhibition 
is still relatively mild, and may worsen as body weight changes occur. Additionally, due 
to time we could not measure circulating levels of insulin, although we would hypothesise 
that following central ADAM10i treatment plasma insulin levels will also be elevated, 
indicative of insulin resistance.  
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In addition to obesity another contributor to insulin resistance is chronic inflammation, 
and this may play a part in the impaired ITT and mild metabolic defects observed with 
ADAM10 inhibition. This is in keeping with our data suggesting BACE1 inhibition 
improves metabolic disease by reducing diet-induced inflammation (section 3.2.11). 
Owing to this, and with the knowledge that AD is associated with increased inflammation 
(Yang & Song 2013), we would hypothesise that treatment with an ADAM10i would 
cause upregulation in inflammatory mediators in both central and peripheral tissues. This 
is in keeping with the fact that known ADAM10 substrates include PGSL-1, which plays 
a role in immune cell function; specifically leukocyte recruitment and migration into 
tissues. (Lichtenthaler et al. 2003; Dislich & Lichtenthaler 2012). Therefore, blocking 
ADAM10 activity will also impact the appropriate response to inflammation and 
inflammatory processing. In support of this, Postina et al demonstrated that ADAM10 
overexpression in AD mouse models not only reduces Aβ levels, but it does so through 
reduced inflammation (Postina et al. 2004). Unfortunately, due to time constraints, the 
inflammatory profile of these mice could not be examined. It would be beneficial to 
conduct the same experiments performed in BACE1 inhibitor studies measuring 
inflammatory markers in the hypothalamus and WAT predominantly, as well as 
measuring levels in the plasma and carrying out flow cytometry to assess actual 
macrophage numbers in tissues. Also of interest would be to examine ER stress markers, 
as ER stress is also implicated in insulin resistance (Ozcan et al. 2004; Ozcan et al. 2006; 
Miller et al. 2007), and we hypothesise that an upregulation of ER stress would be present 
in the hypothalamus and peripheral tissues of ADAM10i treated mice. In support of the 
hypothesis that ADAM10 inhibition will drive increased inflammation, we do observe a 
larger liver size as a percentage of body weight in ADAM10i treated mice in comparison 
to controls. This may be indicative of an increased number of immune cells and 
inflammation in this tissue. Interestingly, this was only observed in the liver with no 
changes detected in the spleen, and notably raw organ weights were unaltered. It is 
possible that at this early stage only the liver is markedly affected, and if we continued 
the study for a longer period of time we may see enhanced inflammatory processing 
associated with changes in the spleen and WAT, accompanied by increased body weight. 
This is supported by the knowledge that inflammation associated with insulin resistance, 
involving increased pro-inflammatory cytokines such as TNFα and IL-6, primarily affects 
the liver, as well as adipose tissue. In addition, ADAM10 has many substrates other than 
APP, of which not all give rise to neuroprotective effects, for example these include both 
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TNFα and IL-6 (Pruessmeyer & Ludwig 2009). This suggests that inhibiting ADAM10 
may actually provide some protective effects in regards to inflammation and highlights 
the importance of other possible functions of ADAM10 and α-secretase activity. The 
complexity of additional substrates and functions needs to be addressed as their 
subsequent effects may account for the mild phenotype observed in our study.  
The rationale behind blocking the α-secretase pathway through inhibition of ADAM10 
was due to the fact ADAM10 is considered the predominant α-secretase responsible for 
constitutive activity (Kuhn et al. 2010). We inhibited ADAM10 centrally as this ADAM 
is present in neurons and is necessary for α-secretase activity in neurons (Marcinkiewicz 
& Seidah 2000). As mentioned, ADAM10 has many other substrates and functions, of 
which not all are fully defined, therefore when inhibiting ADAM10 in these studies we 
will also be affecting other substrates and these may influence the mild phenotype we 
observe. Amongst the known substrates of ADAM10 in the brain is Notch (Pruessmeyer 
& Ludwig 2009), and this is a major substrate indicated by the finding that ADAM10-
deficient mice are embryonic lethal (Hartmann et al. 2002). In addition, other ADAMs 
also exist as the α-secretase (ADAM 9 and 17 being the most characterised), thus in the 
present study we have not exclusively abolished all α-secretase activity. This is supported 
by maintained α-activity, through ADAM9 and ADAM17, in ADAM10-deficient mice 
(Hartmann et al. 2002), demonstrating multiple ADAMs are required to fully regulate α-
secretase activity. Taken together, this may account for the mild affects observed in our 
studies, as some degree of compensation of α-secretase activity may be occurring, 
particularly through ADAM17. ADAM17 is the ADAM which is capable of being 
regulated, therefore conditions such as high-fat feeding may induce ADAM17 causing 
increased α-secretase activity through this ADAM, although there is currently no 
evidence for this. Furthermore, other studies have shown that knock-down of ADAM10 
only mildly elevates β-secretase activity and consequently Aβ levels (Kuhn et al. 2010). 
Therefore, in the present studies, through inhibition of ADAM10, we may not be causing 
a large increase in BACE1 activity and/or levels, comparable to those found with other 
stressors such as HFD, hypoxia, oxidative stress or age, and in turn are only producing a 
mild phenotype. If we inhibited all α-secretase activity this may give rise to a more severe 
obese/diabetic phenotype, yet owing to the neuroprotective functions and other substrates 
of the α-secretase this could be detrimental. Additionally, treatment with an ADAMi in a 
model where BACE1 levels are already high, for example in aged mice, may elicit a 
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worsened metabolic phenotype, and such experiments could be beneficial to conduct in 
the future. 
Overall, the results reported in this chapter support our hypothesis that elevated BACE1 
activity exacerbates metabolic syndrome when challenged with a HFD, as blockage of 
ADAM10-mediated processing should result in increased BACE1 cleavage. Within these 
studies, by altering the balance of APP processing in this way we cannot conclude 
whether the metabolic effects observed are due to sAPPβ or Aβ elevations directly. We 
would hypothesise that the reported effects are due to increased central Aβ levels, 
specifically targeting the hypothalamus; contributing to inflammation and exacerbating 
obesity and insulin resistance. This is supported by work showing that Aβ oligomers 
directly bind to hypothalamic neurons in culture and that central administration of Aβ 
oligomers induces hypothalamic inflammation, impaired glucose homeostasis and insulin 
resistance (Clarke et al. 2015). Importantly, we cannot say definitively that the proposed 
effects are solely due to Aβ in the brain. BACE1 is expressed throughout peripheral 
tissues, including the heart, liver, skeletal muscle and WAT, and furthermore BACE1 
levels are elevated in response to stress (HFD) in a number of peripheral tissues 
(unpublished data). Therefore, although a large component of the suggested effects of Aβ 
may be due to central action there may also be direct effects on peripheral tissues. Recent 
work in our lab also implicates Aβ in metabolic dysfunction, supporting the work by 
Clarke et al, by showing that central infusion of mouse Aβ42 worsens an obese/diabetic 
phenotype in mice challenged with a HFD, through increased body weight gain, and 
impaired glucose and insulin tolerance (unpublished data). Interestingly, Clark and 
colleagues demonstrated that following administration of Aβ oligomers hypothalamic 
inflammation was induced as early as four hours post injection, whereas impairments in 
glucose homeostasis were observed days following administration (Clarke et al. 2015). 
From this study it was concluded that the Aβ-induced inflammation, accompanied by 
hypothalamic ER stress, drove defects in glucose and insulin tolerance. This is supportive 
of our data demonstrating impaired glucose control during glucose and insulin tolerance 
tests prior to changes in body weight, suggestive that these effects are driven by 
inflammation and ER stress. This provides further emphasis on the requirement to 
measure cytokine levels and ER stress markers in our mice. Importantly, the phenotype 
observed following administration of Aβ oligomers by Clark et al, and our lab, mimic the 
phenotype we observe with ADAM10 inhibition, however they represent a far more 
severe phenotype, indicating Aβ is the driving factor for the metabolic dysfunction.  
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4.4.4  Concluding Remarks 
The data presented in this chapter highlight a role for BACE1 in energy metabolism and 
that this may be through the cleavage of APP as a substrate. We have shown that altering 
the balance between non-amyloidogenic and amyloidogenic APP processing to favour 
increased BACE1 cleavage causes mild metabolic dysfunction associated with a HFD. 
This is due to reduced α-secretase activity causing increased BACE1 levels and/or 
activity, which will result in elevated levels of Aβ. Taken together, these data and recent 
work from our lab, show that increased Aβ can drive not only AD progression, but may 
contribute to the onset of obesity and diabetes. Furthermore, therapeutic intervention 
targeting Aβ, for instance through inhibition of BACE1 to reduce Aβ levels, may provide 
a novel treatment strategy for metabolic disease.
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Chapter 5 
 
 
 
The role of BACE1 in the hypothalamus 
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5.1 Introduction 
Within both chapter 3 and chapter 4 we have demonstrated that reducing BACE1 activity 
in DIO mice improves an obese/diabetic phenotype and that alterations in α-secretase 
mediated APP processing exacerbates an obese/diabetic phenotype. However, the precise 
mechanism(s) responsible for these actions are yet to be defined. In particular, inhibition 
of BACE1 reduces the high circulating levels of leptin associated with DIO, potentially 
re-sensitising leptin resistant animals to the effects of leptin. Furthermore, these effects 
are leptin dependent as work from our lab has found treatment of genetically obese ob/ob 
and db/db mice with a BACE1 inhibitor causes no effect (unpublished data). Taken 
together, these data suggest that the mechanism whereby BACE1 alters energy 
homeostasis must involve intact leptin signalling. In addition, we have shown that central 
inhibition of BACE1 causes a dramatic effect on energy balance (section 3.2.7) thus this 
mechanism is likely centrally driven. Furthermore, BACE1 reduction does not alter food 
intake suggesting BACE1 may be acting through the hypothalamic circuitry involved in 
regulating leptin action on energy expenditure. 
The main site of leptin action in the brain is the hypothalamus; predominantly the ARC. 
Within the ARC there is a dense population of leptin receptor-expressing neurons which 
mediate leptin action; the two main populations being POMC/CART-expressing neurons 
(Cowley et al. 2001) and NPY/AgRP-expressing neurons (Hâkansson et al. 1998). The 
accepted model is that leptin binds its receptor on these neurons activating POMC neurons 
whilst inhibiting NPY/AgRP neurons, to reduce food intake and increase energy 
expenditure (Coll & Yeo 2013). Synaptic inputs between these neurons play an important 
role in mediating these effects, as NPY neurons also directly inhibit POMC neurons 
through synaptic innervation from NPY itself or the inhibitory neurotransmitter GABA 
(Horvath 2005; Dietrich & Horvath 2013). Alterations in the synaptic inputs of first order 
ARC neurons are observed in ob/ob mice, where there are increased numbers of synapses 
on NPY neurons and a concomitant increase in inhibitory tone onto POMC neurons, with 
an associated reduction in the number of synapses on POMC neurons (Pinto et al. 2004). 
Interestingly, Pinto and colleagues found administration of leptin reversed this and altered 
the synaptic arrangement prior to any body weight or food intake changes, proposing that 
alterations in synaptic plasticity may account for the metabolic phenotype of ob/ob mice 
(Pinto et al. 2004). As a result, synaptic plasticity in the hypothalamus has received more 
attention recently. Hypothalamic circuits are known to show some plasticity through adult 
life, thus it is considered a potential mediator of the energy regulatory effects of leptin 
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(Horvath 2005). This is supported by studies examining synaptic inputs on first order 
ARC neurons following fasting and high-fat feeding. Horvath et al demonstrated that in 
DIO rats there is a reduction in the number of synapses on POMC neurons and increased 
inhibitory tone on these neurons, with the opposite observed in rats resistant to diet-
induced obesity (Horvath et al. 2010). Subsequent studies showed that following fasting 
there is an increase in inhibitory postsynaptic currents (frequency and amplitude) in 
POMC neurons (Vong et al. 2011). In addition, work by Benani and colleagues found 
that following only one week of high-fat feeding mice show an upregulation of genes 
involved in synaptic plasticity exclusively in the ARC (Benani et al. 2012). This further 
supports the notion that synaptic plasticity may be involved in the regulation of leptin 
action at an early stage in the nutrient challenge, particularly through POMC and 
NPY/AgRP neurons. However, when leptin receptor expression is ablated from POMC 
neurons or AgRP neurons, only mild obese phenotypes are observed (Balthasar et al. 
2004; Van De Wall et al. 2008). Although, when leptin receptor expression is knocked-
out of both POMC- and AgRP-expressing neurons an additive affect is observed, with 
greater body mass and fat mass observed (Van De Wall et al. 2008). Furthermore, 
Berglund and colleagues demonstrated that when leptin receptor expression is ablated and 
only re-expressed in ARC POMC neurons, that this only partially recovers the obesity 
caused by complete leptin receptor ablation, and does not affect food intake (Berglund et 
al. 2012). This demonstrates that POMC/CART neurons and NPY/AgRP neurons play a 
small role in mediating the food intake and body weight effects of leptin, providing strong 
evidence that leptin receptors expressed elsewhere must also be crucial.  
The signalling form of the leptin receptor, ObRb, is found in neuronal populations within 
the ARC which are distinct from POMC/CART and NPY/AgRP neurons. One such 
population are RIPCre neurons (Cui et al. 2004). Due to the localisation of these neurons 
in the ARC and their close proximity to POMC/CART neurons and NPY/AgRP neurons 
it is believed leptin will also act upon these neurons to elicit energy homeostatic effects. 
Furthermore, ObRb is found outwith the ARC, in the VMH, LH and DMH, as well as in 
extra-hypothalamic regions such as the brainstem. One hypothalamic region with 
abundant leptin receptor expression is the VMH, which is also key in facilitating control 
of energy balance. Within the VMH the predominant neuronal population are SF-1 
neurons, and it has been shown that removal of the leptin receptor from these neurons 
causes a similar phenotype to that observed in mice with a lack of leptin receptor 
expression on POMC neurons (Dhillon et al. 2006). Therefore, SF-1 neurons also play a 
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role in mediating the effects of leptin. Interestingly, when ObRb expression is ablated 
from both SF-1 and POMC neurons there is again an additive effect; increased body 
weight, however no change in food intake (Dhillon et al. 2006). This demonstrates leptin 
action is dependent on various populations within the hypothalamus, which will project 
to and communicate with one another.  
The phenotype of ObRb-expressing neurons and their mode of action differ throughout 
the hypothalamus. The two main neurotransmitters utilised by the CNS are the inhibitory 
neurotransmitter GABA and the excitatory neurotransmitter glutamate (Delgado 2013). 
Within the ARC the majority of ObRb-expressing neurons are GABAergic, and when the 
leptin receptor is removed from GABAergic neurons a very large increase in body weight 
and fat mass is observed, accompanied by hyperphagia (Vong et al. 2011). Conversely, 
when ObRb expression is absent in glutamatergic neurons only minimal effects are 
observed, which are likely produced via the VMH as SF-1 neurons are predominantly 
glutamatergic (Vong et al. 2011). Vong et al showed that specifically in the ARC the 
majority of AgRP neurons are co-localised with VGAT; a GABA transporter, however 
minimal co-localisation was observed between VGAT and POMC. Importantly, the ARC 
POMC neurons are surrounded by and in close apposition to the GABAergic neurons, 
suggestive of cross-talk between different populations of leptin responsive neurons. This 
is demonstrated by the aforementioned action of leptin on the GABAergic ARC neurons 
attenuating the inhibitory actions on POMC neurons (Vong et al. 2011; Cowley et al. 
2001).  
Leptin receptors are also expressed in extra-hypothalamic areas such as the NTS where 
the majority of leptin responsive neurons are excitatory, glutamatergic neurons (Vong et 
al. 2011). GABAergic leptin-responsive neurons within the ARC project to other 
hypothalamic areas as well as extra-hypothalamic sites which forms the neural circuitry 
crucial for regulating leptin action. Leptin receptor activation in ARC neurons alters the 
activity of the neurons leading to altered outputs to hypothalamic nuclei such as the PVN 
and LH, affecting catabolic and anabolic pathways involved in energy balance. The NTS 
is the major centre receiving signals from these catabolic and anabolic pathways. Signals 
from peripheral peptides also send input to the NTS via the vagus nerve and the 
sympathetic nervous system (SNS). The NTS integrates all these signals, along with other 
higher brain centres, to mediate desired outcomes, for example inhibition of food intake 
(Schwartz et al. 2000). Furthermore, ObRb-expressing neurons present in the NTS can 
also feed back onto catabolic neurons within the PVN. However, less is known regarding 
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the input and output signals generated by these neurons and the precise circuitry involved 
between the ARC and brainstem requires further research.  
It has been alluded to that BACE may be involved in the neuronal circuitry regulating 
leptin function. However, how BACE1 affects these pathways is unknown. BACE1 
expression in the brain has been extensively studied, in particular during the identification 
of BACE1 as the β-secretase, where it has been shown to be expressed across various 
regions in the brain including the cortex, hippocampus, thalamus, spinal cord and medulla 
(Vassar et al. 1999). Imaging studies have also indicated BACE1 is expressed throughout 
the brain of WT mice with strongest staining present in the hippocampus (Zhao et al. 
2007). Within these areas it has been shown that BACE1 is predominantly expressed in 
neurons and not glia (Zhao et al. 2007; Hussain et al. 1999; Vassar et al. 1999). Owing to 
the role of BACE in AD the majority of studies focus on its expression in the 
hippocampus and the cortex, as these areas are the first affected during AD progression. 
The hypothalamus is less studied in regards to BACE1, although BACE2 has been shown 
to be expressed in the hypothalamus in contrast to its low expression across the rest of the 
brain (Vassar 2004). As a role has emerged for BACE1 in energy homeostasis it is likely 
BACE1 is present in the hypothalamus, potentially acting on leptin responsive neurons 
and their corresponding pathways, and this requires investigation to better understand the 
role of BACE1 in metabolism. 
In the present studies the hypothalamic expression of BACE1 was investigated, primarily 
utilising immunofluorescence (IF) in WT mice brains, to determine where BACE1 is 
expressed and in which cell type(s). Various neuronal populations important in mediating 
the body weight and food intake actions of leptin were examined to observe the presence 
or absence of BACE1. The aim of these experiments was to determine the localisation of 
BACE1 expression in specific hypothalamic neuronal populations to enable further 
studies to be undertaken to ascertain the functions of BACE1 in energy homeostasis and 
how it alters metabolism. 
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5.1.1 Objectives 
 Examine BACE1 expression in the hypothalamus and extra hypothalamic areas 
under normal conditions to investigate if BACE1 is implicated in the neuronal 
circuitry controlling energy homeostasis 
 Use dual-labelling experiments to examine if BACE is co-expressed with the 
following cellular populations in the hypothalamus: 
o Leptin receptor-expressing neurons 
o First-order ARC neurons (POMC, NPY/AgRP and RIPCre neurons) 
o GABAergic and glutamatergic ARC neurons 
o VMH neurons (SF-1 and RIPCre neurons) 
o Astrocytes 
 
5.2 Methods Summary 
Whole brains from adult mice (>8 weeks of age) were fixed and processed for IF or FISH 
(as detailed in section 2.6). In brief, brains were sectioned at 30µm thickness and slices 
containing the hypothalamus selected. Sections were stained for BACE1 alone or co-
stained with markers of different cellular populations and imaged using a confocal 
microscope. For cell counting experiments total cell numbers were counted, using Fiji 
Image Analysis Software, from a number of sections from different animals. The mean 
of the total cell count for each population, from all animals, was then calculated. 
5.3 Results 
5.3.1  BACE1 expression in the brain 
BACE1 is shown to be expressed in the cortex and hippocampus of rodents and humans, 
primarily due to research focused on Alzheimer’s disease, with other brain regions largely 
ignored. Thus, the expression of BACE1 in additional brain regions, in comparison to 
levels in the hippocampus and cortex, was investigated. Initially, using Western blotting 
and IF on WT adult mice, BACE1 protein levels were measured, in four main brain 
regions; the hippocampus, hypothalamus, cerebellum and cortex. BACE1 was detected 
in all four brain regions (Figure 5.1). BACE1 expression was highest in the cortex 
(mean=0.22 arbitrary units), and this expression was significantly greater than all other 
areas investigated (p<0.01, n=6, Figure 5.1A and B). Interestingly, the hippocampus 
exhibited lower BACE1 levels, which were comparable to those measured in the 
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cerebellum and hypothalamus. These data show, although the hippocampus is the most 
widely studied brain area in regards to BACE1, this area does not have the most abundant 
expression. To investigate the expression pattern of BACE1 in these areas further IF was 
carried out. Representative confocal images show BACE1 is expressed throughout areas 
of the hippocampus, hypothalamus, cerebellum and cortex, in line with the Western 
blotting data. The images demonstrate BACE1 expression is high in discrete groups of 
cells (Figure 5.1C). Note, BACE1 is expressed across the whole brain, in other regions 
outwith the hippocampus, hypothalamus, cerebellum and cortex, although there are also 
regions completely negative for BACE1 staining (data not shown). Taken together, these 
data show BACE1 is highly expressed in distinct groups of cells throughout the brain, 
and to a substantial level in brain regions out with the cortex and hippocampus, which 
may also have important functions in regards to the role of BACE1.  
It has been reported that many BACE1 antibodies give non-specific signals, therefore to 
confirm the specificity of BACE1 expression in the brain, IF was carried out on sections 
from BACE1-/- mice and minimal staining was detected (Figure 5.2). This is supported by 
work from our lab that has tested this antibody on brain tissue from BACE1-/- mice using 
Western blotting (Meakin et al. 2012) and work from other groups testing this antibody 
on BACE1-/- mice utilising immunohistochemistry (Zhao et al. 2007); both reporting it is 
highly specific. 
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Figure 5.1 BACE1 protein expression in the brain. 
(A) Representative Western blot showing BACE1 protein expression in different regions 
of the brain. Molecular mass is given in kDa on the left-hand side. (B) Densitometric 
analysis showing BACE1 is highly expressed in the cortex; significantly higher than in 
the hippocampus, hypothalamus and cerebellum (p<0.01, n=9). (C) Representative 
confocal images, taken at x40 magnification, demonstrating BACE1 protein expression 
in areas of the hippocampus, hypothalamus, cerebellum and cortex. 3V, third ventricle. 
CA2, CA2 field. CA3, CA3 field. All scale bars 50µm.  
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Figure 5.2 Specificity of BACE1 antibody staining in a BACE1-/- mouse brain. 
Confocal images, taken at x40 magnification, showing BACE1 (red), neuronal marker 
NeuN (green) and merged channels within a region of the hippocampus from a BACE1-/- 
mouse. Representative images display minimal BACE1 staining. DG, dentate gyrus. All 
scale bars 50um.  
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5.3.2 BACE1 expression in the hypothalamus 
Having previously discussed a role for BACE1 in energy metabolism and observing 
BACE1 protein in abundance in the hypothalamus; the central control centre for whole 
body energy metabolism, this area was examined in greater detail. The distribution of 
BACE1 protein throughout the hypothalamus was examined using IF on WT adult mice 
fed a NC diet. BACE1 was observed throughout the hypothalamus, within the DMH, LH, 
VMH and ARC (Figure 5.3). Throughout the hypothalamus the observed expression is 
not homogenous, BACE1 is present in discrete groups of cells (Figure 5.3 higher 
magnification images). These data show BACE1 is expressed in cells present in the key 
centres of the hypothalamus involved in the control of energy homeostasis, and 
consequently it is likely that these cells may contribute to the functional outputs 
associated with the effects of lowering or increasing BACE1 on whole body energy 
metabolism. 
5.3.3 BACE1 is expressed in neurons throughout the 
hypothalamus 
Having identified distinct populations of BACE1 positive cells throughout the 
hypothalamus the precise phenotype of these cells was investigated. As previously 
mentioned, in the hippocampus and cortex BACE1 is accepted to be predominantly 
expressed in neurons and not glia (Zhao et al. 2007; Hussain et al. 1999; Vassar et al. 
1999), therefore initially the localisation of BACE1 to neurons in the hypothalamus was 
studied. This was examined using IF, with double-staining of BACE1 (red) and the 
neuronal marker, NeuN (green), on brain sections from WT adult mice fed a NC diet. The 
predominate focus is on the ARC, where representative confocal images display BACE1 
is largely neuronal, determined by the majority of BACE1 positive cells co-localising 
with NeuN in this area, observed as yellow (Figure 5.4D).This finding was also observed 
in all other examined regions of the hypothalamus; the DMH, VMH and LH (Figure 5.4B-
C), showing BACE1 is predominantly neuronal throughout the hypothalamus. 
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Figure 5.3 BACE1 is expressed throughout the hypothalamus. 
Representative confocal images showing BACE1 protein expression within regions of the 
hypothalamus. Low magnification (x10) image demonstrates BACE1 expression 
throughout the whole hypothalamus. Higher magnification images (x40) show distinct 
BACE1 cells in the dorsmedial hypothalamus (DMH), lateral hypothalamus (LH), 
ventromedial hypothalamus (VMH) and arcuate nucleus (ARC). 3V, third ventricle. x10 
magnification image scale bar 100µm. All x40 magnification images scale bars 50µm. 
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Figure 5.4 BACE1 is expressed in neurons throughout the hypothalamus. 
Confocal images, taken at x40 magnification, showing BACE1 (red), neuronal marker 
NeuN (green) and merged channels within regions of the hypothalamus. Representative 
images from (A) the dorsomedial hypothalamus (DMH), (B) the lateral hypothalamus 
(LH), (C) the ventromedial hypothalamus (VMH) and (D) the arcuate nucleus (ARC). 
3V, third ventricle. 
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5.3.4 BACE1 is not expressed in astrocytes throughout the 
hypothalamus 
Although BACE1 was found to be predominantly neuronal, not all BACE1 positive cells 
were co-localised with the neuronal marker, NeuN, in the hypothalamus. In the 
hippocampus and cortex BACE1 is not reported to be present in astrocytes under normal 
conditions (Zhao et al. 2007; Hussain et al. 1999; Vassar et al. 1999), therefore whether 
this is also the case in the hypothalamus was investigated. This was achieved using IF 
with double-staining of BACE1 (red) and the astrocyte marker, GFAP (green), on brain 
sections from WT adult mice fed a NC diet. In the ARC, representative confocal images 
show BACE1 is not expressed in astrocytes, demonstrated by a lack of co-localisation 
(lack of yellow staining) of BACE1 positive cells and GFAP (Figure 5.5D). This finding 
was also observed in all other examined regions of the hypothalamus; the DMH, VMH 
and LH (Figure 5.5B-C), showing BACE1 is not astrocytic throughout the hypothalamus.  
5.3.5 Leptin responsiveness of BACE1 neurons in the arcuate 
nucleus 
5.3.5.1  BACE1 neurons express the leptin receptor 
Leptin receptors are abundantly expressed in the ARC of the hypothalamus, with the long 
form of the leptin receptor (ObRb) required for leptin signalling (Tartaglia 1997). Having 
found BACE1 is abundantly expressed in the ARC and that BACE1 plays a role in leptin 
sensitivity and energy metabolism (chapter 3), the presence of ObRb in BACE1-positive 
neurons was investigated. Using IF brain sections from WT adult mice fed a NC diet were 
double-stained for BACE1 (red) and ObRb (green) in the ARC. Representative confocal 
images show a proportion of BACE1 neurons express ObRb, indicated by co-localisation 
of BACE1 and ObRb, observed as yellow (Figure 5.6A). However, not all BACE1-
positive neurons express ObRb. Quantitative analysis of co-localised cells (counted 
across 4 images) found approximately 24% of BACE1-positive neurons express ObRb 
and furthermore 27% of detected ObRb-positive neurons are BACE1-positive neurons 
(Figure 5.6B). Taken together, these data show only a proportion of BACE1 neurons in 
the ARC express ObRb, and therefore only a proportion may be directly responsive to 
leptin. 
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Figure 5.5 BACE1 is not expressed in astrocytes throughout the hypothalamus. 
Confocal images, taken at x40 magnification, showing BACE1 (red), astrocytic marker 
GFAP (green) and merged channels within regions of the hypothalamus. Representative 
images from (A) the dorsomedial hypothalamus (DMH), (B) the lateral hypothalamus 
(LH), (C) the ventromedial hypothalamus (VMH) and (D) the arcuate nucleus (ARC). 
3V, third ventricle. All scale bars 50µm.  
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Figure 5.6 BACE1 neurons in the arcuate nucleus possess the long form of the leptin 
receptor. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
the long form of the leptin receptor (ObRb) (green) and merged channels in the arcuate 
nucleus. All scale bars 50µm. (B) Histogram displaying total number of BACE1+ cells, 
ObRb+ cells and dual-labelled cells per field of view, showing a proportion of BACE1 
neurons express ObRb  (4 fields of view, n=2).  
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5.3.5.2 BACE1 neurons are not directly responsive to leptin 
Upon leptin binding to ObRb there is initiation of the JAK-STAT signalling pathway, 
which ultimately results in phosphorylation of STAT3 to drive transcription of POMC, 
whilst inhibiting NPY/AgRP. To further evaluate the effect of BACE1 on leptin 
signalling, whether the BACE1 neurons expressing ObRb in the ARC are directly 
responsive to leptin through this pathway was investigated. WT adult mice fed a NC diet 
were fasted overnight before an intraperitoneal (i.p) injection of leptin (4mg/kg) and 
sacrificed one hour post-leptin injection. IF was performed on brain sections, double-
staining for BACE1 (red) and pSTAT3 (green). In a separate cohort of animals, saline 
was administered as a control, and minimal pSTAT3 staining was observed (Figure 5.7B). 
Representative confocal images show the vast majority of BACE1-positive neurons in 
the ARC do not respond to leptin treatment by increased pSTAT3, indicated by very low 
levels of co-localisation of BACE1 and p-STAT3 (lack of yellow staining) (Figure 5.7A). 
Quantitative analysis (counted across 6 images)  confirms this by showing approximately 
only 1% of BACE1 neurons are co-localised with pSTAT3 and furthermore from the 
detected number of p-STAT3 cells approximately only 4% co-localise with BACE1-
positive neurons (Figure 5.7B). These data suggest, although a proportion of BACE1 
neurons express ObRb, these neurons may not be directly responsive to leptin and BACE1 
may not directly affect leptin JAK2/STAT3 signalling in the ARC.  
It has been reported that leptin reduces BACE1 expression and activity (Marwarhaet al. 
2014), therefore the observed lack of co-localisation between BACE1- and pSTAT3-
neurons may be due to a lack of detectable BACE1. To investigate if this is the case in 
the ARC, BACE1 staining on brain sections from leptin- and saline-treated mice 
(described above) were examined. Confocal images showed reduced BACE1 expression 
in the ARC of leptin treated animals in comparison to control mice (Figure 5.8). 
Quantitative analysis supports this, showing the actual number of BACE1-positive 
neurons detected is decreased in leptin treated mice (Control; ~95 cells vs. leptin; ~60 
cells, counted across 6-7 images), (Figure 5.8B). Taken together, these data show BACE1 
expression is reduced upon leptin stimulation, and therefore the number of BACE1-
positive neurons present is diminished. Assuming BACE1 neurons which express ObRb 
are those which are reduced, this may account for the lack of co-localisation with p-
STAT3 and the un-responsiveness to leptin.   
183 
 
 
 
 
 
Figure 5.7 BACE1 is not co-localised with pSTAT3 in the arcuate nucleus following 
leptin treatment. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
pSTAT3 (green) and merged channels in the arcuate nucleus of wild-type mice one hour 
post intraperitoneal leptin (4m/kg) treatment. (B) Representative confocal image, taken 
at x40 magnification, showing minimal pSTAT3 staining in the arcuate nucleus following 
intraperitoneal saline (control) treatment. 3V, third ventricle. All scale bars 100µm. (C) 
Histogram displaying total number of BACE1+ cells, pSTAT3+ cells and dual-labelled 
cells per field of view, showing minimal co-localisation between BACE1 and pSTAT3 
(6 fields of view, n=2-3).   
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Figure 5.8 BACE1 expression is reduced in the arcuate nucleus following leptin 
treatment. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 
expression in the arcuate nucleus one hour post intraperitoneal leptin (4m/kg) treatment 
or saline (control) treatment. 3V, third ventricle. All scale bars 50µm. (B) Histogram 
displaying the total number of BACE1-positive cells per field of view, showing a reduced 
number of BACE1 neurons with leptin treatment (6-7 fields of view, n=2-3).  
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5.3.5.3  Leptin sensitivity in the absence of BACE1 
Having observed no pSTAT3 response to leptin in BACE1-positive neurons it is 
undetermined whether BACE1 neurons in the ARC directly affect leptin signalling or 
whether BACE1-positive neurons are modified by leptin. To examine this levels of 
pSTAT3, following i.p leptin, were measured in BACE1-/- mice and age-matched WT 
mice fed a NC diet. Both BACE-/- and WT mice show induction of pSTAT3 in the ARC 
one hour post-i.p of leptin (4mg/kg) (Figure 5.9A). Minimal pSTAT3 staining was 
observed when saline was administered as a control (Figure 5.9B). Quantitative analysis 
shows there is a trend towards an increase in the number of pSTAT3 cells in BACE1-/- 
mice in comparison to WT mice (counted across 8 images), however this is not a 
significant difference (Figure 5.9B).  
5.3.6  BACE1 expression in first order neurons in the arcuate 
nucleus 
Having observed BACE1 protein abundantly expressed in the ARC, and that a proportion 
of these neurons may be involved in leptin signalling, next it was determined if BACE1 
is present in first order neurons involved in this pathway. The two main neuronal 
populations in the ARC are anorexigenic POMC/CART neurons and orexigenic 
NPY/AgRP neurons (Funahashi et al. 2003). Leptin acts on both populations to induce 
food intake actions. As a proportion of BACE1 neurons express the leptin receptor, and 
reducing BACE1 activity alters body weight and fat mass (chapter 3), it was hypothesised 
that BACE1 may be present in these neurons and may evoke at least some of its actions 
on energy metabolism via these neuronal populations. 
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Figure 5.9 pSTAT3 expression is unaltered in the arcuate nucleus of BACE1-/- mice 
following leptin treatment. 
(A) Representative confocal (bright-field) images, taken at x40 magnification, showing 
pSTAT3 expression in the arcuate nucleus one hour post intraperitoneal leptin (4mg/kg) 
treatment in wild-type and BACE1-/- mice. (B) Representative confocal images, taken at 
x40 magnification, showing minimal pSTAT3 staining in the arcuate nucleus following 
intraperitoneal saline (control) treatment in wild-type and BACE1-/- mice 3V, third 
ventricle. All scale bars 50µm. (B) Histogram displaying the total number of pSTAT3-
positive cells per field of view (8 fields of view, n=3).  
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5.3.6.1 BACE1 is expressed in a small number of proopiomelanocortin 
neurons in the arcuate nucleus 
Initially the presence of BACE1 and the ARC anorexigenic neuropeptide population was 
examined. As neuropeptides are constantly being transported along the axons of neurons 
visualisation in the cell body with classic IF (using antibodies) can be difficult, as 
antibodies have a tendency only to pick up nerve fibres, therefore IF on POMC-GFP 
tissue, and IF carried out following fluorescent in-situ hybridisation (FISH) were utilised 
to visualise POMC in WT adult mouse brain. Sections were double stained with BACE1 
(red) to determine if BACE1 is present in POMC-expressing neurons (green). Using both 
FISH and IF confocal images show a small number of BACE-positive neurons are co-
localised with POMC-expressing neurons in the ARC, observed as yellow (Figure 5.10A 
and B). The majority of BACE1 neurons are not co-localised with POMC, however 
representative images show that many of the BACE1 neurons lie in very close apposition 
to POMC neurons, as deomstrated in the higher magnification boxed regions in Figure 
5.10A and B. Quantitative analysis of BACE1 and POMC cells show approximately 5% 
of BACE1 neurons are co-localised with POMC-expressing neurons by the method of 
FISH (counted across 5 images) and IF (counted across 11 images) and 8% of POMC-
expressing neurons are co-localised with BACE1-positive neurons (Figure 5.10C). Due 
to a lack of tissue and FISH probe the anorexigenic neuropeptide CART could not be 
examined, however in the ARC all POMC neurons co-express CART (Elmquist et al. 
1999), therefore it is likely that BACE1 is also not co-localised with CART-expressing 
neurons in the ARC to a large extent (approximately 5-10%). Taken together, these data 
show BACE1 is expressed in a very small proportion of POMC-expressing neurons in 
the ARC, however POMC neuronal cell bodies and processes lie in close apposition to 
BACE1-positive neurons and vice versa, therefore BACE1 may not be acting directly via 
this neuronal population but may still be functionally connected to POMC/CART neurons 
in the ARC.  
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Figure 5.10 BACE1 is co-localised with POMC-expressing neurons in the arcuate 
nucleus. 
Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
POMC (green) and merged channels in the arcuate nucleus. (A) Fluorescent in-situ 
hybridisation (FISH) images showing BACE1 co-stained with POMC, demonstrating co-
localisation between a small proportion of BACE1 and POMC neurons, highlighted with 
higher magnification boxed region.(B) POMC-GFP immunofluorescence (IF) images 
showing BACE1 co-stained with POMC demonstrating co-localisation between a small 
proportion of BACE1 and POMC neurons, highlighted with higher magnification boxed 
regions. 3V, third ventricle. All scale bars 50µm. (C) Histogram displaying total (FISH 
and IF) number of BACE1+ cells, POMC+ cells and dual-labelled cells per field of view, 
showing minimal co-localisation between BACE1 and POMC-positive (FISH: 5 fields of 
view, n=3, POMC-GFP: 11 fields of view, n=2). 
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5.3.6.2  BACE1 is expressed in neuropeptide-Y/agouti related peptide 
neurons in the arcuate nucleus 
Next, the presence of BACE1 in the ARC orexigenic neuropeptide population was 
investigated. As with POMC, NPY was visualised using both FISH and IF on NPY-GFP 
tissue. Sections were double stained with BACE1 (red) to determine if BACE1 is co-
localised with NPY-expressing neurons (green). Using both FISH-IF and NPY-GFP-IF, 
confocal images show a number of BACE-positive neurons are co-localised with NPY-
expressing neurons in the ARC, observed as yellow (Figure 5.11A and B) and highlighted 
in higher magnification boxed regions. A large number of BACE1 neurons are not co-
localised with NPY, however representative images show many BACE1 neurons, alike 
POMC-expressing neurons, are in close apposition to NPY neurons, highlighted by 
higher magnification boxed regions in NPY-GFP images (Figure 5.11B). Quantitative 
analysis of BACE1- and NPY-positive neurons, collectively for FISH-IF (counted across 
6 images) and NPY-GFP-IF (counted across 8 images), shows approximately12% of 
BACE1 neurons are co-localised with NPY-expressing neurons and approximately 14% 
of NPY-expressing neurons co-localised with BACE1-positive neurons (Figure 5.11C). 
Due to a lack of tissue and FISH probe the orexigenic neuropeptide AgRP could not be 
examined, however all NPY-expressing neurons in the ARC co-express AgRP (Broberger 
et al. 1998), therefore it is likely that BACE1 is present in approximately 12% of AgRP-
expressing neurons. Taken together, these data show BACE1 is expressed in a greater 
number of orexigenic neurons than anorexigenic neurons, and BACE1 may elicit some 
of its effects via this population. However a large number of BACE1-positive neurons are 
still distinct from NPY/AgRP-expressing neurons and, as observed with POMC neurons, 
these neuronal cell bodies and processes lie in close apposition to the NPY-expressing 
neurons and therefore BACE1-positive neurons may still act via NPY/AgRP neurons 
indirectly to affect energy homeostasis.  
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Figure 5.11 BACE1 is co-localised with NPY-expressing neurons in the arcuate 
nucleus. 
Representative confocal images, taken at x40 magnification, showing BACE1 (red), NPY 
(green) and merged channels in the arcuate nucleus. (A) Fluorescent in-situ hybridisation 
(FISH) images showing BACE1 co-stained with NPY, demonstrating co-localisation 
between a small proportion of BACE1 and NPY neurons, highlighted with higher 
magnification boxed region. (B) NPY-GFP immunofluorescence (IF) images showing 
BACE1 co-stained with NPY demonstrating co-localisation between a small proportion 
of BACE1 and NPY neurons, highlighted with higher magnification boxed regions. 3V, 
third ventricle. All scale bars 50µm. (C) Histogram displaying total (FISH and IF) number 
of BACE1+ cells, NPY+ cells and dual-labelled cells per field of view, showing a small 
proportion of BACE1 neurons are co-localised with NPY neurons (FISH: 6 fields of view, 
n=3, NPY-GFP: 8 fields of view, n=3).  
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5.3.6.3  BACE1 is expressed in RIPCre neurons in the arcuate nucleus 
Having shown BACE1 is present in a small number of POMC-, and NPY/AgRP-
expressing neurons, a large proportion of ARC BACE1 neurons remain unidentified, 
which highlights the presence of non-POMC and non-NPY/AgRP first order neurons in 
the ARC. One identified population are RIPCre neurons, a small population which have 
Cre expression driven by the rat insulin-2 promoter (Song et al. 2010). These neurons 
have been implicated in the regulation of whole body energy homeostasis, are directly 
responsive to leptin and have shown to be in very close apposition (but distinct) to POMC- 
and NPY/AgRP-expressing neurons (Choudhury et al. 2005). Consequently, the presence 
of BACE1 in RIPCre neurons was examined. This was determined using IF, with double 
staining of BACE1 (red) and GFP (green), on sections from RIPCre-GFP mice. Confocal 
images show a large proportion of BACE1-positive neurons are co-localised with RIPCre 
neurons in the ARC, observed as yellow (Figure 5.12A) and highlighted in the higher 
magnification boxed region. Quantitative analysis (counted across 16 images) revealed 
the observed co-localisation is equal to approximately 58% of BACE1 neurons co-
localised with RIPCre neurons, and furthermore 57% of detected RIPCre neurons co-
localise with BACE1 Figure 5.12B). These data show that a large proportion of BACE1 
neurons, indeed the majority detected in the ARC, are RIPCre neurons and therefore 
changes in hypothalamic BACE1 activity, resulting in altered energy homeostasis, may 
be mediated primarily via this neuronal population.  
Owing to the majority of BACE1 neurons co-localising with RIPCre in the ARC, other 
hypothalamic nuclei known to express RIPCre neurons were examined. As described 
above, sections were double-stained for BACE1 (red) and GFP (green) on sections from 
RIPCre-GFP mice. Confocal images show a proportion of BACE1 neurons are also co-
localised with RIPcre neurons in the DMH and VMH (Figure 5.13), however quantitative 
analysis was not performed.  
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Figure 5.12 BACE1 is co-localised with RIPCre neurons in the arcuate nucleus. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
RIPCre (green) and merged channels in the arcuate nucleus. 3V, third ventricle. All scale 
bars 50µm. (B) Histogram displaying total number of BACE1+ cells, RIPCre+ cells and 
dual-labelled cells per field of view, showing a large number of BACE1 neurons are 
RIPCre neurons (16 fields of view, n=4).  
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Figure 5.13 BACE1 is co-localised with RIPCre neurons in the ventromedial and 
dorsomedial hypothalamus. 
Confocal images, taken at x40 magnification, showing BACE1 (red), RIPCre (green) and 
merged channels within regions of the hypothalamus outwith the arcuate nucleus. 
Representative images from (A) the dorsomedial hypothalamus (DMH) and (B) the 
ventromedial hypothalamus (VMH). 3V, third ventricle. All scale bars 50µm.  
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5.3.7  BACE1 neurons in the arcuate nucleus are a 
heterogeneous population of GABAergic and 
glutamatergic neurons 
Having observed BACE1 is present in distinct neuronal populations in the ARC the 
precise phenotype of these neurons, i.e whether they are excitatory or inhibitory, was 
investigated. In the hypothalamus there is a mixed population of excitatory and inhibitory 
neurons, with these neurons releasing different neurotransmitters as well as responding 
to them. This is the case within the hypothalamus as a whole, but also within sub-
populations of neurons. For example NPY/AgRP and POMC/CART neurons in the ARC 
receive both excitatory and inhibitory synaptic inputs (Delgado 2013). As demonstrated, 
BACE1 is present in a large proportion of RIPCre neurons and the main neurotransmitter 
utilised by these neurons is thought to be GABA. This is an important issue as RIPCre 
neurons in various hypothalamic centres will have distinct roles. The main inhibitory 
neurotransmitter in the hypothalamus, and the CNS overall, is GABA with the main 
excitatory neurotransmitter being glutamate (Delgado 2013). Therefore it was examined 
whether BACE1 positive neurons in the ARC were predominantly GABAergic or 
glutamatergic using IF on GAD67-GFP tissue and VGlut2-GFP tissue, double-staining 
sections for BACE1 (red) and GFP (green) to determine the phenotype in the ARC. 
GAD67 is an isoform of glutamate decarboxylase, an enzyme responsible for the 
synthesis of GABA (Buddhala et al. 2009) and therefore indicates GABAergic neurons. 
Using IF, confocal images show numerous BACE1-positive neurons are co-localised with 
GAD67 neurons in the ARC, observed as yellow and highlighted in higher magnification 
boxed regions (Figure 5.14A), indicating many BACE1 neurons are GABAergic in this 
area. However, a significant proportion of BACE1 neurons are not co-localised with 
GAD67 (Figure 5.14A). Quantitative analysis (counted across 19 images) shows 34% of 
BACE1 neurons are GAD67-positive and furthermore 36% of GAD67-positive neurons 
are co-localised with BACE1 (Figure 5.14B). VGlut2 is a vesicular glutamate transporter 
responsible for packaging glutamate into synaptic vesicles for release and is the dominant 
glutamate transporter present in the hypothalamus, indicative of glutamatergic, excitatory 
neurons in this area (Delgado 2013; Meister 2007). Representative confocal images show 
a proportion of BACE1-positive neurons are co-localised with VGlut2 neurons in the 
ARC, observed as yellow and highlighted in higher magnification boxed regions (Figure 
5.15 
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A), demonstrating BACE1 neurons are also glutamatergic in this area. A proportion are 
not co-localised with VGlut2 (Figure 5.15A), supporting the finding of GABAergic-
BACE1 neurons in the ARC. Quantitative analysis (counted across 17 images)  shows 
30% of BACE1 neurons are co-localised with VGlut2 and furthermore 29% of VGlut2-
positive neurons are co-localised with BACE1 (Figure 5.15B). Taken together, these data 
show that BACE1 neurons are a heterogeneous population of GABAergic neurons and 
glutamatergic neurons within the ARC, and these will contribute different roles in the 
hypothalamic neuronal circuitry involved in maintaining energy homeostasis. 
5.3.8  Extra-arcuate nucleus BACE1 expression  
5.3.8.1  BACE1 is expressed in steroidogenic factor-1 neurons in the 
ventromedial hypothalamus 
Although the ARC is a key site of leptin action, other hypothalamic regions are of 
importance in the regulation of energy homeostasis. Leptin receptors are present in areas 
such as the VMH, which is also involved in regulating leptin actions on body weight and 
food intake. Having found BACE1 is also expressed in neurons throughout this region, 
the phenotype of these neurons was investigated to determine whether BACE1 activity 
may influence leptin action via the VMH, as well as the ARC. The main neuronal 
population in the VMH are steroidogenic factor-1 neurons, which leptin directly acts upon 
to contributing to its body weight actions (Dhillon et al. 2006). Hence the presence of 
BACE1 in SF-1 neurons was examined. This was determined using IF, with double 
staining of BACE1 (red) and GFP (green), on sections from SF-1-GFP mice. Confocal 
images show BACE1-positive neurons are co-localised with SF-1 neurons in the VMH, 
observed as yellow (Figure 5.16A) and highlighted in the higher magnification boxed 
region. However, not all BACE1-positive neurons in the VMH are SF-1 neurons, 
confirmed by quantitative analysis (counted across 14 images) which shows 31% of 
BACE1 neurons are co-localised with SF-1 neurons, and 32% of detected SF-1 neurons 
are co-localised with BACE1 (Figure 5.16B). These data show a substantial proportion 
of BACE1 neurons are SF-1 neurons in the VMH and therefore BACE1 may act via this 
neuronal population to modify leptin action on body weight. However, there are a large 
proportion of unidentified VMH BACE1-positive neurons that may also be implicated in 
regulating energy homeostasis.  
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Figure 5.14 BACE1 neurons are GABAergic in the arcuate nucleus. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
GAD67 representing GABA neurons (green) and merged channels in the arcuate nucleus. 
3V, third ventricle. All scale bars 50µm. (B) Histogram displaying total number of 
BACE1+ cells, GAD67+ cells and dual-labelled cells per field of view, showing a 
proportion of BACE1 neurons are GABAergic neurons (19 fields of view, n=3). 
Data collection was carried out in collaboration with Karolina Parmionova (Masters 
Student). 
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Figure 5.15 BACE1 neurons are glutamatergic in the arcuate nucleus. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
VGlut2 representing glutamatergic neurons (green) and merged channels in the arcuate 
nucleus. 3V, third ventricle. All scale bars 50µm. (B) Histogram displaying total number 
of BACE1+ cells, VGlut2+ cells and dual-labelled cells per field of view, showing a 
proportion of BACE1 neurons are glutamatergic neurons (17 fields of view, n=3).  
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Figure 5.16 BACE1 is co-localised with SF-1 neurons in the ventromedial 
hypothalamus. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
SF-1 (green) and merged channels in the ventromedial hypothalamus. 3V, third ventricle. 
All scale bars 50µm. (B) Histogram displaying total number of BACE1+ cells, SF-1+ 
cells and dual-labelled cells per field of view, showing a proportion of BACE1 neurons 
are SF-1 neurons (14 fields of view, n=3).  
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5.3.8.2 BACE1 expression in the paraventricular nucleus 
Having observed BACE1 expression in first order ARC neurons involved in energy 
metabolism, next it was investigated whether BACE1 is expressed in other hypothalamic 
areas involved in the hypothalamic circuitry. The PVN is a distinct hypothalamic region 
where many neurons project to and pathways converge. For example, NPY and POMC 
neurons from the ARC and orexin neurons from the LH both project directly to the PVN 
(Arora & Anubhuti 2006). Using IF, sections were double-stained for BACE1 and NeuN, 
to determine if BACE1 is present in neurons in the PVN. Representative confocal images 
show that BACE1 is expressed abundantly in this area, and is predominantly neuronal, 
demonstrated by the majority of BACE1 positive cells co-localising with NeuN, observed 
as yellow (Figure 5.17). These data show BACE1 is expressed in the PVN, and suggest 
that BACE1 may be involved in the neuronal circuits associated with PVN neurons that 
control energy balance.  
5.3.9 BACE1 expression in the hindbrain 
The hypothalamus connects to centres within the hindbrain such as the NTS, which has 
dense input from the hypothalamus as well as peripheral signals carried from the vagus 
nerve. NTS neurons project back to areas of the hypothalamus, such as the PVN forming 
neural circuitry which regulates feeding behaviour and energy expenditure (Schwartz et 
al. 2000). Having observed BACE1 neuronal expression within the ARC and PVN the 
presence of BACE1 neurons in the NTS was examined to investigate if BACE1 is 
involved in the CNS circuits controlling energy balance. In particular the NTS has a dense 
population of NPY neurons (Arora & Anubhuti 2006), therefore it was investigated if 
BACE1 was present in these neurons using IF on NPY-GFP tissue. Representative 
confocal images show BACE1 (red) is present in abundance in the NTS, and a proportion 
of neurons are co-localised with NPY neurons (green), observed as yellow and 
highlighted in the higher magnification boxed region (Figure 5.18A), demonstrating 
BACE1 neurons are also NPY-positive in the NTS. A large proportion are not co-
localised with NPY, with quantitative analysis (counted across 6 images) showing only 
11% of BACE1 neurons are co-localised with NPY, however a large proportion of NPY 
neurons (52%) are co-localised with BACE1 (Figure 5.18B). Taken together, these data 
show BACE1 is present in an area of the brainstem involved in receiving and projecting 
information involved in energy regulation, and a proportion of these neurons are NPY 
neurons. Therefore BACE1 may act via this neuronal population within the NTS and the 
neural circuits involved in regulating energy expenditure and food intake. 
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Figure 5.17 BACE1 is expressed in neurons in the paraventricular nucleus. 
Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
neuronal marker NeuN (green) and merged channels in the paraventricular nucleus. 3V, 
third ventricle. All scale bars 50µm. 
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Figure 5.18 BACE1 is co-localised with NPY neurons in the nucleus tractus 
solitarius. 
(A) Representative confocal images, taken at x40 magnification, showing BACE1 (red), 
NPY (green) and merged channels in the nucleus tractus solitarius (NTS). All scale bars 
50µm. (B) Histogram displaying total number of BACE1+ cells, NPY+ cells and dual-
labelled cells per field of view, showing a small proportion of BACE1 neurons are NPY 
neurons however a large proportion of NPY neurons are BACE1 positive (6 fields of 
view, n=3). 
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5.4 Discussion 
5.4.1 Summary 
Within this chapter we set out to investigate the expression of BACE1, particularly in the 
hypothalamus, and identify the cell populations it is expressed in to determine any 
implication in the neuronal circuitry controlling energy balance. Herein, we have found 
BACE1 is expressed throughout regions of the hypothalamus and the brainstem (the 
NTS); all areas involved in the neuronal pathways controlling whole body energy 
homeostasis. Specifically in the ARC, we demonstrated BACE1 is predominantly 
neuronal and a proportion of these neurons express the leptin receptor. In addition, we 
demonstrated BACE1 is expressed in a small population of first-order NPY neurons and 
a large population of RIPCre neurons, of which these neurons are a mixed population of 
both GABAergic and glutamatergic neurons. This large population of RIPCre-BACE1 
neurons may be responsible for the role of BACE1 in metabolism. Furthermore, we found 
BACE1 is also expressed in RIPCre neurons in extra-ARC areas, such as the VMH, where 
BACE1 was also found to be present in SF-1 neurons. These results, and the potential 
implications, will be further discussed in the following sections. 
5.4.2  BACE1 in the hypothalamus 
Herein we have presented novel findings regarding BACE1 expression in the 
hypothalamus. The results show by using both Western blotting and IF that BACE1 is 
expressed throughout the hypothalamus, present in all nuclei shown to play a role in 
regulating energy balance. Interestingly, this expression was not uniform across the 
hypothalamus and BACE1 is present in distinct groups of cells throughout. This localised 
expression is suggestive of a functional output. In keeping with the literature describing 
BACE1 to be largely present in neurons and not glia (Zhao et al. 2007; Hussain et al. 
1999; Vassar et al. 1999), we found throughout all hypothalamic nuclei BACE1 is 
predominantly expressed in neurons. This was anticipated prior to co-staining 
experiments as morphologically the BACE1-positive cells do not resemble astrocytes and 
tend to bear resemblance to neuronal cell bodies. An overall observation from these data 
is the localisation of BACE1 staining within neurons; it can be observed on processes and 
within the cell body, however in some instances there is strong staining in the nuclei.  
In regards to a lack of BACE1 expression observed in glia, it is noteworthy that these data 
were generated from healthy, WT mice fed a NC diet ad libitum. In some instances 
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BACE1 has been shown to be present in astrocytes following stress conditions. Blasko et 
al found that following modelling of traumatic brain injury in rodents, elevated levels of 
BACE1 were present in astrocytes, shown by co-localisation of BACE1 and the astrocyte 
marker GFAP, in the hippocampus and cortex (Blasko et al. 2004). This stress-related 
switch in BACE1-cell type could also occur in the hypothalamus. For example, BACE1 
is mainly neuronal under normal conditions, whereas under stress conditions such as 
HFD, there may be an upregulation within astrocytes. BACE1 has already shown to be 
increased in the hypothalamus following HFD (unpublished data), thus it would be of 
interest to examine if BACE1 expression changes at a cellular level in the hypothalamus 
in response to high-fat feeding. This could be achieved in the future using IF, co-staining 
for BACE1 and the cell specific markers described, on WT mice fed a HFD for a period 
of 20 weeks to induce obesity associated with central leptin resistance. 
Interestingly, under normal conditions not all hypothalamic BACE1 is neuronal as we 
found a small proportion of BACE1-positive neurons that are not co-localised with the 
neuronal marker NeuN, thus an unidentified population of cells which express BACE1 
exists. It can be assumed that we are not missing co-localisation with neurons as NeuN 
has been shown to specifically mark almost all neuronal nuclei in the brain, with the 
exception of a few populations outwith the hypothalamus (Mullen et al. 1992). Therefore, 
the BACE1-positive cells detected must be a separate cell type, such as oligodendrocytes, 
microglia and/or tanycytes and ependymal cells. It is possible BACE1 would be present 
in these cell as oligodendrocytes are involved in the formation of myelin and BACE1 may 
be required in this process as BACE1-/- mice have reportedly thinner myelin sheath (Hu 
et al. 2006). Similarly, we have shown BACE1 may play a role in inflammatory 
programming, with BACE1 inhibition reducing central HFD-associated inflammation 
(section 3.2.11). Consequently, BACE1 may be present in microglia, including resident 
microglia, perivascular macrophages and blood-borne immune cells. In addition, 
tanycytes and ependymal cells line the third ventricle and we observe this staining pattern 
with our BACE1-positive staining. Moreover, tanycyte processes extend to hypothalamic 
nuclei controlling food intake and energy expenditure and may play a role in the control 
of energy balance (Bolborea & Dale 2013), thus BACE1 may also be present in this 
cellular population To clarify this further experiments are required, utilising IF and co-
staining for BACE1 and markers of oligodendrocytes, microglia and tancytyes, both 
under normal conditions and following HFD to observe if BACE1 is upregulated in non-
neuronal cell types under stress conditions.  
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5.4.3  Leptin responsiveness of BACE1 neurons 
Having observed that pharmacological reduction of BACE1 appears to alter leptin 
sensitivity (chapter 3) and BACE1-/- mice are more leptin sensitive than WT littermates 
(unpublished data), we hypothesised that BACE1 directly affects leptin-responsive 
neurons in the hypothalamus and alters leptin signalling. Utilising IF and confocal 
microscopy it was found that approximately 30% of BACE1-positive neurons express 
ObRb, suggestive that only a proportion are responsive to leptin. Notably, there are other 
receptors present in the ARC which also play an important role in energy expenditure, 
food intake and inflammatory processing and it may be that BACE1 still alters energy 
metabolism via alternative receptors. Examples include serotonin and its receptors 5-
HT2cR and 5-HT1BR which are present in the ARC and play a role in regulating energy 
balance (Sohn et al. 2013). Studies on 5-HT2cR and 5-HT1BR deficient mice support this 
as both mouse models display hyperphagia, obesity and impaired glucose tolerance 
(Tecott et al. 1995; Bouwknecht et al. 2001). Interestingly, serotonin acts like leptin in 
the ARC as 5-HT2cR activates POMC neurons whilst and 5-HT1BR inhibits NPY/AgRP 
neurons (Sohn et al. 2013). Additionally, 5-HT2cR activates POMC neurons which are 
completely distinct from those activated by leptin (Sohn et al. 2011). These data 
demonstrate there are neuronal populations key in regulating food intake and body weight 
which do not possess the leptin receptor, and it may be that BACE1-positive neurons in 
the ARC express 5-HT2cR. Similarly, insulin receptors are present in the ARC, and as 
previously discussed a proportion of these are co-expressed with POMC neurons (Benoit 
et al. 2002). As insulin and leptin signalling converge, and BACE1 also affects insulin; 
with BACE1-/- mice displaying reduced circulating insulin levels and improved insulin 
sensitivity (Meakin et al. 2012), BACE1 may also be co-expressed in neurons with the 
insulin receptor. Many other receptor subtypes also exist in the ARC, such as the OX1R 
isoform of the orexin receptor which is thought to play a role in satiety signalling, as well 
as the ghrelin receptor which is also expressed in the ARC (Arora & Anubhuti 2006). 
Thus, there are a number of receptors present in the ARC which BACE1-positive neurons 
may express, and further experiments using IF and co-staining for these receptors and 
BACE1 would be required to examine which/ if any of these receptors may be expressed 
by BACE1 ARC neurons. Further examination of these neurons could also be conducted 
utilising electrophysiological measurements to determine the functional and electrical 
properties of these neurons. 
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It is assumed that neurons within the ARC expressing ObRb are first order neurons that 
directly respond to leptin and project to second order neurons in other hypothalamic 
regions. However, we show that following leptin treatment BACE1-positive neurons do 
not co-localise with pSTAT3, indicative of a lack of leptin responsiveness, disputing our 
hypothesis. One potential reason for this is the observed reduction in BACE1 expression 
in the ARC following leptin treatment, which is a finding reported previously in the 
literature in other brain areas highly expressing BACE1 (Marwarha et al. 2010; Marwarha 
et al. 2014). The precise mechanism whereby leptin causes this presumable degradation 
of BACE1 is unknown, although this is likely to be a physiological process as it occurs 
rapidly with the effects observed in our studies one hour post-leptin treatment. In these 
studies we used a 4mg/kg dose of leptin which others have reportedly used for leptin-
induced pSTAT3 stimulations (Vong et al. 2011), although this could be deemed a high 
dose as many groups observe a pSTAT3 leptin response with lower doses, such as 2mg/kg 
(Enriori et al. 2007; Zabolotny et al. 2002). The reduction in BACE1 expression following 
leptin treatment could therefore be an acute effect due to a high dose of leptin and it would 
be of interest to conduct the same experiments at a lower, sub-maximal dose (for example 
1-2mg/kg) to attempt to overcome this effect. In addition, it would be intriguing to 
conduct these experiments on high-fat fed mice, as the associated leptin resistance may 
cause the BACE1 in the ObRb-positive neurons to no longer become degraded. As 
previously mentioned BACE1-/- mice have improved leptin sensitivity and they also show 
elevated basal pSTAT3 levels (unpublished data), however we find no significant 
difference in the number of pSTAT3-positive cells following leptin treatment in BACE1-
/- mice compared to WT littermates. Again, this could be due to the dose administered 
and we are possibly observing maximal activation in which case no large difference 
would be observed. Noteworthy, is that this was examined in mice fed a NC diet and the 
changes may be mild, therefore the effect may be masked due to the high dose of leptin. 
Of benefit would be to conduct the same experiments in mice challenged with a HFD, as 
this may elicit a greater effect. The high levels of BACE1 as a result of high-fat feeding 
may result in reduced pSTAT3 signalling, an effect avoided in BACE1-/- mice.  
Alternatively, Marwarha and colleagues demonstrated that in SH-SY5Y cells the 
attenuation of BACE1 expression caused by leptin is due to increased sirtuin 1 (SIRT1) 
expression (Marwarha et al. 2014). SIRT1 is a deactylase enzyme which regulates 
metabolism through involvement in many processes including stress responses, oxidative 
metabolism and cell apoptosis and differentiation (Haigis & Sinclair 2010). Marwarha et 
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al suggested the leptin-induced reduction of BACE1 occurs due to SIRT1 inhibiting NF-
κB signalling, which is also implicated in the regulation of BACE1, presenting the notion 
of a leptin-SIRT1-NF-κB pathway controlling BACE1 regulation (Marwarha et al. 2014). 
This also associates SIRT1 with BACE1 and its role in energy metabolism, which is 
possible as SIRT1 is involved in calorie restriction and also plays a role in the neuronal 
response to stress (Duan 2013). Furthermore, in SH-SY5Y cells over-expression of 
BACE1 reduces SIRT1 protein levels (John Findlay PhD Thesis). Owing to this it would 
be interesting to examine if SIRT1 changes following inhibition of BACE1 and if SIRT1 
is highly expressed in the hypothalamus and co-expressed in BACE1-positive neurons, 
to determine if this is responsible for mediating some of our findings.  
Notably, leptin treatment did not completely diminish BACE1 expression which is in 
keeping with only a proportion of BACE1-positive neurons in the ARC expressing ObRb. 
In line with our original hypothesis that BACE1-ObRb-expressing neurons are leptin 
responsive, it may be that these neurons are those that the expression of BACE1 has been 
reduced therefore the pSTAT3 response is merely being missed. To counteract this issue 
we could utilise FISH to stain for BACE1 mRNA, assuming the protein is being degraded, 
and therefore in the presence of all BACE1-expressing neurons observe pSTAT3 co-
localisation. However, Marwarha and colleagues did note a reduction in BACE mRNA 
expression, as well as protein, following leptin treatment (Marwarha et al. 2014), thus this 
technique may not be feasible. In addition, we did not examine BACE1 expression 
following leptin treatment in areas outwith the ARC, away from the dense site of ObRb 
expression. If BACE1 is only reduced in areas where ObRb is expressed this further 
supports our hypothesis that only BACE1 neurons that express the leptin receptor, and 
thus are directly responsive to leptin, are diminished following leptin treatment.  
Importantly, the lack of co-localisation with pSTAT3 may not be conclusive of a lack of 
leptin responsiveness as not all leptin outputs are via pSTAT3. The PI3K pathway is also 
required for mediating the actions of leptin and BACE1 may conduct its role on energy 
metabolism through this signalling cascade. To investigate this further co-staining of 
BACE1 and downstream targets of PI3K; pPKB or PIP3, following leptin treatment could 
be performed in the future. It can be hypothesised that BACE1-positive neurons in the 
ARC are co-localised with PIP3 and/or pPKB and thus BACE1 is acting via this pathway 
to affect leptin outcomes. BACE1 may act through this pathway in particular affecting 
the downstream target FoxO1, which mediates the anorectic effects of leptin. FoxO1 is 
also important in mediating responses to oxidative stress (Nakae et al. 2008), and is 
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implicated in the progression of insulin resistance, potentially through activation of 
inflammatory signalling (Fan et al. 2010), therefore also potentially contributing to AD 
progression (Manolopoulos et al. 2010). Taken together, high levels of BACE1 may be 
associated with impaired hypothalamic (and possibly other brain areas) FoxO1 signalling, 
exacerbating metabolic syndrome, as well as AD, and this is an area worth further 
investigation.  
5.4.4  BACE1 and first order arcuate neurons 
Within this chapter we have shown BACE1 is present in less than 5% of POMC/CART 
neurons and approximately 10% of NPY/AgRP neurons in the ARC. This is somewhat 
unsurprising as we showed that BACE1 inhibition did not evoke large effects on food 
intake (section 3.2.1.1 and 3.2.7.1). Of interest is the slightly greater number of BACE1-
positive neurons that are co-expressed with NPY/AgRP neurons, as this would suggest a 
potential role of BACE1 in fasting. In support of this, our data show BACE1-/- mice 
become hyperphagic following a period of fasting (unpublished data) and DIO mice 
treated with a BACE1 inhibitor display an increased ratio of orexigenic/anorexigenic 
neuropeptide mRNA expression (unpublished data, section 3.2.3 and 3.2.9), reversing the 
suppression which occurs following HFD. Future experiments will be required to 
examine the expression and co-localisation pattern of BACE1 with POMC/CART and 
NPY/AgRP neurons in the fasted state, as all data presented in this chapter are from mice 
fed a NC diet ad libitum, as well as during the course of re-feeding after an overnight fast. 
Following an overnight fast NPY/AgRP transcript expression is increased and 
POMC/CART expression is reduced, and this expression pattern becomes switched 
during re-feeding (Mizuno et al. 1998; Swart et al. 2002), thus BACE1 expression in these 
neurons may also change over the course of fasting and re-feeding.  
Imaging studies described in this chapter to examine first order ARC neurons only looked 
at POMC and NPY expression specifically. As mentioned, within the ARC almost all 
POMC neurons co-express CART (Elmquist et al. 1999) and all NPY neurons co-express 
AgRP (Broberger et al. 1998), allowing the assumption that BACE1 is present in 
approximately 5% of CART neurons and 15% of AgRP neurons. However, this can only 
be assumed to be the case within the ARC, as for instance CART is expressed elsewhere 
in the hypothalamus such as the PVN and DMH, as well as also found in extra-
hypothalamic sites. Although BACE1 did not co-localise largely with POMC/CART or 
NPY/AgRP neurons in the ARC, the staining pattern reveals that BACE1-positive 
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neurons are situated in very close apposition to these first order neurons. In particular, 
BACE1 and POMC cell bodies and processes can be observed lying very close to each 
other, suggestive that although BACE1 is not present in POMC neurons the two 
populations may communicate in some way. To examine this further the utilisation of 
additional techniques are required, such as electrophysiology. Our results indicate, by the 
appearance of the staining, that the contact between BACE1 and POMC, and NPY/AgRP 
neurons, may be through synaptic input as it appears that BACE1 may be present at the 
synapse. This raises an interesting point as synaptic plasticity within the hypothalamus is 
receiving more attention recently as a potential mechanism in the regulation of energy 
homeostasis (Horvath 2005; Dietrich & Horvath 2013). Unfortunately, confocal 
microscopes do not have the adequate resolution to accurately detect synapses, thus we 
cannot definitively conclude that BACE1 is indeed synaptic and this would require 
electron microscopy and primary neuronal cultures for more precision. However, if we 
assume due to the position of the BACE1 neurons in respect to POMC and NPY/AgRP 
neurons, that BACE1 is making synaptic contacts this would be in line with research 
demonstrating that synaptic innervation of these first order neurons is important for their 
response to leptin and thus body weight and food intake actions (Horvath 2005; Dietrich 
& Horvath 2013). Synaptic plasticity occurs in the hypothalamus and is thought to be 
involved in the regulation of energy balance indicated by Pinto and colleagues work 
which showed alterations in the ratio of inhibitory to excitatory synaptic inputs onto 
NPY/AgRP neurons, displaying an increased number of synapses and excitatory tone on 
NPY neurons, in ob/ob mice (Pinto et al. 2004). This work showed leptin has the ability 
to ‘re-wire’ synaptic inputs by normalising this ratio and increasing the number of 
synapses on POMC whilst reducing the number on NPY neurons (Pinto et al. 2004). Of 
interest is that the leptin-induced rearrangement in synaptic densities occurs prior to body 
weight or food intake effects providing further evidence for the role of synaptic plasticity 
in regulating whole body energy homeostasis. Our findings provide potential evidence 
for BACE1 to be involved in this process. 
Within the ARC it has been shown that NPY directly inhibits POMC through synaptic 
innervation from NPY/AgRP neurons or through GABA input (Cowley et al. 2001). 
Although we find BACE1 is not highly expressed in POMC and NPY/AgRP neurons we 
do observe BACE1 is present in approximately 35% of GABA neurons, therefore BACE1 
may be acting upon these neurons via GABA release. The ARC contains a heterogeneous 
population of both GABAergic and glutamatergic neurons (Vong et al. 2011), which 
209 
 
 
 
supports our findings of BACE1 also co-expressing with VGlut2 in approximately 30% 
of neurons in the ARC. GABAergic neurons are the major population in the ARC and all 
NPY/AgRP are considered to be GABAergic whereas few POMC are believed to be 
GABAergic (Vong et al. 2011). Although, this finding is not supported by other groups 
with studies showing approximately 50% of POMC neurons express the GABA 
synthesising enzyme, GAD67, in mice (Wittmann et al. 2013). Regardless, of interest is 
the finding that leptin acts to decrease inhibitory postsynaptic currents on POMC neurons 
through leptin receptor action on presynaptic GABAergic neurons and that these leptin-
responsive neurons described are not NPY/AgRP neurons (Vong et al. 2011). This 
suggests there are GABAergic neurons independent of NPY/AgRP neurons in the ARC, 
which is supported by the phenotype of the BACE1-postive neurons we observe in our 
studies, and significantly it is these neurons that impact synaptic inputs onto POMC 
neurons. Furthermore, leptin induces anti-obesity effects largely by modulating first order 
GABA neurons causing inhibition of other local first order neurons such as POMC. Our 
findings indicate that BACE1 neurons in the ARC, although not present in the majority 
of POMC and NPY/AgRP neurons, may regulate energy homeostasis via synaptic contact 
onto neurons in the melanocortin system (Figure 5.19). 
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Figure 5.19 Schematic diagram showing the potential interaction of BACE1-positive 
ARC neurons in the current two neuron model of energy balance control. 
Adiposity signals insulin and leptin act on ARC first order neurons to inhibit NPY/AgRP 
neurons and activate POMC neurons. POMC neurons release α-MSH which acts on 
second order neurons and AgRP acts to inhibit this action. GABAergic NPY/AgRP 
neurons can also innervate POMC neurons through synaptic GABA, NPY and AgRP 
release, directly inhibiting POMC action. The present data suggest that BACE1-positive 
ARC neurons also respond to peripheral signals and make synaptic contacts with POMC 
neurons. First order ARC neurons (BACE1-positive, POMC and NPY/AgRP neurons) 
project to second order neurons to influence food intake and energy expenditure, 
maintaining energy balance. 
Figure adapted from Ashford Lab teaching material.
 
The notion discussed above is further supported by our finding that a large proportion of 
BACE1 neurons are RIPCre neurons in the ARC, as these neurons are distinct from 
POMC and NPY/AgRP neurons (Choudhury et al. 2005) and the majority are described 
to be GABAergic (Kong et al. 2012). Importantly, Kong and colleagues described that 
GABAergic RIPCre neurons are crucial for regulating energy expenditure, however not 
through alterations in food intake, but through increased BAT thermogenesis (Kong et al. 
2012). This is supportive of our data showing BACE1 inhibition does not elicit major 
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effects regarding feeding behaviour and BACE1 is not largely expressed in neurons 
controlling food intake (POMC neurons), however following genetic or pharmacological 
removal of BACE1 we observe upregulation of thermogenic genes in WAT and BAT 
(unpublished data, section 3.2.10). Taken together, these data suggest BACE1 may be 
acting via RIPCre neurons to alter energy expenditure through BAT thermogenic 
programming.  
Our data also demonstrate a reduction in inflammatory processing following 
pharmacological reduction of BACE1 (section 3.2.11), both centrally and peripherally, 
proposing a role for BACE1 in regulating inflammatory processes. Interestingly, this may 
also be due to the high expression of BACE1 observed in RIPCre neurons, as RIPCre 
neurons have also been implicated in the control of systemic inflammation. When Pten, 
which encodes a phosphatase that negatively regulates PI3K, is ablated from RIPCre 
neurons an anti-inflammatory pathway is activated whereby a phenotypic switch from a 
pro-inflammatory macrophage M1-like state to an anti-inflammatory macrophage M2-
like state occurs in peripheral tissues (Wang et al. 2014). In addition, Wang et al 
demonstrated that this reduced pro- and enhanced anti-inflammatory state in Pten-RIPCre 
deficient mice results in protection from diet-induced obesity (Wang et al. 2014). The 
proposed mechanisms whereby RIPCre mediates the aforementioned role in energy 
expenditure and this role in systemic inflammation occur through central circuitry. In both 
cases it is hypothesised that ARC RIPCre neurons activate second order neurons in the 
PVN which project to the brainstem, notably the NTS, to mediate effects likely via the 
SNS (Kong et al. 2012; Wang et al. 2014). In particular, regarding energy expenditure 
effects, this is believed to occur via GABAergic ARC neurons and the projections to the 
NTS will further stimulate BAT function (Kong et al. 2012). With this in mind, our results 
show BACE1 is present in the ARC, of which a large proportion are GABAergic and 
RIPCre positive, furthermore we have also showed BACE1 is present in neurons in the 
PVN and the NTS, thus BACE1 fits into this proposed circuitry. Moreover, as discussed 
we also observe changes in thermogenic genes in BAT from BACE1 inhibitor treated 
mice and BACE1-/- mice (section 3.2.10, unpublished data), indicating BACE1 action on 
BAT. In regards to the role in systemic inflammation, the proposed mechanism indicates 
that in addition to activation of neurons in the NTS there is also projections from the PVN 
to the dorsal vagal motor nucleus (DVM), also within the brainstem. This controls vagal 
autonomic outflow and results in activation of an anti-inflammatory reflex causing the 
phenotypic switch of classically activated macrophages to an M2 state (Wang et al. 2014). 
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In our studies the expression of BACE1 in other regions of the brainstem (outwith the 
NTS) was not examined and it would be of interest to investigate this as at present it has 
not been shown if BACE1 is expressed in the DVM. As we show BACE1 is expressed in 
all other areas implicated in this circuitry, we would hypothesise BACE1 is also present 
in neurons within the DVM since, as mentioned, we also observe increased anti-
inflammatory programming in both BACE1-/- mice and BACE1 inhibitor treated mice.  
Taken together, we hypothesise that BACE1/RIPCre GABAergic neurons in the ARC act 
upon second order neurons in the PVN, which may also be BACE1-positive. These 
second order neurons project to neurons in the NTS regulating thermogenic and 
inflammatory programming in peripheral tissues, and these NTS neurons may also be 
BACE1-positive (Figure 5.20). This suggests that in instances where BACE1 is elevated, 
such as during diet-induced obesity, this will impair the described neuronal circuitry 
resulting in reduced energy expenditure and increased inflammation; exacerbating 
metabolic dysfunction and causing a vicious cycle to occur. Crucial future work to 
investigate this theory further would be to knock-out BACE1 exclusively in RIPCre 
neurons utilising a conditional BACE1-/- mouse with loxed alleles and crossing this with 
RIPCre transgenic mouse. The expected result would be that mice with BACE1 deletion 
from RIPCre neurons would be protected from diet-induced obesity, display increased 
energy expenditure and reduced systemic inflammation, demonstrating an overall 
improved metabolic phenotype.  
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Figure 5.20 Schematic diagram showing BACE1-positive ARC neurons and the 
proposed neuronal pathway regulating energy expenditure and inflammatory 
processing. 
The present data show a high proportion of BACE1-positive ARC neurons are 
GABAergic RIPcre neurons. These neurons respond to leptin and innervate second order 
neurons in the PVN through GABA release. Second order neurons in the PVN project to 
the NTS which stimulates energy expenditure in BAT through sympathetic output and 
macrophage differentiation in the spleen through vagal output to promote anti-
inflammatory signalling. 
Figure adapted from (Kong et al. 2012)
 
5.4.5  BACE1 expression outwith the arcuate nucleus 
The role of BACE1 in energy metabolism may not be entirely mediated by RIPCre 
neurons as we have established BACE1 is expressed in other areas of the hypothalamus, 
which also regulate whole body energy homeostasis. The VMH plays a key role in energy 
homeostasis, involving control of glucose homeostasis and energy expenditure. We have 
shown BACE1 is co-localised with RIPCre neurons in this area, as well as the DMH, 
however less is known regarding the functions of RIPCre neurons within these nuclei, 
with focus remaining on the ARC. We have shown that throughout the VMH BACE1 is 
co-expressed with approximately 30% of SF-1 neurons, which are the predominant 
population in the VMH. Still, other genes are expressed throughout the VMH and may 
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represent distinct populations of neurons such as brain derived neurotrophic factor 
(BDNF), pituitary adenylate cyclase activating polypeptide (PACAP), and cerebellin 1 
(Choi et al. 2013). Additionally, localised to the ventrolateral region of the VMH the 
estrogen receptor α (ERα), neuronal nitric oxide synthase, somatostatin and CKK also 
exist (McClellan et al. 2006). This supports our data which shows not all BACE1 neurons 
in the VMH are SF-1 neurons. These additional neuropeptides and transcription factors 
present in the VMH are also likely to play a role in metabolism, supported by findings 
that a lack of BDNF mRNA (Liao et al. 2012) or ERα (Musatov et al. 2007) expression 
in the VMH results in obesity and hyperphagia in mice. Furthermore, PACAP is also 
implicated in the control of energy balance with work demonstrating PACAP exerts 
anorexigenic effects in mice, and that PACAP neurons in the VMH are responsive to 
leptin and required for leptin action (Hawke et al. 2009). Future experiments would be 
required to examine if BACE1-positive neurons in the VMH, those in particular that may 
be distinct from some SF-1 neurons, co-express BDNF, ERα and PACAP to further 
unpick the role of BACE1 in the VMH. 
SF-1 neurons are primarily involved in regulating glucose homeostasis and appropriately 
responding to glucose (Tong et al. 2007), proposing a role for BACE1 in the modulation 
of glucose homeostasis. Recent data from our lab supports this concept showing in vitro, 
utilising a hypothalamic (GT1-7) cell line, that BACE1 levels are sensitive to changes in 
glucose, with recurrent hypoglycaemia increasing BACE1 protein levels (John Findlay 
PhD Thesis). To investigate this further in vivo BACE1 could be ablated exclusively in 
SF-1 neurons, again utilising a conditional BACE1-/- mouse with floxed alleles and 
crossing this with a SF-1 transgenic mouse. Additionally, SF-1 neurons are also involved 
in regulating leptin action on energy expenditure. Studies show that global deletion of the 
leptin receptor or leptin receptor ablation on SF-1 neurons impairs the thermogenic 
response to high-fat feeding and reduces energy expenditure (Kim et al. 2011; Dhillon et 
al. 2006). This is in keeping with the proposed mechanism, whereby BACE1 may be 
primarily affecting thermogenesis and energy expenditure, however it may do so not only 
via RIPCre neurons but also SF-1 neurons. Interestingly, leptin action on SF-1 neurons 
may also occur through PI3K mediated mechanisms involving FoxO1, which we have 
proposed to be the case for BACE1 ARC neurons that do not appear to signal through 
pSTAT3 in response to leptin. When FoxO1 is ablated from SF-1 neurons, mice are lean, 
display increased energy expenditure and are more insulin and leptin sensitive (Kim et al. 
2012). These data further support our findings that BACE1 neurons may respond to leptin 
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and alter energy balance through the PI3K pathway. Furthermore, when Ptpn1, the gene 
encoding the negative regulator of leptin and insulin signalling PTP1B, is knocked out of 
SF-1 neurons this causes obesity, impaired sympathetic output and reduced energy 
expenditure (Chiappini et al. 2014). Interestingly, these effects are only observed when 
mice are fed a HFD with no changes on body weight observed when mice are fed a NC 
diet, suggesting the additional stress of high-fat feeding is required which may be 
associated with increased BACE1 levels in SF-1 neurons, further exacerbating an obese 
phenotype and impairing neuronal function. In support of this is data from our lab 
showing PTP1B levels are reduced in BACE1-/- mice fed a HFD. The mechanism whereby 
BACE1 regulates energy metabolism in SF-1 neurons is unknown, as the precise 
connections SF-1 neurons make is not yet defined. In particular, other glucose-sensing 
neurons and how they interact with SF-1 neurons in the VMH is still to be investigated, 
however it can be assumed that these neurons will also connect to the brainstem due to 
their effects on glucose tolerance and in particular they will likely project to the NTS 
owing to their role in sympathetic output and energy expenditure. 
Within this chapter we demonstrated BACE1 is expressed in the NTS and thus may be 
implicated in sympathetic output to peripheral tissues, notably BAT. However, the 
characterisation of BACE1 in the NTS was not examined, and we cannot definitively 
conclude a role for BACE1 in this area. It would be of interest to trace BACE1 neuronal 
projections to achieve a better understanding of the circuitry BACE1 is involved in. This 
could be achieved using electrophysiological measurements or through injection of 
fluorescent beads and channelrhodopsin 2-assisted circuit mapping (Atasoy et al. 2008) 
as utilised by Kong et al in the investigation of RIPCre neuronal projections (Kong et al. 
2012). In addition, measurements of sympathetic activity in BACE1-/- mice and BACE1 
inhibitor treated mice could be ascertained by measuring noradrenaline levels in the 
serum, to indicate whether BACE1 may indeed be implicated in altered SNS activity. Our 
results show that approximately 10% of BACE1 neurons in the NTS are NPY neurons, 
thus a large population are unidentified. Interestingly, approximately half of the NPY 
neurons we observed in the NTS co-express BACE1, suggesting BACE1 may be involved 
in the NPY-central circuitry regulating feeding behaviour. As the NTS receives and inputs 
many signals from hypothalamic areas, extra-hypothalamic areas and the periphery it is 
more complex to pin down the role BACE1 plays in this area. Further experiments 
examining co-expression of BACE1 with other known NTS neuronal populations, such 
as catecholaminergic neurons, CART and POMC neurons and proglucagon-expressing 
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neurons in this area is required (Sobrino Crespo et al. 2014). However, the important 
finding from our results is that BACE1 is present in the NTS, and therefore it may have 
a role in the neuronal circuitry the NTS is involved in. 
The NTS receives an abundance of projections from the PVN, where, as previously 
discussed, we also find BACE1 to be expressed. As with other areas of the hypothalamus 
we find BACE1 is predominantly neuronal in the PVN and thus we can assume BACE1 
is present in second order hypothalamic neurons. However, we did not examine the 
precise neuronal population BACE1 is co-localised with in the PVN. As mentioned, two 
main populations of second order neurons in the PVN are CRH- and TRH-releasing 
neurons, and it would be of interest to examine if BACE1 co-expresses with these 
populations. Another population of benefit to investigate in the PVN are tyrosine 
hydroxylase-expressing neurons. Tyrosine hydroxylase (TH) is an enzyme involved in 
the synthesis of catecholamines, and TH-releasing neurons have recently been shown to 
be targets of ARC NPY neurons and the relationship between the two may affect 
sympathetic tone on BAT impacting thermogenesis and energy expenditure (Shi et al. 
2013). As we have proposed a mechanism whereby BACE1 may alter these processes, 
this is another potential pathway in which this may occur and examining co-expression 
of BACE1 and TH in the PVN and also measuring TH levels in our BACE1-/- and BACE1 
inhibitor treated mice would be of interest to carry out in the future.  
Further examination of BACE1 expression is also necessary in the LH and the DMH. In 
both areas we have shown that BACE1 is expressed and is predominantly neuronal, 
however the precise populations are as yet unidentified. Owing to their involvement in 
satiety and their projections to the ARC and NTS, orexin LH neurons would be of great 
interest to examine. If BACE1 is expressed in orexin neurons in the LH this would be 
another potential mechanism whereby BACE1 alters energy balance, and interestingly 
this would also implicate BACE1 in sleep and wakefulness, as orexin neurons play a 
major role in regulating these processes (Arora & Anubhuti 2006; Inutsuka & Yamanaka 
2013). The role of BACE 1 in these processes is unknown and would be a novel area to 
examine. Firstly, it would be of interest to observe if BACE is present in the SCN; the 
control centre of circadian rhythms, as orexin receptors are found here and these neurons 
receive input from the SCN (Inutsuka & Yamanaka 2013). This could be achieved using 
IF on WT mice and we hypothesis that BACE1 would be co-expressed with LH neurons, 
and in turn in neurons of the SCN, as alterations in circadian rhythms are associated with 
diabetes and obesity (Scheer et al. 2009), and this could be due in part to increasing levels 
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of BACE1 altering the neuronal function of these neurons. In regards to obesity and the 
diet-induced response to thermogenesis, the DMH is crucial for further investigation. In 
particular NPY neurons in the DMH have been described to be important for regulating 
energy balance, as knocking down NPY expression in the DMH improves an obese 
phenotype by increasing energy expenditure and directly increasing thermogenic 
programming in BAT (Chao et al. 2011). Therefore, ARC NPY neurons may differ in 
their functions to DMH NPY neurons and it would be interesting to examine if BACE1 
is expressed in NPY neurons in the DMH and to what extent, as this would further 
implicate BACE1 in the neuronal circuitry impacting energy expenditure and 
thermogenic programming.  
5.4.6  Concluding Remarks 
Collectively, the data presented in this chapter provide novel findings into the expression 
of BACE1 in the hypothalamus and more specifically the neuronal circuitry regulating 
energy balance. BACE1 was found to be expressed throughout hypothalamic nuclei 
controlling energy balance and within distinct neuronal populations involved in this 
control. Further investigation is required to examine BACE1 expression, particularly its 
role in RIPCre neurons, but also to investigate the potential of other novel populations of 
BACE1-positive neurons in the hypothalamus. The knowledge from this research 
implicates a role for BACE1 in the CNS neuronal circuitry controlling energy metabolism 
and allows for further work to investigate the functionality of this role as well as 
additional roles of BACE1 activity in the control or modulation of whole body energy 
homeostasis.  
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Chapter 6 
 
 
 
Final Conclusions 
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6.1 The role of BACE1 in obesity and T2DM 
At present, obesity and T2DM represent major public health problems, with the 
prevalence of both dramatically on the rise. It is estimated that 13% of the adult 
population worldwide are considered obese, a risk factor that is closely associated with 
T2DM (www.who.int). This is extremely worrying owing to the number of comorbidities 
connected with both T2DM and obesity, including cardiovascular disease and AD. 
Of particular interest is the recent association of increased risk of AD to obesity and 
T2DM, with the diseases sharing many common features, including inflammation and 
insulin resistance. The link between AD, T2DM and obesity implicates BACE1, a protein 
whose expression levels and/or activity increase in response to stress conditions, such as 
factors associated with T2DM and obesity. The elevation in BACE1 activity and/or levels 
in response to stressors results in increased Aβ production, which is observed in obese 
mouse models (Julien et al. 2010). Elevations in Aβ protein levels are considered the 
primary causative factor for the progression of AD. According to the amyloid cascade 
hypothesis increased levels of Aβ gives rise to various cellular events, ultimately resulting 
in neuronal dysfunction and cell death (J. A. Hardy & Higgins 1992). The discovery of 
the Icelandic mutation that occurs adjacent to the BACE1 cleavage site, which actually 
reduces BACE1 activity, further supports the amyloid cascade hypothesis as this mutation 
causes reduced Aβ load and lifelong protection from AD. As a result, focus has been 
placed on BACE1 as a target for the treatment of AD, however owing to its association 
with obesity and T2DM it may also be a novel target for metabolic disease. In support of 
this it has been shown that BACE1-/- mice have an improved metabolic phenotype in 
comparison to WT littermates; BACE1-/- mice are resistant to DIO and display improved 
glucose homeostasis and insulin sensitivity (Meakin et al. 2012). Furthermore, 
pharmacological inhibition of BACE1 in skeletal muscle cells in vitro increases glucose 
uptake and oxidation (Hamilton et al. 2014). The same is observed in a neuronal (SH-
SY5Y) cell line and in addition overexpression of BACE1 in these cells causes decreased 
glucose uptake and oxidation (John Findlay PhD Thesis). Taken together, these data 
implicate BACE1 in the control of energy metabolism. For this reason, the data presented 
in this thesis sought to investigate BACE1 as a therapeutic target for metabolic disease, 
with the overall goal to allow for advancements in the treatment of obesity and T2DM. 
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6.2 The pharmacological inhibition of BACE1 as a 
potential treatment for metabolic disease 
The data presented in the current studies strongly suggest BACE1 inhibitors may provide 
a potential therapeutic strategy for the treatment of obesity and T2DM. Currently, 
treatment of these diseases emphasises altering lifestyle factors as the most desirable 
course of action. Reducing calorific intake and increasing energy expenditure are 
encouraged as both can reverse insulin and leptin resistance. However, due to the 
increasing prevalence of obesity and associated T2DM this strategy is clearly proving 
ineffective.  
At present there are two alternative approaches for the treatment of obesity; oral 
medication or surgery. Gastric bypass surgery is considered the only effective treatment, 
resulting in maintained weight loss in the majority of patients, although it is only an option 
for cases of morbid obesity (BMI >40) (Arora & Anubhuti 2006; Adan 2013). Therefore, 
focus is placed upon anti-obesity agents. Early research believed thyroid hormones could 
be effective as anti-obesity agents, through increasing resting metabolic rate and energy 
expenditure, resulting in reduced body weight (Adan 2013). However, many side effects 
were associated with this treatment, such as hyperthyroidism, and as a result focus turned 
to ‘noradrenergic’ and ‘serotonergic’ agents. Noradrenergics, such as phenteramine, 
block noradrenaline uptake, acting to suppress appetite, and serotonergic agents, such as 
fenfluramine and dexfenfluramine, affect serotonin uptake and release. Other, once 
approved anti-obesity agents include sibutramine which acts to inhibit reuptake of 
noradrenaline, serotonin and dopamine (Arora & Anubhuti 2006; Rolls et al. 1998), and 
rimonabant; an antagonist of the endocannabinoid receptor, CB1 (Adan 2013). 
Unfortunately, although many agents, such as the aforementioned, have undergone trials 
for the treatment of obesity and have proven to be effective in causing weight loss, most 
have been withdrawn due to severe side effects (Wong et al. 2012; Adan 2013). However, 
2,4-dinitrophenol (DNP), which has been known for decades to cause rapid weight loss 
through enhancing basal metabolic rate and fat burning, is still currently available despite 
high risks of severe side effects and increasing reports of fatalities (Grundlingh et al. 
2011). Thus, orlistat, an inhibitor of pancreatic lipase, is the only currently available and 
approved anti-obesity drug, acting to reduce efficiency of fat absorption (Padwal & 
Majumdar 2007) Although orlistat is widely prescribed, its weight loss effects are 
relatively mild and it is also associated with many gastrointestinal side effects (Li et al. 
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2005). As a result, newer drugs are also being researched and in the pipeline for obesity 
treatment, including lorcaserin; a serotonin receptor agonist, qsymia; a combination 
therapy of phenteramine and tipiramate (an anticonvulsant), and contrave; a combination 
therapy of a dopamine reuptake inhibitor (bupropion) and an opiod antagonist 
(naltrexone) (Wong et al. 2012; Adan 2013). However, associated side-effects are also 
emerging for these more recently approved compounds, including heart valve problems 
and psychiatric risks. A GLP-1 receptor agonist, liraglutide, has been also recently 
accepted as an anti-obesity agent, which was previously licensed as a treatment for T2DM 
(Adan 2013), although the mechanism for the body weight reducing effects of liraglutide 
are unknown. Alternatively, targeting of inflammatory processing may also present a 
potential therapeutic target due to the close association between inflammation, obesity 
and insulin resistance. In support of this, the use of an inhibitor of NF-κB β-subunit (IKK-
β); salicylate, improves insulin resistance (Fleischman et al. 2008). In addition, anti-
inflammatory cytokines such as IL-10 act as insulin sensitizers, further supporting the 
interference of inflammatory signalling as a potential treatment of obesity and associated 
insulin resistance (Zeyda & Stulnig 2009a).  
Importantly, owing to the various complications and side effects of current drugs there is 
still a need to develop small molecule compounds which target the components involved 
in the development of leptin and insulin resistance to provide effective treatments for 
obesity and T2DM. The issue surrounding many of the current treatments being 
researched is that they target one pathway and therefore may become ineffective due to 
redundant pathways compensating for weight loss. Additionally, as found with many of 
the compounds that have been withdrawn, targeting neurotransmitters will also have non-
satiety effects. Another key issue to be considered is the difficulty in maintaining weight 
loss, which may be due to a compensatory reduction in resting metabolic rate causing 
increased fat storage. Therefore, alternative strategies are required such as targeting 
energy expenditure and the natural control pathways (neuronal and hormonal) that 
regulate metabolic rate and processes such as thermogenesis. Additionally, other 
processes driving the progression of obesity and insulin resistance, predominantly 
inflammation and ER stress, should also be investigated. The data presented in this thesis 
have shown that BACE1 inhibition improves an obese/diabetic phenotype mainly through 
altered thermogenic and inflammatory programming. We hypothesise that BACE1 
inhibitors cause a reduction in body weight by increasing energy expenditure through 
upregulation of thermogenic genes in WAT and BAT, and our data indicate reduced 
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central and peripheral inflammation. These results suggest that BACE1 inhibitors as 
novel anti-obesity agents may be more effective than currently available compounds. 
BACE1 inhibitors currently under clinical trials for AD would be of benefit to determine 
if they can elicit the same metabolic effects in humans produced in the present studies. 
This would allow for further research investigating the comparison between currently 
researched anti-obesity agents with BACE1 inhibitors and potentially broaden research 
trialling BACE1 inhibitors for AD to the treatment of metabolic disease in humans. 
6.3 The role of BACE1 in the hypothalamic neuronal 
circuitry controlling energy balance 
In an attempt to better understand the role of BACE1 in energy metabolism we turned our 
attention to the hypothalamus; deemed the control centre for the regulation of energy 
homeostasis. This control is reliant on intact neuronal circuitry and leptin signalling; 
disruption of this circuitry results in obesity, as demonstrated in the genetic ob/ob and 
db/db mouse models (Zhang et al. 1994; Chen et al. 1996). Such models demonstrate the 
requirement to preserve leptin signalling for regulating energy homeostasis, however 
during DIO there is a state of leptin resistance causing impaired leptin action (Considine 
et al. 1996). Distinct hypothalamic nuclei are involved in this control, although the ARC 
is the main site of leptin action and as a consequence is the main site of leptin resistance 
(Enriori et al. 2007).  
The current neuronal hypothesis of leptin action in the ARC involves POMC and 
NPY/AgRP neurons. In brief, following binding of the long form of its receptor, leptin 
activates POMC/CART neurons and inhibits NPY/AgRP neurons, ultimately resulting in 
reduced food intake and increased energy expenditure (Cowley et al. 2001; Schwartz et 
al. 2000; Bates & Myers 2003). Latterly, this model has been deemed too simplistic as 
when the leptin receptor is removed from these neurons only mild obesity is observed 
(Balthasar et al. 2004; Van De Wall et al. 2008), thus other first order ARC neurons must 
play a role. In support of this, in the present studies we observe BACE1-positive neurons 
in the ARC, which are distinct from POMC and NPY/AgRP neurons. A small percentage 
of ARC BACE1-positive cells are POMC (~5%) and NPY/AgRP (~10%) therefore 
BACE1 may still influence food intake and energy expenditure pathways through these 
neuronal populations. We demonstrated that approximately 50% of the non-
POMC/NPY/AgRP BACE1-positive neurons in the ARC are RIPCre GABAergic 
neurons, which are a relatively novel neuronal population implicated in the regulation of 
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thermogenic and inflammatory processes (Kong et al. 2012; Wang et al. 2014). Our data 
further supports this through finding that BACE1 inhibition may be acting to increase 
thermogenesis in BAT whilst inhibiting central and peripheral inflammation. RIPcre 
neurons have been described to be in close, though distinct, apposition to POMC and 
NPY/AgRP neurons (Choudhury et al. 2005), which is in keeping with our findings that 
BACE1-positive cells appear very close to contacting POMC neurons. Furthermore, 
BACE/RIPcre neurons express leptin receptors and as a result are considered responsive 
to leptin, likely through the PI3K pathway, as the data presented in the current study 
demonstrate a lack of evidence for pSTAT3 activation in BACE1-positive ARC neurons. 
These findings suggest leptin is not acting upon these neurons through the JAK-STAT 
signalling pathway and proposes activation of PI3K and possibly FoxO1, to be 
implicated, although this is yet to be tested. Owing to the co-localisation between 
BACE1-positive neurons and RIPCre neurons, and the positioning of these neurons in 
relation to POMC and NPY/AgRP neurons, allows us to hypothesis that it is more likely 
that a third neuronal population is crucial in the current two ARC neuronal model. This 
suggests leptin signals not only POMC and NPY/AgRP neurons but also BACE1/RIPCre 
neurons that will independently send projections to second order neurons in the PVN. In 
addition, within this proposed ‘three-neuron model’ it may be that BACE1/RIPcre 
neurons also inhibit POMC neurons indirectly from leptin signalling. This is observed 
with NPY/AgRP neurons that directly inhibit POMC through synaptic innervation by 
GABA and NPY release (Cowley et al. 2001). To fully investigate this concept it would 
be necessary to conduct further experiments using electrophysiological techniques, 
utilising a fluorescent BACE1 and/or RIPCre mouse model. A fluorescent BACE1 mouse 
model would be of particular interest, as there remains a population of BACE1-positive 
neurons in the ARC which are undefined and may represent alternative ARC populations 
such as dopaminergic or cholinergic neurons. This mouse model, as well as utilising more 
novel techniques such as DREADD (designer receptors exclusively activated by designer 
drugs) would allow these neurons to be investigated in further detail. DREADD 
technology, based upon mutated human muscarinic receptors which have a high efficacy 
for a pharmacologically inert ligand, allow for targeting of specific neuronal populations 
using viral vectors or over-expressing transgenic mouse models (Alexander et al. 2009). 
This technology permits direct activation and modulation of specific neurons, as 
demonstrated by Krashes et al investigating AgRP neuronal activation on feeding 
behaviour (Krashes et al. 2011), and Kong et al examining the effects on energy 
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expenditure through RIPCre neuronal activation (Kong et al. 2012). Utilising this 
technique, particularly fusing the DREADD with a fluorescent protein such as mCherry, 
would allow for the direct activation of BACE1-positive neurons and for their functional 
role to be investigated through examining their electrical properties.  
The VMH is also crucial for the control of energy homeostasis and was the first site 
recognised to be important in this regulation (King 2006). The predominant neuronal 
population present in the VMH are SF-1 neurons, which are directly responsive to leptin; 
when the leptin receptor is ablated from these neurons an obese phenotype is observed 
(Dhillon et al. 2006). This obese phenotype resembles that of POMC ARC neurons, 
demonstrating the ARC is not the only site important for leptin action, and SF-1 neurons 
in the VMH are also required for leptin action. We find abundant BACE1-positive 
neurons within the VMH, of which approximately 30% are SF-1 neurons, implicating a 
role for BACE1 in leptin action in the VMH. In addition to the body weight and food 
intake actions of leptin on the VMH, this nuclei is crucial for the regulation of glucose 
homeostasis and mediating the counter-regulatory response (CRR) to hypoglycaemia. 
This was first demonstrated by Borg et al who demonstrated that following VMH damage 
rats show a blunted CRR, through reduced glucagon, adrenaline and noradrenaline release 
(Borg et al. 1994). As a result, neurons in the VMH are considered glucose-sensing 
neurons, and play a role in triggering the release of CRR hormones in response to 
hypoglycaemia. SF-1 neurons represent glucose-sensing neurons and are involved in 
mediating the appropriate response to glucose. Work by Tong et al demonstrated that 
when VGlut2 is knocked-out of SF-1 neurons there is blunting of the CRR to 
hypoglycaemia (Tong et al. 2007). Taken together, with our findings that BACE1 is 
present in SF-1 neurons, these data suggest that BACE1 may play an important role in 
glucose homeostasis, in particular the response to hypoglycaemia. This is supported by 
the knowledge that BACE1 levels are sensitive to hypoglycaemia, as there is a large 
increase in BACE1 protein levels observed following recurrent episodes of 
hypoglycaemia in a hypothalamic cell line (John Findlay PhD Thesis). Moreover, our 
data shows that in DIO mice BACE1 inhibition improves glucose homeostasis and 
enhanced BACE1 cleavage (through ADAM10 inhibition) causes defective glucose 
homeostasis, demonstrating a clear role for BACE1 in the regulation of glucose 
homeostasis, as well as whole body energy homeostasis. Importantly, we show there are 
BACE1-positive neurons in the VMH that are undefined, but which may represent 
additional VMH populations, also implicated in the control of energy balance, such as 
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BDNF-expressing and PACAP-expressing neurons, although further investigation would 
be necessary to examine this.  
The neuronal circuitry principally controlling energy balance involves first order ARC 
neurons integrating peripheral signals and projecting to other hypothalamic nuclei, 
namely the PVN and LH. From here, second order neurons input this information to the 
brainstem, principally the NTS, as well as the DVC, where signals are integrated and 
outputs generated through the SNS and vagus nerve (Schwartz et al. 2000). As we 
conclude BACE1-positive neurons represent another population of first order ARC 
neurons we hypothesise these neurons will also project to second order neurons. To 
definitively conclude this it would be necessary to conduct studies using neuronal tracing 
with anterograde labelling and electrophysiology. This would again require the use of a 
fluorescently tagged BACE1 mouse model, so that BACE1-positive cells could be 
identified, patched and injected with a dye to follow the processes and determine where 
the neurons synapse. It would be of particular interest to examine if the second order 
neurons that project to the brainstem are also BACE1-positive neurons and furthermore 
if the NTS neurons, which receive inputs and integrate the signals, are also BACE1-
positive. As we observe BACE1 present in all areas involved in the CNS circuitry 
described, and due to the number of BACE1 positive cells observed, particularly in the 
NTS, this is likely to be the case. These data strongly implicate BACE1 in the control of 
the neuronal circuitry regulating energy homeostasis. 
6.4 Physiological relevance 
The current data implicate BACE1 in the hypothalamic neuronal circuitry controlling 
energy balance, however the specific role under normal conditions is not yet known. As 
BACE1 has been shown to respond to various cellular stressors, it may sense and respond 
to acute stress within hypothalamic neurons allowing for preservation of neuronal 
activity. Conversely, under chronic stress conditions when BACE1 levels and/or activity 
remain elevated, for example following high-fat feeding, it is hypothesised that this will 
lead to dysfunction of the neuronal circuitry due to a loss of sensitivity and activity of the 
neurons. Specifically within RIPCre neurons, when BACE1 becomes elevated this may 
result in impairment of the circuitry to the PVN and NTS causing down-regulation of 
thermogenic programming and increased inflammatory processing; exacerbating 
metabolic disease. 
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 A component of this dysregulation of neuronal circuits may be due to elevated Aβ 
generated from BACE1 cleavage. This is supported by our data that demonstrate that 
altering APP processing, through blockage of α-secretase activity, exacerbates an 
obese/diabetic phenotype. Data showing administration of Aβ oligomers cause the same 
effect, but produces a more severe phenotype, further supporting this concept. (Clarke et 
al. 2015). Additionally, recent work in our lab has supported this by centrally infusing 
mouse Aβ1-42 in mice fed a HFD and demonstrating a large effect on the worsening of an 
obese state (unpublished data). High levels of Aβ, as a result of elevated BACE1 levels 
and/or activity, will activate microglia and astrocytes causing production of cytokines 
contributing to increased inflammation (Johnstone et al. 1999). This is further supported 
by the knowledge that Aβ may act as a danger-associated molecular pattern (DAMP) 
which activates inflammasomes causing increased inflammatory processing (Heneka et 
al. 2014). DAMPs trigger inflammation in brain cells through activation of 
inflammasomes, which are multi-molecular protein complexes found within cells (Guo 
et al. 2015). The inflammasomes activate inflammation via IL-β cleavage and pro-
inflammatory cytokine release, predominantly through pro-caspase 1 cleavage and 
caspase-1 release from the inflammasome (Guo et al. 2015). Inappropriate inflammasome 
activity, for example enhanced activation, is implicated in metabolic disease through 
elevated IL-1β and pro-inflammatory cytokines strongly associating with ER stress and 
insulin resistance. Therefore, Aβ may be specifically activating inflammasomes within 
microglia resulting in elevated inflammation. This enhanced inflammatory processing 
drives increased levels of soluble Aβ oligomers, which may act as secondary DAMPs to 
independently elevate pro-inflammatory cytokines further (Clark & Vissel 2015). This 
exacerbation of inflammatory processing, connected to ER stress and insulin resistance, 
will in turn worsen metabolic dysfunction.  
In the brain there is evidence of the packaging and release of Aβ directly from 
hippocampal neurons through elevated synaptic activity (Cirrito et al. 2005; Cirrito et al. 
2008). Moreover, this release of Aβ following enhanced neuronal activity has the ability 
to directly alter synaptic transmission, through reducing the number of synapses on other 
neurons (Kamenetz et al. 2003). This may also occur in the hypothalamus, where 
following elevation in BACE1, Aβ may be packaged and released from hypothalamic 
neurons (stimulating inflammasomes), which would likely activate astrocytes and 
microglia, driving inflammation, ER stress and insulin resistance, and moreover, may 
reduce synapses on neighbouring POMC and NPY/AgRP neurons. Loss of neighbouring 
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synapses would lead to disruption and further dysfunction of the hypothalamic neuronal 
circuitry controlling energy balance. Conversely, Kamenetz et al demonstrated that 
rodent Aβ, which is not believed to have amyloidogenic properties, also alters synaptic 
transmission following neuronal activation, which in turn reduces neuronal activation 
(Kamenetz et al. 2003). These data suggest that Aβ, under normal circumstances, may 
have a physiological function where it forms a negative feedback loop controlling 
neuronal activity and function. This may also occur in the hypothalamus and is supportive 
of our hypothesis that BACE1 under normal circumstances may act to respond to stress 
and reduce neuronal activity to preserve functionality of neurons and alter energy balance, 
acting as a protective mechanism. In regards to chronic stress and prolonged elevation of 
BACE1 and associated Aβ levels, the current hypothesis suggests that BACE1 inhibitors 
will reduce BACE1 levels and/or activity in hypothalamic neurons and re-sensitise the 
neuronal circuits controlling energy balance to peripheral signals such as leptin. 
Specifically, in RIPCre neurons re-sensitising these cells to leptin would result in 
increased energy expenditure, reversing leptin resistance and targeting body weight, and 
reducing chronic inflammation, improving insulin resistance. Additionally, in SF-1 
neurons re-sensitising these neurons to glucose through reduced BACE1 levels may 
improve and maintain glucose homeostasis, in particular the appropriate response to 
hypoglycaemia. 
The data presented within this thesis describe BACE1 as a novel component of the central 
neuronal circuitry controlling energy balance. This knowledge, accompanied by recent 
findings, implicate BACE1 in the regulation of energy homeostasis, whereby long-lasting 
elevations in BACE1 worsen metabolic disease through impaired thermogenic 
programming and increased chronic inflammation; as a result of defective neuronal 
activity. Furthermore, reducing BACE1 activity may provide a therapeutic strategy for 
the treatment of obesity and T2DM, in which inhibition restores neuronal activity and 
function to allow for the regulation of energy balance. This leaves open the field for future 
studies to investigate the functional properties of BACE1-positive hypothalamic neurons 
to help determine the precise role of BACE1 in energy metabolism. 
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